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ABSTRACT
Using various molecular genetic techniques, attempts have been 
made to identify a tumour suppressor gene (TSG) in prostate 
carcinoma. This gene will act as a genetic marker to identify 
patients at risk of disease progression from prostate cancer. The 
region at chromosome 10q23-24 is postulated to contain a TSG 
that plays an important role in the development and progression 
of tumours as it is deleted in a number of cancers including 
glioblastomas, endometrial and prostate cancer. In glioblastomas, 
chromosome 10 is partially or entirely deleted in approximately 
90% of tumours.
The TSG called Pten has been identified on chromosome 10 in 
the region 10q23.3. The significance of loss of the Pten gene in 
prostate cancer is unknown. In this thesis, the clinical 
significance of single nucleotide polymorphisms (SNP’S) in the 
chromosomal region 10q23-24 was evaluated. Comparisons in the 
distribution of polymorphisms between Ninety-five prostate cancer 
patients and forty-three non-prostate cancer patients were made. 
Three intronic polymorphism markers within the Pten gene were 
used: a single-base A—>G substitution in intron A, 96 bp upstream 
of exon 2. A 5-bp ATCTT insertion / deletion in intron D, 110 bp 
downstream of exon 4 and a single-base T —>G substitution in 
intron H, 32 bp downstream of exon 8. This study did not isolate
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any particular trend in polymorphism distribution in the Pten gene 
when comparisons were made between the two study groups.
The significance of loss of Pten gene in thirty-four prostate 
cancer patients was evaluated using four highly informative 
microsatellite markers: D10S541, D10S2492, D10S1765 and
AFMa086wg9 located within and around the Pten locus. DNA was 
extracted from prostate cancer cells following microdissection of 
archival paraffin embedded radical prostatectomy specimens. 
Loss of heterozygousity (LOH) studies was performed on 
matching blood/tissue DNA using these four microsatellite 
markers.
For these case specimens, frequency of allele loss of 48% was 
found at the D10S541 locus; 39% at D10S1765; 32% at
D10S2492 and 22% at the AFMa086wg9 locus. At all four 
microsatellite, the mean (range) LOH was 35.25% (22%-48%). Of 
the 34 case specimens 17(50%) showed LOH in at least one of 
the informative marker sites.
Correlating the significance of this region of LOH with 
pathological staging and known prognostic indicators in prostate 
cancer showed that the loss of the Pten gene was associated with 
late stage disease and likely to be involved in disease 
progression in prostatic adenocarcinoma.
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CHAPTER ONE
INTRODUCTION
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1.1 Prostate Cancer
1.1.1 Demographics
Adenocarinoma of the prostate is the most common non-skin 
cancer in men. In 2003, an estimated 220,900 men will be 
diagnosed with this disease and 28,900 will die from prostate 
cancer in the USA (Jemal A et al, 2003). Public health records 
document that men in USA have a one in six lifetime risk of 
developing prostate cancer (Jemal A et al, 2003). Overall death 
rate from prostate cancer in the USA in the year 2000 was 30.6 
per 100 000 (Stewart SL et al, 2004).
In the European Union, there are approximately 95,000 new 
cases registered and 35,000 men dying from the disease every 
year (Jensen OM et al 1990) and represents 12% of all new 
cancers diagnosed (Black RJ et al, 1997).
In England and Wales, it is a significant cause of morbidity with 
23,109 new cases diagnosed in 2000 with an annual death rate of 
8,973 for that same year (ONS, 2001). In the British association 
of urologogical surgeon’s registry for 2001, there was 12,892 new 
prostate cancers registered, representing 53% of all new cancers 
and 23 new cases per Consultant for that year (BAUS Cancer 
Registry, 2001)
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The uses of serum prostate specific antigen (PSA), transrectal 
ultrasound (TRUS) and biopsy technology as well as interests in 
detecting this disease (increase public awareness, media interest 
and screening) are major influences in the increase in the 
incidence of prostate cancer (Brawley OW and Kramer BS 1996).
The mortality from prostate cancer in the USA has showed a 
decline in trend at an average rate of 1% per year since 1992 
(Mettlin CJ et al, 2000), Figure 1.1. This was felt to be due to the 
successful impact of PSA screening in the USA population. 
However, In the UK where the population screening for prostate 
cancer is not common practice, the reduction in mortality rate has 
been found to mirror that of the USA (Oliver SE et al, 2000). This 
contrasting observation questions the validitity of PSA testing as 
a screening tool. It has also focused the attention of researchers 
working in prostate cancer field on other factors including 
genetic, dietry and environmental factors as contributory factors 
responsible for the reduction in mortality rate in prostate cancer.
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1.1.2 Aetiology
The mechanisms involved in the pathogenesis of prostate cancer 
are unknown. The disease is thought to occur as a result of a 
complex and yet unclear interaction between the environment, 
age, race, hormones, dietary fat, and genetic factors.
AGE
Prostate cancer has been known as a disease of elderly men. 
Diagnosis of prostate cancer is rare before the age of 50 with 
less than 1% of cases being diagnosed under the age of 40. 
Evidence of prostate cancer has been found in post-mortem 
studies on young males aged between 30 - 3 9  years old who died 
of trauma and had no clinical history of prostate cancer (Sakr WA 
et al 1993). After the age of fourty, the incidence and mortality 
rates both increase exponentially.
CIGARETTE SMOKING
The effect of cigarette smoking on the epidemiology of prostate 
cancer is inconclusive and difficult to interpret. Cigarette smoking 
has been well established as a cause of human malignancies 
such as lung cancer and has been associated with the
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development of certain urological malignancies especially bladder 
cancer. Plaskon, reported on a population-based case-control 
study on middle aged men and found a dose-response 
relationship between the number of pack-years smoked and 
prostate cancer risk (Plaskon LA, 2003). They also reported that 
cessation of smoking resulted in a decline in risk.
DIET
Dietary patterns have long been implicated in the development of 
different types of malignancies. Consumed food components may 
be metabolised to carcinogens, may alter hormonal balance, or 
may contain vitamins, minerals, and nutrients that could protect 
against the development of certain cancers. Dietary differences 
among racial groups, socio-economic classes, and geographic 
sites may explain some of the differences noted in prostate 
cancer epidemiology and behaviour.
There are studies showing that increased energy intake in the 
form of calories may lead to increase risk of carcinoma of 
prostate. A study by Gronberg H (1996) showed that men who 
considered they eat “somewhat more” or “much more” than the 
general population had odds ratios of developing prostate cancer 
of 2.22 and 3.89 respectively. The study also showed Body Mass
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Index >26kg/m2 had significantly increased risk of developing 
prostate cancer. This study implied that excess of calories or 
deficiency in other nutrient factors may influence carcinogenesis.
Soya is a dietary compound widely consumed in Japan: a nation 
with one of the lowest incidences of prostate cancer in the world. 
Soyabean products, whole grain cereals, seeds, nuts and berries 
are believed to have a protective effect against the development 
of prostate cancer. Phytoestrogens, including lignans and 
isoflavonoids such as genistein and daidzein contained in 
soyabeans and cereals may confer protection against prostate 
cancer (Landstrom M et al 1998). A typical western diet contains 
practically no soy products and a minute amount of 
phytoestrogens.
It is hypothesized that intestinal bacteria convert these 
substances into hormone-like compounds with antioxidative 
activities as well as other activities such as, inhibition of 5-a-  
reductase and 17(3-hydoxysteriod dehydrogenase, inhibition of 
angiogenesis and endothelial cell proliferation (Adlercreutz H, 
1995). These effects produce a profound inhibitory influence on 
malignant transformation, cell proliferation and angiogenesis. 
Vitamin A or retinoic acid is essential for normal differentiation of 
epithelial cells. Vitamin A deficiency has been linked to a variety
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of malignancies. It has been shown to have a chemoprotective 
role in head and neck malignancies (Kakizoe T, 2003). Retinoic 
acid is the metabolically active form of Vitamin A. It is fat-soluble 
and intake from vegetable sources is inversely proportional to 
prostate cancer incidence (Clinton SK et al, 1996). The benefit of 
dietry Vitamin A remains uncertain.
Lycopene is a carotenoid that cannot be converted to Vitamin A. 
Dietary lycopene can be found in fruits such as tomatoes, guava 
and watermelon. Lycopene is a potent antioxidant and the most 
significant free radical scavenger among the carotenoid family. In 
a large Seventh-day Adventist cohort study, Giovannucci reported 
that tomato consumption was strongly associated with reduced 
prostate cancer risk (Giovannucci E, et al 1998). This unique 
association suggests that lycopene supplementation may be 
beneficial in preventing progression of prostate cancer.
Vitamin E, is a major intracellular antioxidant in cell membranes, 
inhibits lipidperoxidation and has been demonstrated to have a 
wide range of anti-cancer properties. These properties include 
both protection against carcinogenesis and inhibition of tumour 
progression. The precise pathways of vitamin E’s beneficial 
benefits are largely unknown.
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Although Vitamin D is called a vitamin -  it is in fact a steroid 
hormone. Vitamin D is naturally synthesised under the influence 
of ultraviolet (U-V) light with conversion into biologically active 
compounds by hydroxylation in the liver and kidneys. Although 
vitamin D is primarily involved in bone and calcium metabolism, 
there is increasing evidence that vitamin D may be important in 
preventing prostate cancer. The first suggestion that Vitamin D 
might be related to prostate cancer came from an epidemiological 
study, which showed that individuals with the highest calcium 
intake (which naturally suppresses vitamin D) have a 3-fold 
higher risk of prostate cancer (Schwartz GG and Hulka BS. 1990). 
A prospective evaluation of men in the Health professional follow- 
up study showed that men with high consumption of calcium had 
a relative risk of 2.97 of developing advance prostate cancer 
(Chan JM et al, 1998).
Rotruck and colleagues elucidated the biochemical function of 
selenium by demonstrating that glutathione peroxidase; an 
enzyme that protects the cell from oxidative damage is selenium 
dependent (Rotruck et al, 1972). A randomised control study of 
58,279 men in the Netherlands showed an inverse correlation 
with selenium and risk of prostate cancer (Van den Brandt et al, 
2003).
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Although the precise mechanism by which dietary factors 
contribute to the prevention of prostate cancer is unknown, 
increasing evidence suggests that it may exert its effects by 
inhibiting oxidative damage within the prostate epithelium. 
Oxygen free radicals and oxidative damage to biomolecules is a 
major focus of recent aetiological cancer research (Sikka SC, 
2003). There is strong evidence that oxygen free radicals 
generated both endogenously and from external sources are 
associated with carcinogenesis and cancer progression. Oxygen 
free radicals are generated endogenously as by-products of 
normal metabolic processes and cause oxidative damage to 
important biomolecules such as lipids, proteins and DNA.
In conclusion, the dietry factors discussed above may be 
instrumental in preventing or slowing the growth of prostate 
cancer. The difference between latent and clinical prostate 
cancer suggest that diet may be influential in the progression of 
the disease. However, definitive studies are lacking.
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HEAVY METAL EXPOSURE
The prostate gland contains the highest level of Zinc of all organs 
in the body. Zinc is an essential ingredient of proper enzyme 
function and is required for DNA and RNA replication and repair. 
Cancerous prostate glands contain less zinc than normal glands 
(Platz EA and Helzlsouer KJ, 2001).  No correlation has been 
found between serum levels of zinc and prostate cancer, but one 
study suggests that men with zinc intake of up to 100mg/day had 
a relative risk of advance prostate cancer of 2.29 (Leitzmann MF 
et al, 2003).
Cadmium is a trace element known to act as an inhibitor of zinc 
metabolism. Overexposure to this agent also has been implicated 
in prostate cancer pathogenesis (Achanzar WE et al, 2001). High 
levels of cadmium may result from industrial exposure in those 
who work with batteries, paint and metal weldering. 
Environmental sources of cadmium include cigarette smoke, 
water and soil. Prostate cancer mortality in workers with long 
term exposure to high levels of cadmium has been 
disproportionately high, and cadmium workers often have more 
aggressive tumours (Elghany NA et al, 1990). Cadmium exposure 
may contribute to prostate cancer risk directly, or the risk may 
result from the effect of cadmium on zinc availability.
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HORMONES
The prostate gland consists of stromal and epithelial elements 
under androgenic influence. The hypothalamus produces 
luteinizing hormone-releasing hormone (LHRH), which stimulates 
the anterior pituitary to produce luteinizing hormone (LH) and 
follicle-stimulating hormone (FSH). LH stimulates leydig cells of 
the testicles to produce testosterone. Testosterone enters the 
prostate and is converted by the enzyme 5-a -reductase type 2 
into dihydrotestosterone (DHT), the active metabolite influencing 
prostatic development. Figure 1.2 shows endocrine control. Other 
hormones such as oestrogen and prolactin may also influence the 
growth of the prostate gland, either directly or indirectly by 
negative feedback inhibition.
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RACE
Prostate cancer incidence rates vary significantly between ethnic 
groups (Hsieh K and Albertsen PC, 2003). This variation is 
probably due to a combination of genetic and environmental 
factors, although the relative contribution of each of these is so 
far unknown. Differences in diet and other risk factors appear to 
explain only a small proportion of the observed ethnic variation.
Clinical incidence of prostate cancer is low in Asian men (Shibata 
A et al, 1997). It has a high incidence in Scandinavian countries, 
and the highest incidence (and mortality) rates are known in black 
men in North America and Jamaica (Glover FE et al, 1998). It is 
not known if the fraction attributable to genetic factors is high in 
this group.
The significance of environmental factors is highlighted by data 
showing that when individuals from a low incidence/mortality 
region move to a high incidence/mortality region, within their own 
generation the disease becomes more common. For example 
when Japanese men relocate to the United States or other 
countries, their prostate cancer statistics start to resemble those 
of the local population (Shimizu H et al, 1991). Younger age at 
the time of relocation and the length of time living in the new 
environment appears to correlate with the increase incidence.
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In contrast, African -American men have a 60% higher incidence 
and a 2.3 times higher mortality rate than white men living in the 
same geographic location (Crawford ED 2003). Thus, although 
black men have more advanced disease upon diagnosis (40% are 
more likely to present with metastases), they have a higher 
mortality rate even when compared with white men presenting 
with identical disease stages (Crawford ED 2003).
To understand the genetic, environmental, or social basis of the 
epidemiological differences noted between black and white 
Americans, it is important to understand the biology of prostate 
cancer in Africa. These data are sparse and have started to 
accumulate only recently. Because of political instability, 
economic difficulties, shorter life expectancy, and competing 
morbidities, comprehensive clinical and histopathological data are 
yet to be produced. Nevertheless, new evidence exist that 
prostate cancer is a surprisingly common disease in black 
Africans (Kehinde EO. 1995). When black males in the USA are 
compared to blacks in Nigeria, they were found to have similar 
prevalence of prostate cancer, however the incidence of clinical 
prostate cancer was found to be six times greater in American 
blacks. The study also showed that the prostate cancer in 
Nigerian males was less invasive. In conclusion, race appears to 
be an important factor. However serious technical and conceptual
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limitations hamper the ability of racial comparisons to illuminate 
the causative pathways. Factors concerning impact of socio­
economic status influences, dietary and environmental influences 
must always be considered.
VASECTOMY
A history of vasectomy has been associated with an increased 
risk for prostate cancer (Giovannucci E et al, 1993), although an 
equal amount of studies provide evidence to the contrary (Bernal- 
Delgado E et al 1998, Lesko SM et al, 1999). The directive from 
the World Health organisation states that any causal relationship 
between vasectomy and the risk of prostate cancer is unlikely.
PROSTATIC INTRAEPITHELIAL NEOPLASIA
The search for the precursor of prostatic adenocarcinoma has in 
recent years focused on the spectrum of histopathological 
changes referred to as Prostatic Intraepithelial Neoplasia (PIN)  
(Bostwick DG. 1995). PIN is characterised by cellular proliferation 
within preexisting ducts and acini with cytological changes that 
mimic cancer, including nuclear and nucleolar enlargement.
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The term PIN, was introduced in 1987 and was endorsed by 
consensus at an international conference in 1989 to replace other 
terminology used in the literature for the same lesion, including 
intraductal dysplasia, hyperplasia with malignant changes, 
marked atypia and duct- acinar dysplasia. The consensus group 
also proposed that PIN be divided into two grades (low and high) 
to replace the previous three-grade system (PIN 1, 2 and 3) 
(Bostwick DG and Brawer MK 1987).
The clinical importance of recognising PIN is based on its strong 
association with prostate cancer. It tends to be multifocal and 
occurs in the peripheral zone, as does the prostate cancer. It co­
exists with cancer in more than 85% of cases (Bostwick DG and 
Brawer MK 1987). This finding allows PIN to have a high 
predictive value as a marker for adenocarcinoma. Its 
identification in biopsy specimens warrants further search for 
concurrent invasive carcinoma. If high grade PIN is identified; 
close surveillance and follow-up biopsy are indicated.
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1.1.3 GENETIC EPIDEMILOGY
FAMILY HISTORY
Credit for the awareness of prostate cancer as a familial disease 
must go to the Mormons in Salt Lake City (Woolf CM. 1960). Their 
meticulous genealogical archives are a very valuable source of 
information for research on family aggregations of various 
diseases. In 1960, Woolf CM reported the familial clustering of 
prostate cancer, indicating a threefold higher risk that a relative 
of a prostate cancer sibling would acquire the disease (Woolf CM. 
1960). Modern studies began in 1982, when Bishop DT et al 
reported that brothers of a sibling had a high risk of acquiring 
prostate cancer (a two-to-four fold increase over that expected) 
as compared with their brothers-in-law, who supposedly lived 
under similar environmental conditions (Bishop DT et al, 1982).
Further support that the disease may be truly hereditary and not 
due to a similar lifestyle was provided by the studies performed 
by Gronberg et al in 1997. They used the well-established 
Swedish “Twin Registry” and investigated the frequency of 
prostate cancer in twin brothers. The concordance rate amongst 
heterozygous twins was 0.043(compared to familial cancer), 
whereas the concordance rate in monozygotic twins was 0.192, 
almost five times higher. This value is markedly higher than for
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breast cancer (0.125). Lifestyle was not particularly studied in 
this report, which may have influenced the results, but probably 
only marginally.
There are no prostate cancer associated genes yet identified, so 
the diagnosis of hereditary cancer cannot be confirmed by a 
laboratory test. A potential susceptibility gene, HPC1, has been 
mapped to chromosome 1q24-25(Eeles RA etal, 1997).
BREAST CANCER
Breast cancer has many features in common with prostate cancer, 
in incidence, pathology and hormone responsiveness. Breast 
cancer also occurs in a familial form, but not as marked as 
prostate cancer. In breast cancer two candidate tumour 
suppressor genes have been identified, supposedly linked to 
familial Breast cancer, named BRCA1 on chromosome 17q (Hall 
JM et al 1990) and BRCA2 on chromosome 13q (Tulinius et al 
1992). Tulinius et al also reported that prostate cancer was the 
second most common malignancy related to familial breast 
cancer, and that the prostate cancers were invariably highly 
aggressive.
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Gao et al supported the theory of a link between breast and 
prostate cancer by finding a high frequency of loss of BRCA 1 in 
men with prostate cancer, but this was not based on linkage 
analyses (Gao X et al, 1995). Several reports have favoured a 
link between breast and prostate cancer, indicating an increased 
risk for sons of mothers with breast cancer to develop prostate 
cancer, as well as an increased risk for daughters of fathers with 
prostate cancer to develop breast cancer (Sellers TA et al, 1994). 
However, there are studies, which show a poor relationship 
between familial breast and prostate cancer (Isaacs SD et al, 
1995). Therefore in summary, the real link between breast and 
prostate cancer is in ununknown and needs further proof.
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1.2 Pathology and treatment
1.2.1 The natural history of cancer
Tumour progression and Heterogeneity
The natural history of cancer begins with transformation of a 
normal cell or cells, followed by tumour progression, 
accompanied by the development of tumour-cell heterogeneity 
(Weinstein IB. 1988). Genetic and non-genetic mechanisms have 
been implicated in the development of cancer. Various chemical, 
radioactive, and viral agents act at the genetic level while 
environmental factors are believed to act mainly through non- 
genitic mechanisms (Bishop JM 1991). Most cancers contain 
genetic damage, which may be, associated with activation or 
alteration of proto-oncogenes or tumour suppressor genes. Such 
genetic changes have been identified in many human cancers 
including cancers of breast, lung, colon, retinoblastoma, 
leukaemia and lymphomas. Genetic and karyotypic changes in 
prostate cancer have also been well documented.
The rate of growth of a particular tumour depends upon the size 
of the growth fraction and the balance between the rate of cell 
production and loss (Templeton DJ and Weinberg RA 1991).
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The growth of a tumour is exponential during early stages of 
development but as it enlarges, growth becomes slower and at a 
clinically detectable size the majority of tumour growth is no 
longer exponential (Laster WR. 1969). Malignant transformation is 
also associated with acquisition of genetic instability, which 
makes the cells susceptible to a high rate of spontaneous genetic 
mutation (Nowell PC. 1976). Consequently, tumour cells develop 
increasing phenotypic diversity during progression. By the time a 
tumour is diagnosed, it consists of a heterogenous population of 
cells, which vary, in Karyotype, invasiveness, growth rate, 
hormonal responsiveness, metastatic abilities and susceptibility 
to cytotoxic drugs (Cotran, Kumar & Robbins 1989). Only those 
cell which survive host defence and ischaemic conditions, grow 
further. As a result, any emerging tumour will be enriched with 
those subclones that are most capable of survival, growth, 
invasion, metastasis and resistance to cytotoxic drugs.
Metastasis
Death from cancer usually occurs due to effects of metastatic 
disease (Liotta 1991). Treatment modalities currently available to 
treat metastatic disease have severe limitations. Drug and 
hormone resistance has emerged as major obstacle in the 
successful treatment of metastatic cancer. Radiotherapy and 
surgery play a role only in selective cases.
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Metastatic cells are less cohesive and are characterized by the 
ability to traverse tissue boundaries. Tumour cells detach from a 
primary tumour and sequentially invade the epithelial basement 
membrane, extracellular matrix, and endothelial basement 
membrane before entering the lymphatics or vascular circulation.
Once within a vessel, those tumour cells, which survive immune 
defences, are carried as emboli to sites where they are arrested 
in the capillary bed. These tumour cells may then extravasate into 
the local target organ interstitium and parenchyma in a manner 
that is the reserve of that employed to invade from primary sites.
There are various theories regarding factors, which determine the 
site of metastasis. The “anatomical hypothesis” suggests that the 
eventual metastatic site is determined by the anatomic site of a 
primary tumour (Evans CW. 1991); The “Seed and Soil” 
hypothesis suggests that provision of a fertile environment in 
which the compatible tumour cells could grow is the principal 
determinant of metastatic sites and the “paracrine/autocrine 
hypothesis” suggests that seeding could be determined either by 
release of paracrine factors by target organs or autocrine factors 
by tumour cells in response to organ derived signals (Hart L, 
1988).
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1.2.2 Pathology
The prostate is an accessory sex gland which surrounds the 
urethra at the base of the bladder and functions by contributing 
secretory proteins to the seminal fluid. Found exclusively in 
mammals, the prostate is not required for viability or even basal 
levels of fertility: therefore, its primary significance stems from its 
relevance for human disease. In deed, it is intriguing to note that 
malignant prostatic tumours are among the most common 
neoplasia in men, whereas other ductal organs of male urogenital 
system, such as the seminal vesicles and bulbourethral 
(Cowper’s) gland are virtually immune to neoplasia.
In the adult male, the prostate gland is a small acorn-shaped 
tissue composed of small glandular acini of varying shape and 
sizes embedded in fibromuscular stroma -  a mixture of smooth 
muscle and connective tissue containing neurovascular and 
lymphatic tissue.
Adenocarcinoma arising from the prostatic epithelium accounts 
for 95% of prostatic malignancies and is usually composed of 
small glandular acini that infiltrate in an irregular, haphazard 
manner (Ellis WJ and Lange PH 1994). The critical feature in 
prostate adenocarcinoma is absence of the basal cell layer, which
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may be detected immunohistochemically by using monoclonal 
antibodies against high molecular weight cytokeratin.
Prostatic adenocarcinoma originates in the peripheral zone in 
approximately 75% of cases, with the rest occurring in the 
transitional zone (McNeal JE et al, 1998). Figurel. 3 illustrate the 
view of the three zones of the Prostate. The tumours arising from 
these separate zones have different pathological features and 
clinical behaviour. Transitional zone tumours arise in or near foci 
of benign prostatic hyperplasia and are usually smaller and better 
differentiated. Peripheral zone cancers are often less well 
differentiated, larger in volume than transition zone tumours, and 
are frequently associated with greater stromal fibrosis, 
extracapsular extension, seminal vesicle invasion and lymph node 
metastases.
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c
Figure 1.3: The zones of the prostate
Illustration of three zones of the prostate
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Histological grading
The Gleason system (Figure 1.4) for grading prostate cancer is 
based on the degree of architectural differentiation (Gleason DF. 
1992). The system identifies five patterns that are often seen in 
prostatic adenocarcinoma. As a result of the morphological 
heterogeneity of prostate cancer, two different grades are given 
for the first and second most prevalent patterns. Hence, the 
Gleason score is given as their sum, ranging from 2 to 10, with 
the dominant pattern recorded first, example, 4+3 = 7. The 
Gleason score correlates strongly with crude survival, tumour free 
survival and is a significant predictor of time to recurrence 
following radical prostatectomy (Humphrey PA et al 1993).
Grading errors are common in needle biopsy specimens of the 
prostate, with underestimation (33-45%) and overestimation (4- 
32%) when compared with the whole specimen following 
prostatectomy (Bostwick DG. 1994). Grading errors occur more 
readily in biopsies containing small foci and low-grade cancers, 
reflecting sampling error and tumour heterogeneity. 
Nevertheless, Gleason grading needle biopsies can provide 
useful predictive information (Bostwick DG. 1994).
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Prostatic
Adenocarcinoma
(Histological
Patterns)
Pattern Margins
of
Tumour
areas
Gland
pattern
Gland
Size
Gland
Distribution
H 1 Welldefined Single,Separateround Medium Closelypacked
2 Less
defined
Single,
separate
More
irregular
Medium Spaced up 
to one 
gland 
diameter 
apart, on 
average
f ? m m  cm
l l l i l
3 Poorly
defined
Single,
separate
More
irregular
Small, 
medium 
or large 
medium 
or 
Large
Spaced > 
one gland 
diameter 
apart, 
rarely 
packed. 
Round 
masses 
with 
smooth 
edgesmmm
mmm
4 Ragged
infiltrating
Fused
glandular
masses
Small Fused in 
ragged 
masses
ppS
I
5 Ragged
infiltrating
or
Poorly
defined
Almost 
absent, 
few tiny 
glands or 
signet 
ring cells
Small Ragged 
anaplastic 
masses of 
epithelium
Figure 1.4: Gleason pattern for adenocarcinoma of the 
Prostate
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TUMOUR STAGING
The TNM (tumour, node, and metastasis) system is the most 
common classification used worldwide (Sobin LH & Wittekind CH. 
1997). The classification of prostate cancer published in 
1997(Table 1.1) was used in the staging of the patient’s prostatic 
adenocarcinoma in this thesis as that was the classification in 
use at the time of experiements reported in this thesis. The 
classification has been revised in 2002 with a modification made 
to pT2 stage in which pT2b is defined as tumour involving more 
than half of one lobe but not both lobes and pT2c is defined as 
tumour invading both prostatic lobes.
RULES FOR CLASSIFICATION OF PROSTATE CANCER
The classification applies only to adenocarcinoma. There should 
be histological confirmation of the disease.
The following are the procedures for assessing T, N, and M 
categories:
T. categories Physical examination, imaging, endoscopy,
biopsy, and biochemical tests.
N categories Physical examination and imaging.
M categories Physical examination, imaging, skeletal studies,
and biochemical tests.
Regional Lymph Nodes are the nodes of true pelvis, which
essentially are pelvic nodes below the bifurcation of the common
iliac arteries. Laterality does not affect the N classification.
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T- Primary Tumour
Tx Primary tumour cannot be assessed
To No evidence of primary tumour
T 1
T1a
T1b
T1c
Tumour clinically inapparent, not palpable nor visible 
by imaging
Incidental finding following TURP <5% of issue 
Incidental finding following TURP >5% of tissue 
Tumour identified by needle biopsy (e.g, because of 
elevated PSA).
T2
T2a
T2b
Tumour confined to the prostate, palpable or visible 
by imaging
Tumour involves half of one lobe 
Tumour involves both lobes
T3
T3a
T3b
Tumour extends through the prostatic capsule. 
Extracapsular extension (Unilateral or Bilateral) 
Seminal vesicle invasion
T4 Tumour is fixed or invades adjacent structures other 
than seminal vesicles; i.e bladder neck, rectum or 
external sphincter, levator muscles and/ or fixed to 
pelvic wall.
N -  Regional Lymph Nodes
NX
No
N1
Regional lymph nodes cannot be assessed 
No regional lymph nodes metastasis 
Regional lymph node metastasis
M -  Distant Metastasis
Mx 
Mo 
M1 
M1a 
M1b 
M1 c
Distant metastasis cannot be assessed. 
No distant metastasis 
Distant metastasis present 
Non-regional lymph nodes 
Skeletal metastases 
Other sites
Table 1.1: The 1997 TNM Classification of Prostate cancer
In this thesis the above classification for prostatic 
adenocarcinoma was used to stage the patient’s disease.
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Unique Features of Prostate carcinoma
Several features tend to distinguish prostate adenocarcinoma 
from other common cancers. This list is not exhaustive but serves 
to highlight important questions in prostate cancer biology.
1. Extreme age dependency of incidence. Although the most 
common malignancy in men, this disease does not appear (at 
least in the detectable form) at a significant rates until the sixth 
decade of life (Sakr WA et al, 1993).
2. Slow growth rate. Doubling times measured in years are not 
uncommon.
3. Sensitivity to androgens. Most cancers respond to androgen 
therapy, virtually all become insensitive (Crawford ED. 1990).
4. Multifocality. The prostate of a man diagnosed with cancer 
contains an average of five independent lesions (Bastacky SI et 
al, 1995). These lesions are genetically heterogeneous, both inter 
and intratumourally. This multifocality is independent of family 
history of prostate cancer (Bastacky SI et al, 1995).
5. Lack of ability to establish cell lines from clinical specimens of 
prostate cancer. After hundreds of attempts by numerous 
investigators only a handful of cell lines exist (Limon J. 1990).
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1.2.3 Prostate cancer Presentation and Detection
Historically, prostate cancer was diagnosed with the development 
of symptoms, either due to local disease resulting in voiding 
dysfunction, or disseminated disease commonly resulting in 
general lethargy, bone pain, pathological fractures and weight 
loss. This situation has changed dramatically with the PSA testing 
as an available tool which, when combined with the digital rectal 
examination (DRE) and transrectal ultrasound (TRUS), results in 
much greater ability to detect prostate cancer while still confined 
to the gland. The use of these methods is primarily responsible 
for the approximately threefold increase in incidence rates 
observed since 1988 (Brawley OW and Kramer BS 1996).
Prostate Specific Antigen (PSA)
PSA is a serine protease from the kallekrein family of 
glycoproteins with a molecular weight of 34kiloDaltons. 
Chromosome 19 contains the gene, which encodes for PSA. It is 
produced within the ductal cells of the prostate. PSA is secreted 
into the seminal plasma, where it is responsible for proteolysis of 
the sperm entrapping seminal coagulant formed in the ejaculate 
(Lilja H and Abrahamsson PA. 1988). It was first characterised 
following a forensic investigation in 1985 (Graves HC. 1985).
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The antigen circulates in the blood mainly bound to protease 
inhibitors, including a-1-antichymotrypsin and a-2-macroglobulin; 
only a small fraction of the total PSA exists in a free state. 
Whereas a-2-macroglobulin encapsulates all the epitopes of the 
PSA protein, a-1-antichymotrypsin leaves some exposed; 
therefore, immunoassay techniques have been developed to 
assess free PSA bound to a-1-antichymotrypsin but not to a - 2 -  
macroglobulin (Christensson A et al, 1993). The use of free: total 
PSA ratios is used clinically to improve the postivity predictive 
value for transrectal ultrasound and biopsy in the diagnosis of 
prostate cancer. (Woodrum DL et al, 1998).
Serum concentrations of PSA are normally of the order below 
4mg/mL, although this varies with age (Dalkin BL et al, 1993). 
With prostate pathology these levels can increase, in particularly 
dramatic fashion in the case of carcinoma. PSA is now well 
established as a useful investigation in the diagnosis and follow- 
up of patients with prostate cancer. A focus of intense research 
effort is on the ability to accurately interpret slightly elevated PSA 
levels that can be indicative of either benign or malignant disease 
(Oesterling JE et al, 1991). Serum PSA detection after 
prostatectomy or other treatment for prostate cancer is a reliable 
indication of disease progression (Oesterling JE et al, 1988).
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Serum PSA has become the mainstay of screening and detection 
in some countries (Farkas A et al, 1998). PSA has the strongest 
positive predictive value for prostate cancer. In population 
selection and biopsy studies, the chance of finding cancer on 
biopsy are approximately 22% with a PSA value of 4.0ng/ml to 
10ng/ml, rising to over 63% in those with a PSA greater than 
10ng/ml (Catalona WJ et al, 1991). However in a multicentre 
study, it was shown that 18% of cancers would be missed if PSA 
alone was utilised as a screening tool (Catalona WJ et al, 1994). 
The combination of DRE and PSA testing improves the rate of 
cancer detection in the selection of patients for biopsy (Catalona 
WJ et al, 1994).
The greatest limitation of PSA is its lack of specificity. Various 
conditions can cause “false positive” results such as BPH and 
prostatitis. However, PSA concentrations are the best overall 
predictor of bone scan findings and can be used as a screening 
test for prostate cancer. (Catalona WJ et al, 1994).
Transrectal ultrasound (TRUS) guided biopsy
Prostate cancer may appear as a hypoechoic lesion on 
ultrasound. The degree of echogenicity is variable and dependent 
upon the amount of solid tumour per unit area. Only macroscopic 
cancer can be detected on TRUS. The sensitive 7MHz probe 
facilitates biopsy and the 18-gauge Biopty needle has improved
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the accuracy of the biopsy needle placement. TRUS-guided  
biopsies of hypoechoic areas have increased the detection rate of 
prostate cancer in screening populations (Cooner WH 1990).
The protocol for TRUS-guided prostate biopsies vary between 
hospitals. During this research project the antibiotic prophylaxis 
protocol used in the prostate laboratory at The Royal Free 
Hospital was Gentamicin 120mg administered intravenously prior 
to the procedure followed by three day course of Ciprofloxacin 
500mg twice daily. The use of periprostatic infiltration of local 
anaesthetic prior to biopsy is currently advocated; however this 
technique was not used, at the time of this study. Six (Sextant) 
biopsies were taken routinely from the base, mid-zone and apex 
of the prostate bilaterally. Additional biopsies were taken if 
suspicious looking areas were identified separate from the region 
of initial biopsy.
The radionuclear bone scans.
Prostate cancers most commonly metastasise to bone. The 
radionuclear bone scan using y-camera images following an 
intravenous injection of a technetium salt can identify a potential 
bone metastasis long before it becomes apparent on plain X-ray. 
Simple technetium salts do not localise in the skeleton, but 
complexes or chelates of technetium with a number of 
phosphorous containing compounds do concentrate in bone.
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Abnormalities on a skeletal technetium-99 labelled bone scan 
appear as areas of increased uptake which can represent areas 
of pathological process such as neoplasia or infection and is not 
a direct indicator of the pathological process itself. This is an 
important concept because it explains why bone scan itself 
cannot be used to accurately monitor progress of disease. 
However bone scan remains the most sensitive diagnostic tool 
that we have to detect small bone metastases in untreated 
patients. Recent trauma, infection, inflammatory joint disease, 
and Paget’s disease can produce false positive results. These 
can usually be excluded on clinically together with plain X-ray.
Studies have shown that it is unnecessary to perform bone scans 
if a patient with prostate cancer has a PSA of below 10ng/ml 
(Chybowski FM et al, 1991). This is only true for an untreated 
patient because therapy, especially hormone treatment, may 
often lower the serum PSA to near normal levels, reflecting a 
decrease in PSA secretion by cancer cells, but leaves the 
metastasis still evident.
Computer Tomography (CT).
Cross-sectional imaging with CT is used in an attempt to detect 
local extension of prostate cancer and/or the presence of lymph 
node metastases. However, it is not routinely useful because of 
low sensitivity (Wolf JS Jr et al, 1995). Pelvic imaging for lymph
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node assessment may be warranted in men at higher risk for 
metastases suspected by locally advanced on DRE, marked PSA 
elevation (PSA £ 20pg/l), or the presence of poorly differentiated 
cancer on needle biopsy.
Magnetic Resonance Imaging (MRI)
The role of MRI is to improve the accuracy of clinical staging by 
identifying patients, whose prostate disease has perforated the 
capsule. This prevents inappropriate therapy with risk of 
additional morbidity. Gross violation of the capsule by carcinoma 
with tumour invading the periprostatic fat is readily detectable 
(Chelsky MJ et al 1993). MRI is the only modality that can provide 
good images of the seminal vesicles. On T2 weighted images the 
seminal vesicles have a honeycomb appearance, the fluid having 
high intensity and the stroma low intensity. Work by Hricak and 
colleagues showed that MRI could have a direct influence on 
current decision making in the clinical management of prostate 
carcinoma (Hricak H 1994). The negative predictive value of 
extracapsular (92%) and seminal vesicle (98%) extension (i.e., 
that the capsule and seminal vesicles are not involved) is 
reasonable high and should reliably predict which patients may 
benefit from prostatectomy. MRI also has the advantage over CT 
scan in that the staging for extracapsular extension can be 
undertaking at the same time as looking for lymph node 
involvement.
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1.2.4 Treatment of Early Prostate Cancer.
The treatment of early prostate cancer remains controversial, as 
there are no prospective randomised clinical trials comparing all 
treatment modalities to ascertain which treatment is most 
effective. As mentioned PSA has become the mainstay of 
detection and is used as a screening tool in many countries. 
However, the effect of PSA as a screening tool is itself 
controversial. A number of studies have indicated the potential of 
PSA in allowing early detection and treatment of prostate cancer, 
which may lead to a survival benefit (Lu-Yao GL & Yao SL 1997), 
(Labrie F et al 1999).
Currently the main treatment choices for early-localised prostate 
cancer involve radical therapy in the form of surgery or 
radiotherapy (external beam or brachytherapy), or a conservative 
approach using active surveillance and deferred treatment if 
necessary. The management decision is difficult due to the fact 
that the difference between the outcomes of the modalities is 
unknown and the natural history of the disease itself is not clearly 
understood.
Studies assessing conservative management have shown that a 
large percentage of men with prostate cancer will not die of their 
disease over 15 year follow-up period. Based on Gleason score of
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histopathological samples from biopsies or TURP specimens, 767 
men with localised cancer were followed-up 10-20 years after 
their initial diagnosis. Some men had undergone deferred 
hormonal therapy during this period. In those men with well- 
differentiated (Gleason score<4) carcinoma 4-7% were at risk of 
cancer specific death at 15 years. A Gleason score of 5 raised 
the risk to 6-11%, score of 6 to 18-30%, score of 7 to 42-70% and 
a poorly differentiated cancer gave 60-87% risk of death over 15 
years. In the older man with a cancer that has a Gleason score of 
6 or less, a conservative approach is a very real choice with a 
generally favourable outcome (Albertsen PC et al, 1998). Chodak 
et al had previously shown that in men with low grade prostatic 
carcinomas, 10 years disease specific survival was 87%, but only 
34% in those with high grade lesion (Gleason score>7). In those 
men who were free of metastases at 10 years, 81% had prostate 
cancer with Gleason score<4 cancer, 58% with Gleason score 4-6 
and 26% with Gleason score>7 (Chodak GW et al, 1994).
In a Swedish prospective population study, the disease specific 
survival was 85% at 10 years and 81% at 15 years (Johansson JE 
et al, 1994). These patients had undergone a programme of 
surveillance and deferred treatment (exogenous oestrogens or 
orchidectomy) if symptomatic, with excellent outcomes 
(Johansson JE et al, 1994).
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Due to lack of prospective randomised controlled trials, various 
groups have tried to compare results retrospectively using pooled 
data analysis or population studies to gain information concerning 
the best radical treatment, surgery or radiotherapy, compared to 
conservative or deferred treatment. Adolfsson J et al (1993). 
Examined the literature from 1980 with respect to radical 
prostatectomy, external radiotherapy and deferred treatment. 
They tried to calculate a weighted mean disease specific survival 
at 10 years by using the number of patients per group as the 
weights. A 10 years the disease specific survival was 93% for 
surgery, 74% for radiotherapy and 83% for deferred treatment. 
This study suffers from bias in that prognostic factors were 
unevenly distributed. There were more poorly differentiated 
tumours in the surgery and radiotherapy arms compared to the 
conservative arm and although the stages were evenly spread, 
the group undergoing surgery had smaller tumours than in the 
other 2 groups. Those men undergoing radical prostatectomy had 
pelvic lymph node sampling and only in absence of disease did 
surgery proceed, thereby biasing patient selection.
The American Urological Association also attempted a similar 
literature search, the results of which were similar to those above 
but the main conclusion was that the data was unreliable and 
could not be used to compare the different treatment modalities 
(Middleton RG et al, 1995). Analysis of the Surveillance,
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Epidemiology and End Results (SEER) program of nearly 60,000 
patients with localised prostate cancer showed that for well or 
moderately differentiated tumours there was not a large 
difference between the three common treatment options. Only in 
those patients with a poorly differentiated lesion did radical 
prostatectomy have a survival benefit at 10 years of 67% versus 
53% for radiotherapy and 45% for deferred treatment. This study 
is not without its problems of patient selection but the very 
considerable number of men in each group (15,000-25,000)  
makes it an important study (Lu-Yao GL, Yao SL. 1997).
The discussions concerning radical treatment against deferred 
treatment are in part due to the lack of concrete evidence that 
radical treatment is better in terms of risk-benefit analysis. That 
there maybe a moderate survival benefit over 10-15 years with 
radical treatment in some patients has to be set against the 
complications of radical pelvic surgery of radiotherapy. Radical 
prostatectomy is associated with a 0.3% mortality rate, 
incontinence rates of between 5-30% depending on whether the 
surgeon or patients is directly questioned and erectile dysfunction 
rates of between 25-75%. This also has to be seen in the context 
of an overall positive margin rate of 28% (Wieder JA and Soloway 
MS. 1998), thereby theoretically not curing the patient. However, 
this does not always translate into disease progression or directly 
impact upon survival (Pound CR 1999). The PIVOT trial, which
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was set up in 1994, comparing Intervention against expectant 
management in patients with early prostate cancer, would 
hopefully demostrate which management approach will provide 
superior survival and quality of life in men (Wilt Tj & Brawer Mk
1994).
Radical radiotherapy is not without its side effects. It has been 
associated with a mortality rate of 0.2%, incontinence rate 0.9% 
and erectile dysfunction rates of between 40-70%(Shipley WU et 
al, 1999) however Intensity modulated radiation therapy (IMRT)  
reduces side effects to adjacent structures allowing for dose 
escalation to the prostate (Teh BS et al, 2002).
New therapies such as brachytherapy are gaining popularity but 
are yet not substantiated with long-term data. The 5-year 
biochemical free survival for brachytherapy is quoted as 71% 
(Brachman DG et al, 2000).
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1.2.5 Treatment of advanced Prostate Cancer
Testosterone and its more potent metabolite Dihydrotestosterone 
are essential for normal prostate growth and also play a role in 
the growth of prostate adenocarcinoma. Since 1940, bilateral 
orchidectomy has been the mainstay of treatment of metastatic 
prostate carcinoma (Huggins C and Hodges CV. 1941). 
Subsequently, medical methods of anti-androgen therapy and 
medical castration have been employed. Lutenizing hormone 
releasing hormone (LHRH) agonist act by stimulating the pituitary 
gland to produce gonadotrophins which then inhibit further 
production due to a negative feedback mechanism. Testosterone 
levels rise initially but reach castration levels after 2-3 weeks. 
These agents are usually well tolerated by patients and may be 
administered every 3 months as depot injections.
The time to commencement of hormonal manipulation has been 
the subject of a number of investigations. After the 
commencement of hormonal therapy, relapse can occur and it has 
been thought that delaying treatment would stave off hormone 
relapse. Alternatively early treatment to prevent the onset of 
symptoms has been anecdotally been thought to aid survival. This 
question was addressed by MRC study of immediate versus 
deferred treatment, which showed a decrease in morbidity from 
local extension and also a survival benefit in the group receiving
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immediate hormonal therapy (Kirk D, 1997). The use of 
radiotherapy in locally advanced disease has been shown to 
improve survival in patients who did not have lymph node 
involvement. Radiotherapy with adjuvant androgen suppression 
has shown improvements in both local control of disease and 
conferred survival benefit in those with poorly differentiated 
disease (Bolla M et al 1997, Pilepich MV et al 1997). These 
studies also imply a benefit may be gained from early use of 
androgen suppression. However, these benefits need to be seen 
in the context of side effects such as decreased libido, erectile 
dysfunction, lethargy, depression and osteoporosis.
The adrenal glands are also responsible for the production of a 
small concentration of androgens. There are classes of drugs, 
which have been developed to decrease production of androgens, 
such as ketoconazole, or to inhibit androgen receptor, such as 
bicalutamide (Casodex). These receptor antagonists have several 
benefits in that they have few side effects and preserve libido.
No matter which method of androgen ablation is used for locally 
advanced or metastatic carcinoma of the prostate, most patients 
show disease progression at a year or eighteen months. No 
therapy has been shown to prolong survival once the disease is 
hormone resistant and the survival is typically 2-3 years from the 
time of diagnosis of metastatic disease (Crawford ED 1990).
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1.3 GENETICS
1.3.1 Cytogenetics of prostate cancer.
There is much evidence that cancer is the result of a primary 
genetic event. As the chromosome carries the genetic material, it 
is natural to study them to see if chromosomal changes lead to 
cancer.
The primary informational molecule of the cell is deoxyribonucleic 
acid (DNA). It is damage to this DNA that is considered to cause 
cancerous growths. DNA consists of two polynucleotide chains 
that coil around one another to form a double helix. The two 
chains are held together by hydrogen bonds between the nitrogen 
bases. For DNA there are four possible bases: adenine (A), 
guanine (G), cytosine (C) and thymine (T). It is the 
complementary base pair sequence (A=T and C=G) that contains 
the information necessary for cell growth, proliferation and 
differentiation. DNA is transcribed into ribonucleic acid (RNA), 
which acts to direct the formation of proteins. A gene is a 
segment of DNA involved in the manufacture of a single protein. 
Within the human nucleus, the DNA is tightly coiled in association 
with proteins to form chromatin. During cell metaphase, chromatin 
condenses for cell division and only then are characteristic 
chromosomes seen. Each chromosome is seen to be consisting of
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two chromatids joined at the centromeres. Each chromosome has 
a short arm labelled p and a long arm labelled q.
Humans possess 46 chromosomes as 23 homologous pairs. There 
are 22 autosomes and 2 sex chromosomes. Genes located at the 
same point on each of pair homologous chromosomes are called 
alleles. One allele is inherited from each parent. If both alleles 
are identical, an individual is homozygous for that gene. If the 
alleles are different, the individual is heterozygous for that gene. 
Each species has a complement of chromosomes that is 
characteristic in number and structure and is referred to as the 
species Karyotype.
Somatic cells contain 46 chromosomes and are called diploid 
(2n). Germ cells contain 23 chromosomes and are called haploid 
(n). Prostate cancer cell may contain more than the normal 
number of chromosomes. If their chromosome complement is an 
exact multiple of the haploid number, then they are polyploid (e.g. 
triploid, 3n). If they contain an excess that is not an exact 
multiple of the haploid number they are termed aneuploid. 
Numerical abnormalities occur at the time of cell division.
Apart from numerical chromosomal abnormalities, there may be 
structural anomalies. These result from chromosomal breakages, 
which occur commonly in tumours. In normal cells chromosome
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breakage occurs, but repair mechanisms join areas of breakage 
without delay.
Structural chromosomal abnormalities may be of different types. 
A translocation is the transfer of chromosomal material between 
two chromosomes. An insertion translocation occurs when there 
is a break in one chromosome that is filled by material from 
another chromosome. Loss of material from one chromosome is 
called a deletion. Duplication is the presence of two copies of a 
chromosome fragment. Inversion occurs when there are two 
breaks in a chromosome and the inverting fragments rotate 180°. 
An isochromosome occurs when one arm of a chromosome is 
deleted and the other is duplicated. Loss of heterozygousity 
(LOH) is the loss of an allelic band in tumour constitutional DNA 
and is recognized as indicative of putative tumour suppressor 
genes.
Several studies have attempted to address the relationship 
between prostate cancer karyotype, and tumour grade, stage and 
prognosis. Unfortunately because there are no consistent 
abnormal (marker) chromosomes, this has proved to be very 
difficult.
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Clinicians are still unable to predict which tumour is likely to 
progress and which is will remain quiescent. It remains unclear if, 
how or when a latent tumour undergoes malignant transformation. 
The molecular mechanisms involved in the progression of 
prostate cancer remain relatively unknown in comparison with 
other common cancers. Since Nowell PC et al (1976) first 
described a genetically based model of clonal development and 
expansion (Nowell PC, 1976), accumulating evidence has 
implicated activation of oncogenes and inactivation of tumour 
suppressor genes within a cell l ineage as the generally accepted 
model of carcinogenesis (Fearon ER and Vogelstein B. 1990). 
Such genetic malfunctions can occur spontaneously or they may 
be inherited. There has been no identification as yet of a 
conclusive, consistent ‘marker’ gene or genes for prostate 
cancer.
DNA transfection assays were heavily used in the early 80s to 
identify active oncogenes. Frequent allelic losses observed at 
specific chromosomal loci in several types of human carcinomas 
imply that putative tumour suppressor genes have been 
inactivated in the regions where deletions are detected. Although 
in prostate cancers the roles of most allelic losses have not been 
clarified, such losses appear to be frequent on chromosome arms 
7q, 8p, 10q, 16q and 17p in prostate cancer tissue (Isaacs WB. 
1995, Carter BS et al, 1990).
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1.3.2 Oncogenes
The Conversion of normal cells to malignant cells appears to be a 
multistage process, and it appears that several mutational events 
are required for the development of carcinomas (Klein G and 
Klein E. 1985). The development of cancer at the molecular level 
appears to be determined by the complex interactions by two 
major groups of genes, the oncogenes and the tumour 
suppressors genes.
Cellular oncogenes
Some retroviruses induce neoplastic transformation in normal 
cells in culture and susceptible animals. This occurs when certain 
genes, viral oncogenes (v-onc), are integrated into the host cell’s 
genome. In 1976 it was discovered that DNA homologous to viral 
oncogenes was present in all vertebrates (Stehelin D et al, 1976). 
These cellular homologues of viral oncogenes are called cellular 
or c-onc oncogenes. They appear to be critically involved in the 
regulation of normal cell growth and differentiation, since they are 
highly conserved and expressed in normal cells at various stages 
of the cell cycle and in the process of cell maturation. When 
activated, the oncogenes have the ability to transform cells to a 
malignant form, either by expression of an altered form of a 
normal cellular protein, or by over expression of an otherwise
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normal gene. One mechanism of oncogenes activation is 
chromosomal translocation. Several proto-oncogenes are located 
near chromosomal breakpoints involved in translocations specific 
to certain malignancies (Mitelman F and Heim S. 1988).
Examples of oncogenes include c -MYC  and ras gene. These 
oncogenes has been thoroughly investigated for their possible 
involvement in prostate tumourigenesis, but much of the data 
have strongly indicated that they do not play a significant role in 
prostate cancer (Carter BS et al, 1990) (Evans Gl 1992). The bcl- 
2 gene, an inhibitor of apoptosis located on chromosome 18q21 is 
thought to be associated with the transition prostate cancer to 
androgen resistant state (Colombel M et al 1993).
Aberrant expression of the oncogenes Bcl-2, Ras and MYC  have 
been detected in prostate cancer cells, compared to expression in 
normal tissue. However, none of these genes have been shown to 
be consistently activated in prostate cancer and the 
overexpression mechanisms remain largely undefined (Isaacs WB
1995).
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1.3.3 Tumour suppressor genes
Evidence for the existence of tumour suppressor genes came 
from an analysis of the inheritance of rare hereditary childhood 
cancers. Based on retinoblastoma, Knudson AG et al (1985), 
proposed a “two-hit” inactivation process in which both copies of 
a critical gene had to be inactivated for the disease to manifest. 
Work on retinoblastoma and Wilms tumours has shown that 
individuals affected inherit inactivation or deletion of one of the 
tumour suppressor genes. It is when the gene develops a 
mutation or deletion of the remaining allele that the tumour 
develops. A number of studies have investigated tumour 
suppressor genes in prostate cancer.
RB gene.
The RB gene was the first tumour suppressor gene found in 
human malignancies. This gene is the second most mutated 
tumour suppressor gene in human cancers. It is located on 
chromosome 13p and codes 110kDa nuclear phosphoprotein, 
which has been implicated in the regulation of cell cycle 
progression (Lee WH 1988). Loss of the RB gene is thought to 
occur in at least 50% of prostate tumours (Cooney KA et al,
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1996). Although further studies are required to full assess the 
role of RB alterations in prostate carcinogenesis, studies carried 
out thus far, suggest that it is infrequently mutated in prostate 
cancer (Konishi N et al 1996) and that abnormal Rb expression 
has little prognostic significance in prostate cancer (Vesalainen S 
and Lipponen P 1995).
p53  gene
The p53  gene is located on the short arm of chromosome 17 and
encodes a 53 kDaltons nuclear phosphoprotein. Often referred to
as the guardian of the genome, p53  causes a G1-S cell cycle
arrest in cells exposed to DNA damaging agents, which
presumably allows the cell sufficient time to repair or restore its
DNA damage before replication in S phase, or, depending on the
degree of damage, induce apoptosis (Bellamy CO et al, 1997).
The mechanisms by which p53  induces apoptosis are still poorly
understood. When p53  is inactivated, damaged DNA can 
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accumulate leading to the progression of the cells into a 
malignant transformation. In addition, inactivating mutations of 
p53 have been shown to confer resistance to apoptosis induced 
by radiation and multiple chemotherapeutic agents (Me Donnell 
TJ et al, 1997).
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Genetic abnormalities of the p53  tumour suppressor gene are 
associated with several human malignancies including bladder 
cancer (Sarkis AS et al 1993) and breast cancer (Borresen-Dale 
AL. 2003). Although p53  mutations in early invasive prostate 
cancers tissues are relatively infrequent (Henke RP et al 1994), 
they occur more frequently in metastatic disease (Stapleton AM et 
al, 1997). In a study by Bookstein, almost all of the p53 mutations 
were associated with high grade, metastatic, or hormone- 
refractory prostate cancer (Bookstein R et al, 1993). Therefore, 
p53 mutations are not only late events in prostate tumour 
development, but are also less frequent (10-20%) than in other 
types of cancer (Bookstein R et al, 1993).
E-Cadherin  gene
The concept of the tumour suppressor gene has been extended to 
genes, which are subjected to frequent downregulation in cancer, 
suggestive of an important tumour-suppressing activity despite 
the lack of evidence for mutation. The E-Cadherln gene is such 
an example, located at chromosomes 16q22.1 and encodes a cell 
adhesion molecule protein, which plays an important role in 
tissue development and epithelial cell differentiation (Umbas R et 
al, 1992). When down regulated, this cell adhesion molecule may 
be involved in oncogenic processes through inactivation of cell
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adhesion-mediated growth control pathways. E-Cadherin protein 
is frequently reduced or absent in high Gleason grade prostate 
cancers, and this finding has prognostic significance (Umbas R et 
al, 1992). Although the predominant mechanism for down 
regulation of this gene has not been determined, studies have 
shown that inactivation via promoter methylation of E-cadherin 
gene is a common finding in prostate cancer cell lines, and at low 
but detectable rate in clinical specimens of prostate cancer (Graf 
JR et al, 1995).
1.4 Pten  GENE.
1.4.1 Introduction
The region at chromosome 10q23-25 was postulated to contain a 
prostate cancer tumour suppressor gene. Enthusiasm for this 
hypothesis stems from work performed by the Imperial Cancer 
Research Fund, Clare Hall Laboratories (Gray IC et al, 1995). 
Using microsatellite dinucleotide triphosphate cytosine: Adenine 
(CA) repeat markers, the group constructed a detailed deletion 
map spanning chromosome 10q23-25 that incorporated Mxil, a 
candidate tumour suppressor gene which encodes a negative 
regulator of the Myc oncoprotein. Sixty-two percent (23 of 37) of 
the prostate tumour analysed exhibited some degree of loss in 
the region 10q23-25. Closer inspection of their data suggested 
the presence of a prostate tumour suppressor gene(s) near
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the10q23-24 boundary, which was deleted in the overwhelming 
majority (22 of 23) of tumours showing loss. This area of loss was 
narrowed down more specifically, to between markers 
AFMa124wd9 and D10S583, a region spanning approximately 
9cM. The study failed to show specific loss of Mxil gene.
Following this report by the Imperial Cancer Research Fund 
group, several groups isolated the putative tumour suppressor 
gene at chromosome 10q23 using different approaches.
One group (Li J et al, 1997) called it Pten because the gene 
product shares homology with a protein tyrosine phosphatase 
domain and extensive homology to tensin, a protein that interacts 
with actin filaments at focal adhesion complexes.
Another group (Steck PA et al, 1997) called it MMAC1 (Mutated in 
advanced cancers 1) as alterations to the 10q22-25 region has 
been reported in prostate, renal, small cell lung and endometrial 
carcinomas, melanoma and meningiomas, suggesting the 
existence of one or more tumour-suppressive loci affecting 
several cancers in this chromosomal region.
A third group called the gene TEP1 (Transforming growth factor (B 
regulated and Epithelial cell enriched Phosphatase 1) (Li D-M and 
Sun H. 1997).
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1.4.2 Pten /  MMAC 1 ITEP 1 a candidate tumour
suppressor gene.
A number of studies have investigated the frequency of Pten 
mutations in various cancers. Such studies reported that Pten 
was mutated/deleted in 44% (Wang SI et al, 1997) of 
glioblastomas; 43% (Cairns P et al, 1997) or 50% (mostly by loss 
of expression) (Whang YE et al, 1998) of prostate cancers; and 
50% in endometrial carcinomas (Tashiro H et al, 1997). Pten is 
also mutated in 80% of the autosomal dominant cancer 
predisposition disorders, Cowden disease (Liaw D. 1997, Marsh 
DJ 1998), Lhermitte-Duclos disease (Eng C. 1994) and 
Bannayan-Zonana syndrome (Bannayan G.A. 1971, Zonana J et 
al). Cowden disease is characterised by hamartomas of multiple 
organs including the lower gastrointestinal tract, breast, thyroid, 
central nervous system and hyperkeratosis of the skin. Lhermitte- 
Duclos disease is characterised by similar features, but also 
shows dysplastic gangliocytoma of the cerebellum that leads to 
altered gait, seizures and mental retardation. Bannayan-Zonana 
syndrome is characterised by hamartomatous polyps and multiple 
lipomas.
The tumour suppressor activity of Pten was demonstrated using 
adenoviral transfer of the Pten gene in glioma cells. This resulted 
in decreased proliferation, loss of anchorage-independent growth
75
in soft agar, and loss of tumourigenicity in mice in which the pten 
gene had been removed from both aleles (Cheney IW et al, 1998).
The generation of Pfen-null (neither alleles present) mice has 
given further evidence to support the role of Pten as a tumour 
suppressor. Di Cristofano et al reported that Pten null mice (-/-) 
were embryonic-lethal and that chimeric mice (Pten +/-) tended to 
develop a number of neoplasia spontaneously (Cristofano A et al, 
1998).
The study of Pten +/- mice revealed neoplastic growth in multiple 
organs, including endometrium, liver, prostate, gastrointestinal 
tract, thyroid, and thymus (Podyspanina K et al 1999). These 
results suggest a possible, causative role for Pten mutations in 
tumourigenesis, and are reminiscent of the results obtained from 
other known tumour suppressors, such as retinoblastoma gene 
product or p53, where mice with loss of these genes exhibit a 
marked increase in tumour susceptibility.
Patients with Cowden disease provided another line of genetic 
evidence to support the tumour suppressor role of Pten, where 
increased cancer susceptibility is correlated with germ line 
mutations of Pten (Liaw D 1997).
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1.4.3 Structure and function of Pten.
The Pten protein
The pten cDNA encodes 403-amino-acid peptides with a relative 
molecular mass of 47 KDaltons. Two major RNA transcripts of 
approximately 2 and 5kb were detected in a wide variety of cell 
lines (Li J et al, 1997),( Li DM and Sun H 1997). PTEN is a 
cytoplasmic protein as observed by immunoflurescence (Li DM 
and Sun H 1997).
The structure was investigated for common motifs, which would 
indicate possible activities of the protein. PTEN contain a motif 
C(x5) R that defines the protein tyrosine phosphatase (PTPase)  
supergene family. PTEN exhibits dual specificity protein 
phosphatase activity in vitro (Myers MP et al, 1997). PTEN has 
been shown to dephosphorylate the inositol lipid second 
messenger phosphatidylinositol-3-4-5-triphosphate (PIP3). 
Generation of PIP3 is an upstream event in signalling through the 
serine/threonine kinase AKT-1, a mediator of cell survival and 
anti-apoptopic signaling.
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Phosphoinositide is a component of signalling pathways that 
control critical cellular functions. Regulation of phosphoinositide 
levels is complex, requiring kinases, phosphatases and lipases to 
control biosynthesis and degradation of inositol lipids.
High levels of PIP3 are indirectly required to activate AKT-1 
(Figure 1.4), resulting in inhibition of apoptosis and allowing 
cellular proliferation (Wu X et al, 1998). PTEN dephosphorylates 
PIP3 to PIP2. The levels of PIP3 decrease, AKT-1 is not activated 
and proliferation is inhibited. When pten gene is inactivated or 
mutated, the levels of PTEN protein is reduced; PIP3 can build up 
and send out the signals for inhibition of apotosis, cellular 
proliferation resulting in tumourogenesis.
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PI (4 ,5 ) P2 Phosphatidylinositol-4-5-bisphosphate 
PI (3 ,4 ,5 )  P3 P hosphatidyli nositc)l-3-4-5-tri phosphate
growth factor
growth factor 
receptor
Pten
Akt-1 Pathway
Survival, Growth and inhibition of apoptosis
Figure 1.5 Substrate specificity of Pten.
Pten prevents the development of high 
intracellular concentrations of PIP3, which is 
required for the activation of AKT-1 pathway.
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1.4.4 Microsatellite markers
Microsatellites are tandem arrays of short stretches of nucleotide 
sequences, which were identified, by Litt M and Luty JA in 1989. 
They are usually repeated between 15 and 30 times in a gene 
(Braaten DC ef a/, 1988). They are also called simple sequence 
length polymorphisms (SSLPs) (Tautz D. 1989) and short tandem 
repeat polymorphisms (STRs) (Edwards A et al 1991). They 
belong to the family of repetitive non-coding DNA sequences, 
which can be classified as follows:
1. Satellite sequences: arrays with repeat sizes ranging from 
5 to 100 basepairs (bp) characteristically organised in a cluster 
up to 100 megabases (Mb). These are located in the 
heterochromatin near chromosomal centromeres and telemeres 
and are not as variable in size within populations as the other 
members of this family (Tyler-Smith C and Willard HF. 1993).
2. Minisatellites sequences: arrays with repeat sizes of 15 - 
70 bp, which range in size from 0.5 to 30 kilobases (kb). These 
are found in euchromatic regions of the gene and are highly 
variable in repeat size within populations (Armour JA and Jeffreys 
AJ, 1992).
3. Microsatellite sequences: arrays with a repeat size of 2 -  6 
bp. These are highly variable in size but ranging around a mean
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of 100bp and are found in the euchromatin (Tautz D and Renz M 
1984).
Microsatellites were initially identified in eukaryotic genomes as 
stretches of Thymine nucleotide = Guanine nucleotide (T=G)  
alternating sequence with varying length (Miestfield R et al, 
1981). Subsequent reports demonstrated the PCR typability of 
T=G, C=A dinucleotide repeat microsatellites and showed the 
Mendelian co-dominant inheritance of the size polymorphisms 
(Litt M and Luty JA 1989). In order of decreasing abundance, A, 
C=A, A=A=A=N, A=A=N and A=G nucleotide repeats were 
identified as the most frequent sequence motifs in human 
microsatellites (Beckman JS and Weber JL. 1992). Disregarding 
(A) n multimers, whose size polymorphisms are difficult to type by 
PCR, (C=A) n microsatellites are estimated to number between 
35 000 and 100 000 copies in the human genome, a marker 
density of approximately one microsatellite every 100 OOObp, 
even in the most conservative of estimates (Weber JL. 1990) 
(Beckman JS and Weber JL. 1992).
It must be noted that although widely distributed. Microsatellites 
are not uniformly spaced along chromosomes, being under 
represented in subtelomeric regions (Weissenbach J 1993).
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1.4.4.1 Origin and function of Microsatellite Sequences.
The origin and function of repetitive sequences is not clear at 
present. The initial occurrence of short repeat sequences could 
be due to chance (in a random sequence the probability of a 
(C=A)3 repeat is 1/256), or they could have arisen as mutations 
from the poly (A )n sequences (Beckman JS and Weber JL. 1992).
The selective prevalence of (C=A)n repeats may be explained by 
the methylation of Cytosine nucleotide residues at 5 'G=C3'  
sequences normally present in the genome. Methylated Cytosine 
nucleotide residues can be deaminated, producing a transition of 
Cytosine to Thymine. This process leads to an abundance of 
5'G=T3'  motifs and their complementary 5 'C=A3' motifs 
(Levinson G and Gutman GA 1987). Subsequently, the expansion 
of the repeat may occur due to strand slippage during DNA 
replication, creating length polymorphisms differing by a few 
repeats at a time. Additional sequence motifs may then arise by 
mutation of expanding C=A repeats (Schlotterer C et al, 1992).
It was originally thought that repeat sequences possessed a 
functional role in the genome, either directly via a role in gene 
regulation (Hamada H et al, 1984) or indirectly as hot spots for 
recombination (Slighton JL et al, 1980). To date no definite 
function can be ascribed to microsatellite sequences.
82
1.4.4.2 SINGLE NUCLEOTIDE POLYMORPHISMS (SNPs)
Single nucleotide polymorphisms (SNPs) are sites on the DNA 
sequences in which two or in some cases more than two bases 
can occur in different individuals. SNPs comprising some 80% of 
all known polymorphisms, and their density in the human genome 
are estimated to be on average 1 per 1,000 base pairs, however, 
their distribution is not uniform (Kwok PY et al 1996). SNPs have 
a low mutation rate per generation, making them the marker of 
choice in association studies, a commonly used technique for 
identifying polymorphisms with a role in a disease. In this design, 
the frequencies of the different alleles of a given polymorphism 
are compared in a control population and in prostate cancer 
group being investigated. If a significant difference in frequency 
is found then it is said that a positive association exists.
These SNPs are major contributors to genetic variation in the 
human genome (Kwok PY et al, 1996). These variations in SNPs 
may or may not be of functional significance, i.e. lead to a change 
in the structure or action of the protein coded for by that gene. 
This in turn may not have clinical significance. However, genes 
interact with other genes and also with their products, thus a 
polymorphism that on its own is of no significance may produce
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phenotypic changes in conjunction with other genes or 
environmental factors.
If a SNP is found within a small, unique segment of DNA, it 
serves both as a physical landmark and as a genetic marker 
whose transmission can be followed from parent to child. This 
property makes SNPs useful markers in population genetics and 
evolutionary studies (Hacia JG et al, 1999). Most SNPs are 
located in non-coding regions of the genome, and have no direct 
known impact on the phenotype of an individual.
There is an enormous interest in SNPs because it is hoped that 
they could be used as markers to identify genes that predispose 
individuals to common, multifactorial disorders by using linkage 
disequilibrium mapping (Risch N and Merikangas K 1996).
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2.5 Principles of polymerase chain reaction.
The polymerase chain reaction (PCR) is used to amplify a 
segment of DNA that lies between two regions of known 
sequence. The double-stranded DNA sample to be amplified, 
referred to as the template, is denatured by incubation at high 
temperature. The two strands, now dissociated, remain free in 
solution until the temperature is lowered sufficiently to allow them 
to reanneal. The primers are defined as the pair of synthetic 
oligonucleotides, which anneal to sites flanking the region to be 
amplified. These oligonucleotides typically have different 
sequences and are complementary to sequences that lie on 
opposite strands of the template. Thus they will only anneal to 
one of the strands. Primers are typically 15 to 30 nucleotides in 
length and have similar melting temperatures (where the melting 
temperature is the temperature at which the primer melts and 
therefore denatures; above this temperature the primer does not 
anneal and so disassociates from the template). The primer 
sequence is determined by the sequence of the DNA sample, at 
the boundaries of the region to be amplified. In the reaction the 
primers are present in large excess over the template as are the 
four deoxy-nucleotides triphosphate (dNTPs). When the 
temperature of the reaction mix is lowered, because of the excess 
of primers, the formation of primer-template complex is favoured 
over the reassociation of the two DNA strands. This is called the
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annealing step. After this annealing the primers are extended with 
a thermostable DNA polymerase. Such an enzyme adds on the 
appropriate dNTP guided by the sequence on the template. This 
step is called extension. It occurs in the 5 '—» 3' directions.
The typical set of three steps (i.e. denaturation, annealing and 
extension) is referred to as a cycle. A cycle is repeated many 
times, typically up to 30- 35. Because the product of one round of 
amplification serves as templates for the next, each successive 
cycle essentially doubles the amount of desired DNA product.
The major product of this exponential reaction is a segment of 
double -  stranded DNA whose termini are defined by the 5' 
termini of the oligonucleotide primers. This major product is 
termed the “short product”. In addition, longer DNA molecules are 
generated during the reaction. For example, the products of a 
successful first round of amplification are heterogeneously sized 
DNA molecules, whose lengths may exceed the distance between 
the binding sites of the two primers. In the second round, these 
molecules generate DNAs of defined length that will accumulate 
in an exponential fashion in later rounds of the reaction. Although 
longer molecules continue to be produced from the original 
template DNAs in every round, they accumulate only at a linear 
rate (as the original DNA template remains constant) and
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therefore do not contribute significantly to the final mass of target 
sequences.
Although extremely efficient, exponential amplication of target 
sequences is not an unlimited process. This is due to product 
annealing and limited enzyme concentration. If further 
amplification is required, a sample of the amplified DNA can be 
diluted and used as the template for further rounds of synthesis in 
a fresh polymerase chain reaction.
Taq DNA polymerase is isolated from a ubiquitous thermopilic 
bacterium, Thermus aquaticus. It is heat stable at high 
temperatures and can survive extended incubation at 95°C. It is 
not inactivated by the heat denaturation step and does not need 
to be replaced at every round of the amplification cycle. Another 
commonly used enzyme is Tub DNA polymerase.
AmpliTaq Gold DNA polymerase is the enzyme used for the PCR 
reactions in this thesis. It has a special feature in that it has an 
antibody connected to the enzyme’s active site, which is stable at 
lower temperatures and only becomes denatured at 95°C. This 
property prevents activation of the DNA polymerase enzymes 
whilst the double stranded DNA are still separating at lower 
temperatures.
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1.6 AIMS AND OBJECTIVES OF THE STUDY
Background
Following this brief review of aetiological agents implicated in the 
development of prostate cancer, it is clear that genetic factors 
are of great importance. However, the contribution of underlying 
genetic factors is less certain. It may be that different genetic 
aberrations are cumulatively responsible for promoting the 
pathway of pathogenesis of prostate cancer.
It is postulated that study of genetic mutations may shed some 
light on the pathogenesis of prostate cancer and provide markers 
to identify patients at risk of disease progression. The initial 
study performed by the Imperial Cancer Research Fund, Clare 
Hall Laboratories (Gray IC et al, 1995) postulated that the region 
at chromosome 10q23-25 contain a prostate cancer tumour 
suppressor gene. Several groups have narrowed the region 
containing the tumour suppressor gene, Pten to 10q23.3(Li J et 
al, 1997, Steck PA et al, 1997, Li D-M and Sun H. 1997).
Various techniques have been used to analyse the frequency of 
Pten mutation in prostate cancer. These techniques produced a 
wide range of results in the frequency of allele losses. The extent 
of the tumour suppressor activity of pten gene in prostate cancer
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is unknown. Hence the rationale for investigating the Pten gene in 
this thesis was to evaluate the magnitude and significance of LOH 
at Pten in prostate cancer DNA. This has led to the hypothesis 
expressed below, which formed the basis for this research 
project.
i. Prostate cancer DNA can be successfully extracted from 
paraffin embedded radical prostatectomy specimens. Experiments to 
extra pure cancer cell DNA in prostate cancer are often difficult. 
This is due to the large concentration of non cancerous DNA 
contained within stromal epithelial cells which may cause 
contamination of the DNA extraction process.
ii. Comparison of SNPs in the Pten gene in prostate cancer 
patients and non-prostate cancer patients will show a difference.
lii. Analysis of the frequency of LOH within Pten gene using 
microsatellite markers will illustrate a correlation in the frequency 
of mutation of the Pten gene and the different stages of prostate 
cancer disease progression.
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CHAPTER TWO
Polymorphisms in pten
90
2.1 Introduction
The aim of the first study is to compare the distribution of known 
polymorphisms in the region of chromosome 10q23 in prostate 
carcinoma patients with a non-prostate cancer group; and 
furthermore, to evaluate the significance of the distribution of 
polymorphisms in the prostate cancer patients in the study.
The population required for the study were selected based on 
strict criteria. DNA extracted from blood samples from both the 
prostate carcinoma patients and non-prostate cancer patients 
were subjected to analysis using three intronic polymorphisms 
within the Pten gene (Figure 2.1): a single-base A—>G substitution 
in intron A 96 bp upstream of exon 2; a 5-bp ATCTT insertion / 
deletion in intron D 110 bp downstream of exon 4 and a single­
base T —>G substitution in intron H 32 bp downstream of exon 8.
Association studies were then carried out between the prostate 
carcinoma patients and non-prostate cancer group using the three 
polymorphisms in the pten gene. Comparisions of the 
polymorphism distribution with PSA readings at the time of 
diagnosis and Gleason score of prostate cancer group were 
made.
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OF SIZE 40kb 25-30kb 5.5kb 1.9kb 18kb 5kb 3kb 5kb
POLYMORPHISM
A -G
substitution
ATCTT 
deletion /insertion
T->G
substitution
Figure 2.1 Intronic polymorphism variants
The position of the three polymorphisms analysed in 
Pten: a single-base A-*G substitution in intron A 96 
bp upstream of exon 2; a 5-bp ATCTT insertion / 
deletion in intron D 110 bp downstream of exon 4 and 
a single-base T—>G substitution in intron H 32 bp 
downstream of exon 8.
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2.2 Ethics
In 1990 Royal College of Physicians "guidance on the practice of 
ethical committees in medical research involving human subjects" 
which in paragraph 13.20 states "The anonymous use for 
research of tissues genuinely discarded in the course of medical 
treatment, for example discarded blood samples, pleural fluid or 
left over biopsy tissue, is a traditional and ethically acceptable 
practice that does not need consent from patients or relatives and 
need not be submitted to an ethics committee", see appendix 1.
A different ethical climate now exists since “Alder Hey". The rules 
were changed after the report on Alder Hey came out in January 
2001 .
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2.3 Case selection in SNPs study
2.3.1 Criteria for selection
The diagnosis of adenocarcinoma of the prostate was made on 
the basis of investigative procedures that included serum PSA, 
DRE, bone scans and histological evidence of the disease taken 
from TURP and TRUS and biopsies. The presence or absence of 
distant metastases did not affect inclusion in this study. Men 
under the age of 40 were excluded from the study group.
2.3.2 Selection of cases
The patients were recruited from The Royal Free Hospital. They 
included patients, newly diagnosed with prostate cancer and 
patients with prostate cancer on a follow up program.
The control group consist of patients in whom the diagnosis of 
adenocarcinoma of the prostate had been excluded following 
DRE, PSA testing and negative prostatic biopsies.
2.3.3 Collection of patient data in SNPs study
I interviewed each patient personally to discuss the proposed 
study with them and the possible implications to each individual. 
A verbal consent was obtained. The information requested from 
each patient is illustrated in appendix 2 and patients’ data sheet 
is illustrated in appendix 3.
94
2.3.4 Sample collection
Each patient had 3 millilitres of blood withdrawn into a plastic 
tube containing EDTA to prevent the blood sample from clotting. 
The sample was stored at 2-8°C for not more than five days to 
reduce DNA degradation.
The blood samples were obtained from patients attending the 
prostate labouratory at The Royal Free Hospital. The two groups 
were divided into patients diagnosed with prostate cancer and 
patients with no evidence of prostate cancer following 
investigations. An age-matched control group was used.
2.4 DNA extraction protocol
This consisted of extracting DNA from the blood sample, 
amplifying the segment of genome of interest by the PCR. In 
order to ensure the PCR had worked, the PCR product is run on 
an agarose gel containing ethidium bromide staining and 
visualised by ultraviolet excitation. The product is purified, 
sequenced using appropriate primers and run on an acrylamide 
gel to assess the three SNPs status of the subject.
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2.4.1 Preparation of genomic DNA
The DNA was extracted from lymphocytes separated from 
heparinized blood using Puregene™ DNA isolation kits.
Red cell lysis
Three millilitres of whole blood is added to a 15ml tube containing 
9mls RBC lysis solution. The tube is inverted to mix and incubate 
for 10 minutes at room temperature then centrifuged for 10 
minutes at 13 000 revolutions per minute (rpm). As a result of 
spinning a visible white cell pellet is formed in the bottom of the 
tube. The RBC lysis solution serves to disrupt the erythrocyte 
cell wall containing the non-nucleated red blood cells (lacking in 
genomic DNA) and separate them from white blood cells.
The supernatant, which consist of erythrocyte cell walls, 
haemoglobin, plasma and platelets, is removed leaving behind 
the visible white cell pellet and 100-200pl of residual liquid. The 
tube is vortex vigorously to resuspend the white blood cells in the 
residual supernatant; this greatly facilitates cell lysis.
Three millilitres of cell lysis solution is added to the tube 
containing the resuspended cells and pipetted up and down to 
break down the white blood cell walls and nuclear membranes, 
thus leaving the DNA accessible. Usually no incubation is 
required however if cell clumps are visible after mixing, the tubes 
were incubate at 37° C until the solution is homogeneous.
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RNAse treatment
Fifteen microlitre of RNase A solution is added to the cell lysate. 
The sample is mixed by inverting the tube 25 times and incubated 
at 37° C for 15 minutes. The Rnase A enzymes destroys the RNA 
released from the cell lysate and prevents the contamination of 
the DNA in solution.
Protein precipitation
The sample is cooled to room temperature. One millilitre of 
Protein precipitation solution is added to the cell lysate. The 
solution is vortexed vigorously at high speed for 20 seconds to 
mix the protein precipitation solution uniformly with the cell lysate 
and then centrifuged at 13 OOOrpm for 10 minutes. This step 
allows the cellular proteins to precipitate out to form a tight, dark 
brown pellet.
DNA precipitation
The supernatant containing the DNA (leaving behind the 
precipitate protein pellet) is poured into a clean 15ml tube 
containing 3 millilitres of 100% Isopropanol. The sample was 
inverted gently 50 times until the white threads of DNA form a 
visible clump. It is Centrifuged at 13 000 rpm for 3 minutes; the 
DNA is visible as a small pellet. The supernatant is poured off 
and the tube drained on clean absorbent paper. Three millilitre of
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70% ethanol is added. The tube is inverted several times to wash 
the DNA pellet and centrifuged at 13 000 rpm for 1 minute. The 
ethanol is carefully poured off whilst watching the pellet, as it 
may be loose. The tube is drained on clean absorbent paper and 
the pellet dried by placing the tube in an incubator at 37°C for 15 
minutes.
The final step is to resuspend the pellet of DNA in sterile water 
by adding 250pl of DNA hydration solution (250pl will give a 
concentration of 400pg/ml if the total yield is 100pg of DNA) and 
tapping periodically to help disperse DNA. This DNA is allowed to 
rehydrate overnight at 23°C and subsequently stored at 2-8°C.
Quantification of DNA by spectrophotometer
The DNA present in 250pl of hydration solution is diluted with 
sterile water by a ratio 1 in 100 dilution. This step is essential to 
improve the accuracy of the spectrophotometer reading, which 
would encounter diffulty if the solution contained high 
concentration of DNA. The DNA is examined between wavelength 
260nm (Optical Density OD2 6 0 ) and 280nm (OD2 8 0 ).
Absorbant A260 = A260 X Dilutional factor X 50 X 1000 = mg/ml 
UV light (1:100)
PCR works best with 30-50 ng of genomic DNA. Therefore further 
dilution of the working stock was performed.
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2.4.2 PCR amplification of SNPs region.
In order to analyse the region containing the polymorphisms, 
known Pten intronic sequence oligonucleotide primers were 
required to PCR amplify these area of interest. These 
oligonucleotide primers (Table 2.1) were formulated based on the 
Pten sequence described by Gary IC et al (1998) and were 
synthesised and supplied by The Imperial Cancer Research Fund, 
Clare Hall Laboratories.
Primers Oligo
nucleotide
primers
Sequence of primers
Amplifies
segment
A 81167
84305
5 - TACGGTAAGCCAAAAAATGA 3’ 
5’- TACGGTAAGCCAAAAAATGA 3’
upstream 
exon 2
B 84314
84315
5 - GGGGGTGATAACATTATCTA 3’ 
5 - CTTTATGCAATACI I I ICCTA 3’
Downstream 
exon 4.
C 71429
81694
5 - AACAGATAACTCAGATTGCC 3’ 
5’ CGTAAACACTGCTTCGAAATA3’
Downstream 
exon 8
Table2.1: Sequence of oligonucleotide primers.
The sequence of oligonucleotide primers runs from 5 ’—> 3 ’ end 
and is used to amplify the region containing the polymorphisms.
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The volumes and concentrations of reagents used for the 
amplification of genormic DNA in the PCR is illustrated below:
PCR solutions
10 X PCR Buffer (10pl) 2.5
dNTPs (2mMoles.) 2.5
Oligonucleotide primer 1 (10pM) 1.25
Oligonucleotide primer 2 (10pM) 1.25
DNA template (working stock) 2.0
Taq Polymerase (5pl) 0.25
Sterile distilled water 16.25
Volume per PCR reaction 25ul
Experimental procedure: -
Place the requisite numbers of reaction tubes in a tray. For 
example, if there were 20 DNA samples to be amplified, then 20 
reaction tubes need to be set up. Place the reagents stated above 
into a 0.2ml reaction tube together with the DNA extract to be 
amplified. Place caps over the tubes and assemble them into the 
sample block of PCR machine.
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The PCR machine was programmed to carry out the following 
cycles automatically.
PCR Settings
Temperature (°C) 
96 
95 
55 
72 
72
Time (Minutes)
4.00 
0.30 
0.15
1.00 
5.00
Repeat 30X
oo
The samples were initially denatured at 96°C for 4 minutes, then 
subjected to 30 cycles of 30 seconds denaturising at 95° C, 15 
seconds annealing at 55° C and polymerisation at 72° C for I 
minute allowing for extension at 1 Kb per minute. There is a final 
step of extension at 72° C for 5 minutes to ensure completion of 
all amplification events. The PCR product is then cooled to 4° C.
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Separation of PCR product by electrophoresis.
This step is to check whether the PCR was successful and free of 
contamination. 2% Agarose was used as the support matrix for 
enabling the PCR product to be separated under the influence of 
an electrical current. A small pore gel results when agarose 
undergoes change from a liquid to a solid form. Smaller PCR 
fragments will travel further down the gel in a given time; thus
fragments of differing sizes will be separated.
Gel constituents used
2%Agarose 3grams
0.5 TBE (Triss, Borate, EDTA) 150mls
Ethidium bromide 3.5pl
Ethidium bromide is known to contain a planar group that
intercalates between the stacked bases of DNA. The fixed
position of this group and its close proximity to the bases causes 
dye bound to DNA to display an increased fluorescent yield 
compared to dye in free solution. Ultraviolet irradiation absorbed 
by the DNA at 260nm and transmitted to the dye, or irradiation 
absorbed at 300nm and 360nm by the bound dye itself, is emitted 
at 590 nm in the red/orange region of the visible spectrum.
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Each electrophoresis gel had a standard marker in the first lane. 
On electrophoresis this marker separated into fragments of known 
molecular weight. Thus by using this as a comparison one could 
estimate the sample fragment sizes. The first electrophoresis well 
contains standard molecular weight marker of known size. 
TheOX174 DNA IHae  III Marker was used. They are made by 
digesting double stranded 0 X 1 74  DNA to completion with Hae III.
Experimental procedure
Mix the 2% agarose gel constituents thoroughly in a glass beaker. 
Heat the glass beaker in a standard domestic microwave, at high 
power for 5 minutes. Allow the beaker to cool by leaving it 
standing for 2 minutes. Add 3.5pl of ethidium bromide into 150ml 
of 0.5 X TBE solution and allow bottle to cool for further 
5minutes. Whilst still in the liquid form, pour the solution into 
perspex receptacle containing two 24 toothed plastic comb. When 
the liquid set, remove the comb forming two 24 wells.
Mix 4pl PCR product with 2pl of loading buffer (Orange G and 
30% Glycerol) and pipet into each well. Pour 0.5 x TBE Into the 
reservoirs on the assembly to cover the electrodes. Connect the 
assembly to a power supply and run the gel at 250 volts for 
20minutes. Inspect the gel under ultraviolet light wearing UV safe 
goggles. A Polaroid picture was taken of the illuminated gel in 
order to provide a permanent record (Fig 2.2).
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Figure 2.2: Separation of PCR product by electrophoresis.
Lane one labelled M contains the<t>X174 DNA/Hae III marker that 
separates into fragments of known size and molecular weight. 
This allows for the PCR product fragment size to be estimated 
and assessed for contaminants. Nine DNA samples were 
examined on this gel. Primers A, B&C amplifies the region 
containing the single-base A-+G substitut ion, the 5-bp ATCTT 
insertion / deletion and the single-base T—»G substitution 
respectively. If the PCR product was contaminated, they would 
separate out at different molecular weight.
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2.4.3 Purification of PCR product
The PCR product is contaminated with unwanted primers and 
impurities such as salts, enzymes and unincorporated dNTPs. It 
is essential that the product be purified for good DNA sequence 
to be obtained. The QIAquick PCR purification protocol is 
designed to purify PCR products by removing unwanted 
contaminants using QIAquick spin columns in a microcentrifuge.
The QIAquick system combines the convenience of spin-column 
technology with the selective binding properties of a uniquely 
designed silica-gel membrane. Special buffers listed below are 
optimised for efficient recovery of DNA and removal of 
contaminants in each specific application. DNA absorbs to the 
silica membrane in the presence of high salt while contaminants 
pass through the column. Impurities are efficiently washed away, 
and the pure DNA is eluted with distilled water. Adsorption of 
DNA to silica membrane depends on pH. Adsorption is typically 
95% if the pH is < 7.5, and it reduced drastically at higher pH.
Buffer PB allows the efficient binding of PCR product as small as 
100bp and quantitative (99.5%) removal of primers up to 40 
nucleotides. It is therefore used to remove oligonucleotide 
primers after cDNA synthesis or to remove unwanted linkers in 
cloning experiments.
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During the DNA adsorption step, unwanted primers and impurities 
such as salts, enzymes, and unincorporated dNTPs do not bind to 
the silica membrane, but flow through the column. Salts are 
washed away by the ethanol containing Buffer PE. Any residual 
Buffer PE, which may interfere with subsequent enzymatic 
reactions, is removed by an additional centrifugation step.
Experimental procedure: -
Centrifuge steps are at >10, 000 x g (= 13,000 rpm) in a 
conventional domestic tabletop microcentrifuge.
Add 125mls of Buffer PB to 25pl of PCR product. Place the 
QIAquick spin column into a 2 ml collection tube.
To bind DNA, apply the sample to the QIAquick column and 
centrifuge for 60 seconds. Discard the flow through. Place the 
QIAquick column back in the same tube. To wash, add 0.75mls of 
Buffer P.E to the QIAquick column and centrifuge for 60seconds. 
Again, discard the flow through. Return the QIAquick column to 
the same tube and centrifuge for an additional one minute at 
maximum speed. Place the QIAquick column in a clean 1.5ml 
microfuge tube. To elute DNA, add 30pl Buffer E.B to the centre 
of the QIAquick column and allowed to stand for one minute then 
centrifuged for one minute leaving an elution of bound DNA.
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2.4.4 DNA sequence reaction
The purified PCR product is added to set primers (Table 2.2) and 
ABI PRISM™ dRhodamine terminator cycle sequencing ready 
reaction mix in order to incorporate florescence dNTPs. The 
reaction mix combines the unique properties of AmpliTaq® DNA 
polymerase, FS and new dRhodamine dye terminators with 
convenience of the ready reaction mix.
In this format, the dye terminators, dNTPs, enzymes, magnesium 
chloride, and buffer are premixed into a single tube of Ready 
Reaction Mix and are ready to use. These reagents are suitable 
for performing florescence-based cycle sequencing reactions on 
single or double stranded DNA templates or PCR fragments.
The sequencing enzyme AmpliTaq® DNA polymerase is a variant 
of Thermus acquaticus DNA polymerase that contains a point 
mutation in the active site. This results in less discrimination 
against deoxynucleotides, which leads to a greater peak intensity.
This enzyme has a second mutation in the amino terminal domain 
that virtually eliminates the 5 '-» 3' nuclease activity of AmpliTaq 
DNA polymerase. The enzyme has been formulated with a 
thermally stable inorganic pyrophosphate to eliminate problems 
associated with pyrophosphorolysis.
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Primers Primers
Numbers
DNA Sequence of primers
A 81167 5 ’- CCATGTGGAAGTTATTTTTTA - 3 ’
B 84314 5 ’- GGGGGTGATAACAGTATCTA - 3 ’
C 81819 5 ’- GGGTAAATACATTCTTCATACCAGG - 3 ’
Table 2.2: Sequence of primers used for sequence reaction
The sequence of oligonucleotide primers runs from 5 ’—► 3’ end.
The volumes and concentrations of reagents used in the PCR to 
incorporate florescence dNTPs is illustrated below:
Ml
9.0
8.0 
3.0
20.0 pi
The PCR machine is programmed to carry out the following cycles 
automatically.
Temperature (°C)
96 
96 
50 
60
4
Time (Minutes)
4.0 
0.10
0.05 Repeat cycles 25 X
4.00
00
Solution used: -
PCR Product
dRhodamine terminator 
ready reaction mix
Primers A 
Primers B 
Primers C 
Total volume
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2.4.5 Purification of Extension Products
This step is incorporated to remove excess dye terminators by a 
process called ethanol precipitation.
Experimental procedure: -
Add 2pl of 3M Sodium acetate (PH 5) and 40pl of 95% ethanol to 
the extension products present in the 0.2ml microcentrifuge tube 
Mix the solution thoroughly and allow it to sit at room temperature 
for 10 minutes.
Placed tubes in a microcentrifuge at 4°C for 30 minutes at 13,000 
rpm. Remove and discard the supernatant carefully. Add 
100pl of 70% ethanol and centrifuge at 13, 000 rpm for 5 minutes. 
Aspirate the ethanol leaving the DNA extention product as a 
pellet. The pellet is dried in a SpeedVac vaccum centrifuge.
As a result of this ethanol precipitation, traces of incorporated 
terminators may be seen at the beginning of the sequence data 
(up to base 40), but this is usually minimal.
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2.4.6 Analysis of extension products on a sequencer
The next stage is to run the extension products on a sequencer to 
obtain a reading of the nucleotides in order to establish the 
polymorphisms present within the amplified region.
4pl of sequence dye (blue) is added to the dried DNA pellet and 
heated at 95°C for 2 minutes then placed on ice.
Acrylamide is used as the support matrix for enabling the 
oligonucleotide to be separated under the influence of an 
electrical current. A small pore gel results when acrylamide 
undergoes change from a liquid to a solid form. Polymerisation of 
the acrylamide is accomplished by adding ammonium persulphate 
(APS) and N, N, N', N' -  tetramethylethylenediamine or TEMED.
The constituents required for the acrylamide gel are listed below 
with each gel able to support and analyse 32 samples.
Solution used: -
4.2% Acrylamide 
10% APS 
TEMED
50ml
250pl
35pl
Experimental procedure:-
Clean the gel plates thoroughly with10% alconox then rinse twice 
with double distilled water. This ensured the plates are clean and 
reduced interference when the sequences are analysed.
Mix the acrylamide gel constituents together and pour between 
the two glass plates separated by a small gap and standing in a 
gel assembly kit. When pouring the gel mixture ensure there are 
no air bubbles as this causes interference when the DNA 
sequence are being analysed. Place an inverted 30-toothed comb 
between the top ends of the plate. When the liquid sets as a gel 
(a process which takes 11/4hours) remove the comb and orientate 
correctly to form 36 wells for the DNA to be placed.
Mount the gel assembly kit onto the Perkin-Elmer ABI Prism 377 
DNA Sequencer. Pour a sufficient amount of 0.5 X TBE into the 
reservoirs to ensure the electrodes and wells are covered. 
Connect the assembly kit to a power supply and pre-run at 48°C. 
for 10minutes. Load the samples into alternate wells and run the 
gel for 2 minutes and pause the sequencer. Load the remainder 
of the wells and allow the gel to run at 950 voltages overnight.
112
2.4.7 Multicomponent analysis of SNP’s results
Multicomponent analysis is the process that separates the four 
different florescent dye colours into distinct spectral components. 
The four dyes used in the sequencing ready reaction kit are 
dR110, dR6G, dTAMRA and dROX.
Each of these fluorescent dyes emits its maximum fluorescence 
at a different wavelength. During data collection on the ABI Prism 
377 instruments, the collection software collects light intensities 
from four specific areas on the CCD camera, each area 
corresponding to the emission wavelength of a particular 
fluorescent dye. Each of these areas on the CCD camera is 
referred to as a “virtual” filter, since no physical filtering hardware 
(like band-pass glass filters) is used. The information that 
specifies the appropriate virtual filter settings for a particular set 
of fluorescent dyes is contained in each appropriate ABI Prism 
collection module file.
In the dRhodamine dyes, dRMO emits the shortest wavelength and 
is detected as black, followed by dR6G (green), dTAMRA (blue) 
and dROX (red) (Table 2.3). Although each of these dyes emits 
its maximum florescence at a different wavelength, there is some 
overlap in the emission spectra between the four dyes. The goal 
of multicomponent analysis is to isolate the signal from each dye 
so that there is as little noise in the data as possible.
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Terminator Dye Label Colour of Raw Data on 
ABI PRISM 377 Gel 
image
A Dichlor [R6G] Green
C Dichlor [TAMRA] Blue
G Dichlor [R110] Black
T Dichlor [ROX] Red
Table 2.3: The (dRhodamine) dye terminators.
The colour each dye labels emits.
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The precise spectral overlap between the four dyes is measured 
by running DNA fragments labelled with each of the dyes in 
separate lanes of a gel. These dye-labelled DNA fragments are 
called matrix standard samples. The instrument file contains 
tables of numbers with four columns and four rows. These 
numbers are normalised fluorescence intensities and represent a 
mathematical description of the spectral overlap that is observed 
between the four dyes.
Multicomponent analysis of sequencing data is performed 
automatically by the sequencing Analysis software, which applies 
a mathematical matrix calculation (using the values in the 
instrument file) to all sample data.
The sample data are interpreted using the sequencing analysis 
software. The three intronic polymorphism markers within the 
Pten gene was analysed: a single-base A—»G substitution in 
intron A 96 bp upstream of exon 2(Figure 2.3); a 5-bp ATCTT  
insertion / deletion in intron D 110 bp downstream of exon 
4(Figure 2.4) and a single-base T —>G substitution in intron H 32 
bp downstream of exon 8(Figure 2.5).
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Figure 2.3: Polymorphism in Pten intron A
A single-base A—>G substitution in intron A is noted by the 
position of the downward arrows. The colours represent 
nucleotide bases. Green=A, Black=G, Blue=C and Red =T and the 
sequence is show above the trace. The numbers seen above the 
trace are of no signiicance and vary for every sequence analysed 
by the software.
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Figure 2.4: Polymorphism in Pten intron D
A 5-bp ATCTT insertion / deletion in intron D 110 bp downstream 
of exon 4. The colours represent nucleotide bases. Green=A, 
Black=G, Blue=C and Red =T and the sequence is show above 
the trace. The numbers seen above the trace are of no 
signiicance and vary for every sequence analysed by the 
software.
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Figure 2.5: Polymorphism in Pten intron H
A single-base T—»G substitution in intron H 32 bp downstream of 
exon 8. The colours represent nucleotide bases. Green=A, 
Black=G, Blue=C and Red =T and the sequence is show above 
the trace. The numbers seen above the trace are of no 
signiicance and vary for every sequence analysed by the 
software.
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2.5 Statistical Analysis
Mann-Whitney U test, Chi squared test and Fisher’s exact test 
from the statistical package for social science (SPSS) software 
version 11 were used to determine the statistical significance of 
any associatons between the molecular and clinical data, and 
within the molecular data.
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CHAPTER THREE
Results and discussions on polymorphism 
study on the Pten  gene
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3.1 Results of analysis of polymorphisms in Pten.
3.1.1 Analysis of study population
A total of 138 blood specimens were studied. Ninety-five of these 
blood samples were obtained from patients with prostate cancer 
and fourty three blood samples were from patients with no clinical 
evidence of prostate cancer following investigations. These acted 
as the source for the control arm of the study. The sequencing 
analysis software in the ABI Prism 377 DNA sequencer performed 
analysis of all the samples data automatically.
The age range of patients with adenocarcinoma of the prostate in 
the study was 46 -  90 years with a mean age of 70.36years. The 
age range of the control arm of the study was 40 -  91 years with 
a mean age of 68.47years.
The PSA at the time of diagnosis for the prostate cancer group 
ranged from 2 -  425.0pg/l with a mean of 28.4pg/l. The prostate 
cancer group had a mean Gleason score of 6 with a range of 2 -  
10. The PSA at the time of diagnosis for the control group ranged 
from 0.3 -  22.8pg/l with a mean of 6pg/l. The comparison in PSA, 
at the time of diagnosis for the cancer group compared to the 
control groups was statistically significant (p<0.05) using Mann- 
Whitney U test.
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3.1.2 Polymorphisms distribution in study population
The distribution of the three polymorphisms studied and the 
clinical data for each patient is illustrated in Table 3.1.
Table 3:1 Results of polymorphisms
Clinical data for each patient and the position of the three 
polymorphisms analysed in Pten: a single-base A—>G substitution 
in intron 2; a 5-bp ATCTT insertion / deletion (+/-) in intron 4 and 
a single-base T —>G substitution in intron 8.
ID number 133—>137 are missing due to initial numbering error 
whilst collecting samples from the patients.
ID-
num
Pre
op
PSA
Post
op
PSA
Diag
nosi
s
Glea
son
Score
TNM
Stage
A to G 
sub 
intron 2
ATCTT 
Ins/del 
intron 4
T to G 
Sub 
intron 8
1 50 3 CA 6 pT1 c A/G +/- G/T
2 • 4.3 0.2 CA 6 pT1 b A/A -/- T/T
3 1.7 0.1 CA 3 pT1 b A/G +/- G/T
4 1 1.4 CA 3 pT1 a A/G +/- G/T
5 6 0.1 CA 5 pT2a A/A -/- T/T
6 5 0.1 CA 5 pT2b A/G +/- G/T
7 31 3.7 CA 7 pT1c A/G +/- G/T
8 33 0.2 CA 7 pT3a A/G +/- G/T
9 8.4 13.9 CA 6 pT1c A/G +/- G/T
10 4.2 0.2 CA 3 pT1 c A/G +/- G/T
11 0.2 0.2 CA 4 pT1 c A/A -/- T/T
12 4.4 10 CA 7 pT1c A/G +/- G/T
13 27 2 CA 8 pT1c G/G +/+ G/G
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14 5.1 11.3 CA 4 pT1 c A/G +/- G/T
15 13 0.2 CA 2 pT1c A/A -/- T/T
16 82 0.2 CA 7 pT1c A/G +/- G/T
17 22.8 12.5 BPH NA NA A/G +/- G/T
18 4.1 2 BPH NA NA A/G +/- G/T
19 3.2 2 BPH NA NA A/G +/- G/T
20 10.5 0.2 CA 7 pT3a A/G +/- G/T
21 26.6 2.2 CA 7 pT1c A/G +/- G/T
22 425. 30.5 CA 6 pT1 c A/G +/- G/T
23 17.5 21.1 CA 6 pT1 a A/A -/- T/T
24 13 0.2 CA 8 pT2b A/G +/- G/T
25 4.5 4.4 BPH NA NA A/A -/- T/T
26 5.4 0.8 CA 5 pT1 c A/G +/- G/T
27 12.1 3.4 BPH NA NA A/G +/- G/T
28 40 3.3 CA 7 pT1 c A/G +/- G/T
29 10.2 0.2 CA 6 pT2b A/G +/- G/T
30 35.6 1.7 CA 5 pT1c A/A -/- T/T
31 17.8 11.5 BPH NA NA A/G +/- G/T
32 1.6 0.2 CA 4 pT1c G/G +/+ G/G
33 10.8 10.2 BPH NA NA A/G +/- G/T
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34 8.4 8.4 BPH NA NA A/G +/- G/T
35 8 38 CA 7 p H  c A/G +/- G/T
36 4.5 2.3 BPH NA NA A/A -/- T/T
37 26 177 CA 10 pT1a G/G +/+ G/G
38 8.3 6.1 BPH NA NA G/G +/+ G/G
39 7.1 5.1 BPH NA NA A/A -/- T/T
40 6 0.2 CA 7 pT3a G/G +/+ G/G
41 10.4 4.5 BPH NA NA A/A -/- T/T
42 10.9 0.6 CA 4 pT1 c A/A -/- T/T
43 16.9 0.5 CA 6 pT1 c G/G +/+ G/G
44 7.6 6.2 BPH NA NA A/G +/- G/T
45 8.6 0.6 CA 8 pT1 c A/G +/- G/T
46 9.9 0.2 CA 5 pT2a A/G +/- G/T
47 203 4 CA 6 pT1b A/G +/- G/T
48 34.2 0.1 CA 6 pT1a A/G +/- G/T
49 19.3 9.4 BPH NA NA A/A -/- T/T
50 186 7.1 CA 5 pT1c A/A -/- T/T
51 16.1 13.9 CA 7 pT1c A/A -/- T/T
52 14.2 0.2 CA 7 pT3a A/G +/- G/T
53 4.4 4.3 BPH NA NA A/G +/- G/T
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54 13 0.7 CA 7 pT3a A/A -/- T/T
55 16 0.2 CA 6 pT2a A/A -/- T/T
56 5 0.2 CA 7 pT3a A/A -/- T/T
57 30 0.4 CA 6 pT2b G/G +/+ G/G
58 4.3 3.9 BPH NA NA A/G +/- G/T
59 31.6 2.7 CA 3 pT3a A/G +/- G/T
60 7.5 2 BPH NA NA A/A -/- T/T
61 4.3 1.8 BPH NA NA A/A -/- T/T
62 4.1 3.9 BPH NA NA A/G +/- G/T
63 3.9 2.9 BPH NA NA G/G +/+ G/G
64 4.8 1.4 BPH NA NA A/G +/- G/T
65 5.2 4.8 BPH NA NA A/G +/- G/T
66 6 0.2 CA 4 pT3a G/G +/+ G/G
67 15.7 13.8 CA 7 pT1c G/G +/+ G/G
68 5.5 3.2 BPH NA NA A/G +/- G/T
69 5.1 4.2 BPH NA NA A/A -/- T/T
70 4.9 3.0 BPH NA NA A/G +/- G/T
71 20 0.2 CA 8 pT2a A/A -/- T/T
72 3.3 1.3 BPH NA NA A/A -/- T/T
73 8 0.2 CA 6 pT3a G/G +/+ G/G
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74 6.2 0.5 CA 4 pT1c A/G +/- G/T
75 8 0.1 CA 7 pT2b A/A -/- T/T
76 0.2 0.5 CA 3 pT1a A/A -/- T/T
77 25 0.7 CA 8 pT1 b A/A -/- T/T
78 6.2 0.2 CA 6 pT3a G/G +/+ G/G
79 4.7 4.4 BPH NA NA A/A -/- T/T
80 12.6 0.5 CA 5 pT1a A/A -/- T/T
81 5 0.1 CA 5 pT3a A/G +/- G/T
82 5.2 0.3 CA 7 pT1 b A/G +/- G/T
83 9.2 7.1 CA 9 pT1 c A/A -/- T/T
84 32 23 CA 7 pT1 c A/A -/- T/T
85 48 13 CA 8 pT1a G/G +/+ G/G
86 26 0.8 CA 5 pT2b A/G +/- G/T
87 28 0.2 CA 7 pT3a A/G +/- G/T
88 32 0.2 CA 5 pT3a A/G +/- G/T
89 3.7 3.7 BPH NA NA G/G +/- G/G
90 24.4 0.2 CA 7 pT3a A/G +/- G/T
91 11.8 0.2 CA 6 pT3a A/G +/- G/T
92 8.6 0.6 CA 4 pT1 c A/G +/- G/T
93 6 0.2 CA 7 pT2b A/G +/- G/T
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94 9 0.2 CA 9 pT2b A/A -/- T/T
95 6.1 0.2 CA 6 pT2a A/G +/- G/T
96 10 0.8 CA 8 pT2a A/A -/- T/T
97 17.5 0.2 CA 6 pT2b A/A -/- T/T
98 2.1 1.2 BPH NA NA A/A -/- T/T
99 59 110 CA 7 pT1 b A/A -/- T/T
100 6.7 2.2 BPH NA NA A/G +/- G/T
101 4.3 0.2 CA 6 pT2b A/A -/- T/T
102 6.4 0.4 CA 8 pT2a A/G +/- G/T
103 9 0.2 CA 5 pT3a G/G +/+ G/G
104 6.1 0.1 CA 6 pT3a G/G +/+ G/G
105 5 0.2 CA 4 pT2b A/G +/- G/T
106 5.2 0.2 CA 6 pT2a A/A -/- T/T
107 72 0.2 CA 9 pT1 b A/A -/- T/T
108 4.2 2.1 BPH NA NA A/G +/- G/T
109 4.2 4.2 BPH NA NA A/G +/- G/T
110 14.8 8.5 BPH NA NA A/G +/- G/T
111 10.9 44.8 CA 7 pT1 c A/G +/- G/T
112 4.5 2.9 CA 6 pT1 c A/G +/- G/T
113 4.9 4.2 BPH NA NA A/A -/- T/T
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114 18 0.2 CA 6 pT2a G/G +/+ G/G
115 2.2 0.2 CA 6 pT3a A/A -/- T/T
116 210 0.2 CA 5 pT2b A/G +/- G/T
117 39 0.5 CA 6 pT3a A/G +/- G/T
118 6 0.2 CA 7 pT2b A/G +/- G/T
119 8.9 3.6 BPH NA NA A/A -/- G/G
120 5 3 CA 6 pT2a A/G +/- G/T
121 4.3 0.2 BPH NA NA A/A -/- T/T
122 4.1 3.1 BPH NA NA A/A -/- T/T
123 1 0.2 CA 2 pT1 a A/A -/- T/T
124 3.9 4.4 BPH NA NA A/G +/- G/T
125 4.8 1.9 BPH NA NA A/G +/- G/T
126 17.4 0.3 CA 6 pT1c A/G +/- G/T
127 10 0.2 CA 6 pT2a A/A -/- T/T
128 252 0.2 CA 5 pT3a A/G +/- G/T
129 12.6 0.5 CA 6 pT2a A/A -/- T/T
130 5.9 0.2 CA 5 pT2a A/A -/- T/T
131 6.7 0.3 CA 6 pT2b G/G +/+ G/G
132 13.5 2.2 CA 7 pT2b A/A -/- T/T
138 4.6 5.6 BPH NA NA A/A -/- T/T
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141 12.2 0.2 CA 9 pT3a A/A -/- T/T
142 6.1 4.2 BPH NA NA A/A -/- T/T
143 11.1 7.9 CA 7 pT2a G/G +/+ G/G
144 5.4 4.2 BPH NA NA A/G +/- G/T
145 6.8 3.2 BPH NA NA A/A -/- T/T
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3.1.3 Comparison of the polymorphisms in the BPH
group with the prostate cancer group.
Analysis of the distribution of the polymorphisms at each intron in 
the prostate cancer group was compared to that of the BPH group 
(Figure 3.1; 3.2 and 3.3). At intron 2 the Adenine nucleotide (A) 
substitution for Guanine nucleotide (G) was analysed. Of the 138 
samples studied, fivety one were homozygous A/A (33 cancer: 18 
BPH), nineteen homozygous G/G (15 cancer: 4 BPH) and sixty- 
eight heterozygous A/G (47cancer: 21 BPH).
The insertion or deletion of the polymorphic nucleotide sequence 
ATCTT at intron 4 was analysed. Homozygous insertion of the 
sequence ATCTT (+/+) was detected in 19 of 138 samples 
(15cancer: 4 BPH), 51 of 138 samples were homozygous deletion 
for the sequence ATCTT (-/-)(33 cancer: 18 BPH) and 68 of 138 
samples were heterozygous insertion / deletion (+/-) with a 
distribution of 47cancer and 21BPH.
At intron 8 the Guanine nucleotide (G) substitution for Thymine 
nucleotide (T) was analysed. Of the 138 samples studied, sixty 
eight were heterozygous G/T (47cancer: 21 BPH). Fivety one 
were homozygous T/T (33 cancer: 18 BPH) and nineteen were 
homozygous G/G (15 cancer: 4 BPH).
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Figure 3 .1 :Distribution of Adenine nucleotide (A) substitution 
for Guanine nucleotide (G) polymorphism in intron 
2 with the Pten gene.
A/A and G/G i l lustrate homozygous and A/G il lustrates 
heterozygous at that polymorphic site.
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Figure 3.2: Distribution of ATCTT insertion or deletion
polymorphism in intron4 within the Pten gene
(+)=insertion, (-) =deletion, +/+ & -/- illustrates 
homozygous and +/- illustrates heterozygous at 
that polymorphic site.
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Figure 3 .3:Distribution of Guanine nucleotide (G) substitution 
for Thymine nucleotide (T) polymorphism in intron 
8 within the Pten gene.
G/G and T/T i l lustrate homozygous and G/T il lustrates 
heterozygous at that polymorphic site.
□ BPH
□ Cancer
G/G G/T T/T 
G to T Polymorphisms
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These results showed no greater frequency of occurance of a 
specific polymorphism in either the prostate cancer or BPH 
population (p=0.518).  However, linkage between the three 
haplotypes investigated was demonstrated. If intron 2 is found to 
be homozygous A/A, then intron 4 will also have homozygous 
deletion for ATCTT and homozygous T/T at intron 8. The other 
linkage demonstrated was homozygous G/G +/+ G/G and 
heterozygous A/G +/- G/T.
On the assumption that the three intronic polymorphisms within 
the pten gene were linked genetically, analysis of this distribution 
was performed (Table 3.2). It did not show any significant 
difference (p=0.518) in the distribution of the polymorphism 
linkage in either the cancer or BPH population.
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POLYMORPHISMS DIAGNOSIS TOTAL
LINKAGE BPH CANCER
HETEROZYGOUS 21 47 68
(A/G +/- G/T) 30.9% 69.1%
HOMOZYGOUS 18 33 51
(A/A - / -  T/T) 35.3% 64.7%
HOMOZYGOUS 4 15 19
(G/G +/+ G/G) 21.1% 78.9%
TOTAL 43 95 138
Table 3.2: Distribution of the three linked haplotypes
Using Pearson Chi-Square test, there was no 
statistical difference in the distribution 
(p=0.518).
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3.1.4 Correlation of SNPs with Gleason score.
At intron 2 the correlation between each polymorphism and the 
Gleason score was analysed to assess wheather a particular 
polymorphism was related to more aggressive disease using 
Mann-Whitney test. On observation of the graph (Figure 3.4), the 
polymorphism G/G appears to correspond with higher-grade 
disease. However, statistical analysis failed to show a significant 
difference when the G/G was compared to the A/A (p=0.394) and 
a trend towards significance when the G/G was compared to the 
polymorphism A/G (p=0.105).
At intron 4 the homozygous insertion of ATCTT/ATCTT (+/+)  
appears to correspond with higher-grade disease (Figure 3.5). 
Statistical analysis did not show a significant difference when 
compared to the homozygous deletion -/- (p=0.394) but showed a 
trend towards significance when the homozygous insertion of 
ATCTT/ATCTT (+/+) was compared to the heterozygous 
insertion/deletion of ATCTT (+/-) (p=0.105).
Observation of the analysis at intron 8 (Figure 3.6) shows that the 
polymorphism G/G was associated with more aggressive prostate 
disease but comparisons with the polymorphism G/G showed no 
statistical clinical significance (p=0.394), however, comparison of
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the polymorphism G/G with the polymorphism G/T showed a trend 
towards significance (p=0.105).
Based on the assumption that the three intronic polymorphisms 
within the Pten gene were linked genetically, analysis of the 
correlation of these polymorphisms with the Gleason score was 
compared (Figure 3.7). Patients who were homozygous G+G 
appear to have a tendency of having a higher Gleason score 
within their prostate adenocarcinoma compared to patients who 
were homozygous A-T and patients who were heterozygous at 
these three point mutations. However these findings were not 
statistically significant.
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Figure 3.4: Correlation between each polymorphism at
inton 2 and the Gleason score
Y-axis demonstrates 95% confidence intervals. X-axis 
demonstares the 95 cancer patients’ distribution at intron 2
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Figure 3.5: Correlation between each polymorphism at
intron 4 and the Gleason score
Homozygous insertion of ATCTT/ATCTT (+/+) appears to 
correspond with higher-grade disease however, there was no 
statistical significant difference when compared to the 
homozygous deletion -/- (p=0.394).
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Figure 3.6: Correlation between each polymorphism at
intron 8 and the Gleason score
Polymorphism G/G was associated with more aggressive prostate 
disease but there was no statistical clinical significance when 
compared to the other two groups (p=0.394).
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Figure 3.7: Correlation between the genetically linked
polymorphism sites and the Gleason score.
HOMO (A-T)= Homozygous (A/A - / -  T/T), HOMO (G+G)= 
Homozygous (G/G +/+G/G) &HETERO=Heterozygous(A/G +/- G/T)  
Patients who were homozygous G+G appear to have a tendency 
of having a higher Gleason score within their prostate 
adenocarcinoma compared to patients who were homozygous A-T 
and patients who were heterozygous at these three point 
mutations.
3.1.5 Correlation of SNPs with pre-op PSA.
At intron 2 the correlation between each polymorphism and the 
pre-operative or pre-diagnosis PSA on all 138 samples was 
analysed to assess wheather a particular polymorphism was 
related to higher PSA levels at presentation using Mann-Whitney 
test. On observation of the graph (Figure 3.8), the polymorphism 
A/G appears to correspond with higher PSA levels at 
presentation. However, statistical analysis failed to show a 
significant difference when the polymorphism A/G was compared 
to the polymorphism A/A (p=0.768) and the polymorphism G/G 
(p=0.996).
At intron 4 the heterozygous insertion/deletion of ATCTT (+/-) 
appears to correspond with higher PSA levels at presentation 
(Figure 3.9). Statistical analysis failed to show a difference when 
the heterozygous insertion/deletion of ATCTT (+/-) was compared 
to the homozygous deletion -/- (p=0.768) or homozygous insertion 
of ATCTT/ATCTT (+/+) (p=0.996).
Observation of the analysis at intron 8 (Figure 3.10) showed that 
the polymorphism G/T was associated with higher PSA levels at 
presentation. Statistical analysis showed no clinical significance 
when the polymorphism G/T was compared with the polymorphism 
G/G (p=0.917), and with the polymorphism T/T (p=0.574).
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Based on the assumption that the three intronic polymorphisms 
within the Pten gene were linked genetically, analysis of the 
correlation of these polymorphisms with the pre-operative PSA 
was compared (Figure 3.11). Patients who were genetically 
heterozygous at these three point mutations had a tendency to 
present with a higher pre-operative PSA compared to patients 
with who were homozygous A-T and patients who were 
homozygousG+G. However these findings were not statistically 
significant.
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Figure 3.8: Correlation between each polymorphism at
intron 2 and pre-operative PSA.
This graph includes the PSA on all 138 patients with or without 
prostate cancer. The polymorphism A/G appears to correspond 
with higher PSA levels at presentation.
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Figure 3.9: Correlation between each polymorphism at
intron 4 and pre-operative PSA.
This graph includes the PSA on all 138 patients with or without 
prostate cancer. Heterozygous insertion/deletion of ATCTT (+/-) 
appears to correspond with higher PSA levels at presentation.
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Figure 3.10: Correlation between each polymorphism at
intron 8 and pre-operative PSA.
This graph includes the PSA on all 138 patients with or without 
prostate cancer. The polymorphism G/T was associated with 
higher PSA levels at presentation.
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Figure 3.11: Correlation between the genetically linked
polymorphism sites and the Gleason score
HOMO (A-T)= Homozygous (A/A - / -  T/T), HOMO (G+G)=  
Homozygous (G/G +/+G/G) HETERO = Heterozygous (A/G +/- G/T) 
Patients who were genetically heterozygous at these three point 
mutations had a tendency to present with a higher pre-operative 
PSA compared to patients with who were homozygous A-T /G+G.
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3.3 Discussion on SNPs
In prostate cancer, polymorphisms have been identified in two 
genes, the 17-hydroxylase cytochrome P450 gene (CYP17) and 
the steroid 5a-reductase type II gene (SRD5A2) that are involved 
with androgen synthesis (Lunn RM et al, 1999). The CYP17 A2 
allele contains a T - *C  transition in the 5 ’ promoter region that 
creates an additional Sp1-type (CCACC box) promoter site. The 
SRD5A2 valine to leucine (V89L) polymorphism has been 
correlated with lower DHT levels. There is evidence that high 
activity allele (A2) of the CYP17 gene, increase levels of 
testosterone and may be associated with prostate cancer (Lunn 
RM et al, 1999).
SNPs are an abundant form of genome variation with a low 
mutation rate per generation. This property makes them the 
marker of choice for association studies in genetic analysis of 
complex diseases such as prostate cancer. In this series of 
experiments, association studies was performed to look for 
differences in frequency of genetic variants between prostate 
cancer patients and a control group with no clinical diagnosis of 
prostate cancer. Such study design has long been used to test 
the involvement of candidate genes in diseases by linkage 
(Lander ES and Schork NJ. 1994).
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According to the theoretical models, if the genotype of a group of 
individuals with a common disease and that of a group without the 
disease are studied, certain genotypes will be consistently 
associated with those individuals who have the disease (Risch N 
and Merikangas K 1996). Based on the population genetic 
phenomenon of linkage disequilibrium (Risch N and Merikangas K 
1996), particular genetic markers (haplotypes) in close proximity 
to a mutation responsible for a disease are often found to be 
associated with the disease.
Three intronic polymorphisms within the Pten gene were 
analysed: a single-base A -*G  substitution in intron A 96 bp 
upstream of exon 2; a 5-bp ATCTT insertion / deletion in intron D 
110 bp downstream of exon 4 and a single-base T—»G substitution 
in intron H 32 bp downstream of exon 8. Comparisons between 
the prostate cancer population and the non-prostate cancer 
control group did not show any specific association between any 
of the polymorphism and prostate cancer.
The control group consisted of patients with negative prostate 
biopsies. This investigative tool has a high sampling error (false- 
negative) and does not entirely exclude the presence of prostate 
cancer. A more accurate non-cancer control group would have 
been obtained from TURP chipping submitted for histological 
analysis. This method would allow for more accurate sampling of
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the patient’s prostate tissue and disease state. If this 
methodology had been adopted, it might have reflected in the 
results, as the clinical data might have been different.
Attempts were made to identify a correlation between these SNPs 
and high-grade prostate cancer as well as an association 
between the SNPs and PSA at presentation. No identifiable 
correlation was established.
Depending on where a SNP occurs, it might have different 
consequences at the phenotypic level. SNPs in the coding 
regions of genes that alter the function or structure of the 
encoded protein are a necessary and sufficient cause of most of 
the known inherited monogenic disorders.
By performing these series of experiments, I had set out to 
illustrate an association between one of the polymorphisms 
investigated and prostate cancer. If an association had been 
established, a marker could be developed to identify individuals 
at risk of developing prostate cancer and may predict subsequent 
disease behaviour such as the likelihood of disease recurrence or 
progression. As well as a potential role in the natural history of a 
disease, SNPs may well determine an individual’s response to 
treatment such as chemotherapy or radiotherapy. To date, no 
such marker has been found for prostate cancer. The experiments 
in this chapter have also failed in the quest to discover such a 
marker in prostate cancer.
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CHAPTER FOUR
LOSS OF HETROZYGOUSITY 
WITHIN THE Pten GENE.
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4.2 Introduction
The Pten gene is located at chromosome 10q23 and is a putative 
tumour suppressor gene thought to play a role in development 
and progression of prostate cancer. Pten gene is known to be 
deleted in 90% of glioblastomas, however, the frequency and 
significance of Pten deletion in prostate cancer remains unknown.
The aim of this work was to determine the frequency of Loss of 
heterozygousity (LOH) within and around the Pten locus when an 
individuals’ normal DNA profile is compared to the DNA obtained 
from prostate cancer cells of the same individual. The cancer 
DNA is obtained from archival paraffin embedded radical 
prostatatectomy specimens.
The study was performed using fluorescence-based allelotyping 
with four highly informative microsatellite cytosine-adenine (CA)n 
dinucleotide repeat markers: D10S541, D10S2492, D10S1765 and 
AFMa086wg9 located within and around the Pten locus (Fig 4.1). 
This study also investigates the significance of these LOH in 
relation to clinicopathological findings.
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approx lOOkb
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intron 28 31 5.5 1.9 18 5.6 2.8 4.1
size kb kb kb kb kb kb kb kbkb kb kb
T ' ' 1 1 1 11 11 v
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D10S1765 AFM086wg9
D10S2492 D10S541
Figure 4.1: Position of microsatelli te markers in Pten
Demonstrates the location of the four microsatell ite markers 
within and around the pten  gene.
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4.2 Case selection for LOH study
4.2.1 Criteria for selection
In this study all cases of prostate adenocarcinoma were retrieved 
from the archives of the histopathology department at The Royal 
free Hospital. These patients had radical prostatectomy as the 
treatment option for their prostate cancer. A total of 34 tumours 
were selected for analysis from the database of 155 radical 
prostatectomy specimens due to the strict inclusion criteria. The 
criteria only allowed inclusion of specimen if large concentrations 
(>70%) of prostate cancer cells were present on analysis of the 
Hematoxylin and Eosin (H & E) stained slides. These slides 
mirrors the archival paraffin embedded radical prostatectomy 
tissue sections.
4.2.2 Criteria for exclusion
The patients with prostate cancer whose archival paraffin embedded 
radical prostatectomy specimen would have produced a low 
concentration (<70%) of cancer DNA following manual 
microdissection of the tissue.
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4.3 Source of prostate tissue
Tumour tissue was obtained from archival paraffin embedded 
radical prostatectomy specimens from the histopathology 
department at the Royal Free hospital. The histopathologist 
retrieved and reviewed H & E stained slides in the archives and 
selected only specimens with large concentrations (>70%) of 
prostate cancer cells on the slides. Three 3pm thick sections 
were obtained from the corresponding paraffin-embedded tissue 
block and were subjected to histological evaluation to ensure the 
high tumour cell density was maintained. These areas were 
circumscribed with a marker pen allowing me to focus on the area 
for manual microdissection (Figure 4.2).
The distribution of disease and exact source of each paraffin 
block was indicated clearly on a diagram as the entire gland had 
been submitted for microscopic evaluation allowing for a final 
diagram of the prostatic diseases to be generated documenting 
anatomic distribution and multifocality when present (Figure 4.3). 
The tumour areas are mapped in red ink indicating the geographic 
and zonal distribution of the neoplasm(s) and the states of the 
surgical margins, seminal vesicles, and extracapsular tissue. This 
allows for a highly accurate microscopic characterisation of each 
minor image sample (proportion of tumour present, histological 
grade(s), proportions of benign epithelium, stroma, premalignant 
lesions, etc).
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Slides containing prostate cancer stained 
with Hematoxylin and Eosin. Demarcate areas 
of high tumour concentration (>70%).
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Figure 4.3 Site mapping on prostate specimen
m  Areas containing adenocarcinoma 
Areas containing PIN (High grade).
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4.4 DNA extraction protocol
4.4.1 Microdissection of Cancer cells
Microdissection of the demarcated areas on the slides was 
performed manually with a fine blade. This step was essential, as 
I found in my earlier experiments that the DNA produced following 
removal of paraffin was heavily contaminated with DNA from 
stromal or other non-malignant cells. Microdissection of area with 
low tumours density was resulting in underestimation of the true 
frequency of LOH at a locus.
4.4.2. Deparaffination and DNA extraction
This process removes the paraffine, which the prostate tissue 
was embedded allowing for extraction of DNA from cancer cells.
Solutions used
3mls of 99% Xylene
3mls of Industrial methylated spirits
1 ml of Proteinase K
1 X PCR buffer (15mM MgCl2 )
158
E x p e r i m e n t a l  p r o c e d u r e
Soak the slide in Xylene for 5 minutes to deparaffinate the tissue 
on the slide, then repeat this process. Transfer the slide into a 
solution of industrial methylated spirits for 5 minutes in order to 
remove the xylene, and then allow slide to air dry.
Manually microdissect out the area of high tumour density marked 
out on the slide by the histopathologist. Place the tissue in the 
solution of 1 X PCR buffer (MgCl2 ) containing Proteinase K and 
keep at 55°C in a heating block for 2 days to allow for digestion 
of cellular protein, forming a cloudy solution. Incubate the 
solution at 96°C for 10 minutes to deactivate the Proteinase K. 
Centrifuge the solution at -1 3 ,0 0 0  rpm and carefully transfer the 
supernatant into 1.5ml sterile eppendorf tube. This supernatant is 
the source for the genomic prostate cancer cell DNA.
In order to analyse the region of LOH in prostate cancer, 
comparison needs to be made with DNA obtained from non­
cancer tissue obtained from the same patient. In this thesis non­
cancer DNA was obtained from lymphocytes separated from 
heparinized corresponding blood using DNA Puregene™ DNA 
isolation kits as described earlier in chapter 2.4.1 (Preparation of 
genomic DNA).
1 5 9
4.4.3 PCR of cancer and corresponding blood DNA.
PCR is performed on DNA extracted from the adenocarcinoma 
cells obtained from the archival prostate tissue and the 
corresponding blood sample obtained from the patient. The 
solutions used are similar for both PCR reactions except, the first 
PCR used genomic DNA obtained from the patients blood and the 
working solution volume was 25pl compared to the second set of 
reactions, which used DNA, obtained from prostate cancer tissue 
and used 50pl solutions in order to dilute out contaminants such 
as formalin fixatives which inhibits polymerase chain reactions.
Solutions used pi
DNA template (50ng) 1.0
AmpliTaQ Gold Buffer 2.5
dNTP's (2mM) 2.5
Primer A (10pM) 1.25
Primer B (1 OpM) 1.25
AmpliTaq Gold Polymerase 0.125
Sterile dH20 16.375
Total 25 ul
The oligonucleotide primers were obtained from the Genebank 
database and synthesised by the ICRF, Clare Hall laboratories. 
The sequences of the fluorescent primers for microsatellite 
analysis are listed in Table 4.1.
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Markers Primer Number Sequence of primers
D10S541 A
B
100650
103596
5 ’-AAGCAAGTAAGTCTTAGAACCACC-3 ’
5 ’-GTTCTTCCACAAGTAACAGAAAGC-3 ’
D10S2492 A
B
100653
106578
5 ’-TGCA GTGAGCTGTGAA GA TG-3 ’
5 T T T C T T T G T T T C T C T T A C T A C C T A T G T 3 ’
D10S1765 A
B
100655
106581
5 ’-ACACTTACATAGTGCTTTCTGCG- 3 ’ 
5 ’-GTTTCTTCAGCCTCCCAAAGTTGC - 3 ’
AFMa086
wg9
A
B
100654
106579
5 ’-AAATGTACGGTTCATTGACTT-3 ’
5 ’-TTTCTTGACTGACTACAAATGGGCA3’
Table 4.1: Sequence of oligonucleotide primers.
The DNA sequence of the oligonucleotide primers used to
sequence the DNA in the region of the four microsatellite
markers. The sequence runs from 5’—» 3 ’ end.
1 6 1
E x p e r i m e n t a l  p r o c e d u r e
PCR Parameters used were: 
Temperature (°C) Time (minutes)
96 10.00
96 00.15
55 00.30
72 03.00
72 10.00
4 00
The samples were initially denatured at 96°C for 10 minutes, then 
subjected to 35 cycles of 15 seconds denaturising at 96° C, 30 
seconds annealing at 55° C and polymerisation at 72° C for 3 
minute allowing for extension at 1 Kb per minute. There is a final 
step of extension at 72° C for 10 minutes to ensure completion of 
all amplification events. The PCR product is then cooled to 4° C.
1 6 2
4.4.4 Separation of PCR product by electrophoresis.
This step is to check whether the PCR was successful and free of 
contamination. 2% Agarose was used as the support matrix for 
enabling the PCR product to be separated under the influence of 
an electrical current. A small pore gel results when agarose 
undergoes change from a liquid to a solid form. Smaller PCR 
fragments will travel further down the gel in a given time; thus 
fragments of differing sizes will be separated.
Solution used
2% Agarose 3grams
0.5 X TBE (Triss, Borate, EDTA) 150mls
Ethidium bromide 3.5pl
Ethidium bromide is known to contain a planar group that 
intercalates between the stacked bases of DNA. The fixed 
position of this group and its close proximity to the bases causes 
dye bound to DNA to display an increased fluorescent yield 
compared to dye in free solution. Ultraviolet irradiation absorbed 
by the DNA at 260nm and transmitted to the dye, or irradiation 
absorbed at 300nm and 360nm by the bound dye itself, is emitted 
at 590 nm in the red/orange region of the visible spectrum.
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Each gel had a standard marker in lane 1 of the gel. On 
electrophoresis this marker separated into fragments of known 
size and molecular weight. Thus by using this as a comparison 
one could estimate the sample fragment sizes. First well contains 
standard molecular weight marker of known size. TheOX174  
DNAIHae  III Marker was used. They are made by digesting double 
stranded 0 X 17 4  DNA to completion with Hae III.
Experimental procedure
Mix the 2% agarose gel constituents thoroughly in a glass beaker. 
Heat the glass beaker in a standard domestic microwave, at high 
power for 5 minutes. Allow the beaker to cool by leaving it 
standing for 2 minutes. Add 3.5pl of ethidium bromide into 150ml 
of 0.5 X TBE solutions and allow bottle to cool for further 
5minutes. Whilst still in the liquid form, pour the solution into 
perspex receptacle containing two 24 toothed plastic comb. When 
the liquid set, remove the comb forming two 24 wells.
Mix 4pl PCR product with 2pl of loading buffer (Orange G and 
30% Glycerol) and pipet into each well. Pour 0.5 x TBE Into the 
reservoirs on the assembly to cover the electrodes. Connect the 
assembly to a power supply and run the gel at 250 volts for 
20minutes. Inspect the gel under ultraviolet light wearing UV safe 
goggles. A Polaroid picture was taken of the illuminated gel in 
order to provide a permanent record.
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4.4.5 Purification of PCR product
The PCR product is contaminated with unwanted primers and 
impurities such as salts, enzymes and unincorporated dNTPs. It 
is essential that the product be purified for good DNA sequence 
to be obtained. The QIAquick PCR Purification protocol is 
designed to purify PCR products by removing unwanted 
contaminants using QIAquick spin columns in a microcentrifuge.
The QIAquick system combines the convenience of spin-column 
technology with the selective binding properties of a uniquely 
designed silica-gel membrane. Special buffers listed below are 
optimised for efficient recovery of DNA and removal of 
contaminants in each specific application. DNA absorbs to the 
silica membrane in the presence of high salt while contaminants 
pass through the column. Impurities are efficiently washed away, 
and the pure DNA is eluted with distilled water. Adsorption of 
DNA to silica membrane depends on pH. Adsorption is typically 
95% if the pH is < 7.5, and it reduced drastically at higher pH.
Buffer PB allows the efficient binding of PCR product as small as 
100bp and quantitative (99.5%) removal of primers up to 40 
nucleotides. It is therefore used to remove oligonucleotide 
primers after cDNA synthesis or to remove unwanted linkers in 
cloning experiments.
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During the DNA adsorption step, unwanted primers and impurities 
such as salts, enzymes, and unincorporated dNTPs do not bind to 
the silica membrane, but flow through the column. Salts are 
washed away by the ethanol containing Buffer PE. Any residual 
Buffer PE, which may interfere with subsequent enzymatic 
reactions, is removed by an additional centrifugation step.
Experimental procedure: -
Centrifuge steps are at >10, 000 x g (~ 13,000 rpm) in a 
conventional domestic tabletop microcentrifuge.
Add 125mls of Buffer PB to 25pl of PCR product. Place the 
QIAquick spin column into a 2 ml collection tube.
To bind DNA, apply the sample to the QIAquick column and 
centrifuge for 60 seconds. Discard the flow through. Place the 
QIAquick column back in the same tube. To wash, add 0.75mls of 
Buffer P.E to the QIAquick column and centrifuge for 60seconds. 
Again, discard the flow through. Return the QIAquick column to 
the same tube and centrifuge for an additional one minute at 
maximum speed. Place the QIAquick column in a clean 1.5ml 
microfuge tube. To elute DNA, add 3 0 |jI Buffer E.B to the centre 
of the QIAquick column and allowed to stand for one minute then 
centrifuged for one minute leaving an elution of bound DNA.
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For the sequence reaction, 1 in 20 dilution of blood PCR product 
and 1 in 10 dilution of tissue PCR product is used for gene typing 
to reduce fluorescence and allow for product to be in the range 
for suitable for the ABI Prism 377 DNA Sequencer.
4.4.6 Analysis of sequenced fragment
The next stage is to run the extension products on a sequencer to 
obtain a reading of the nucleotides in order to establish the 
magnitude of LOH present within the amplified region.
Solutions used 
PCR product
Loading buffer containing dextran blue and formamide.
TAMRA 500bp ladder
Experimental procedure
1pl of dilute PCR product and 3pl of loading buffer is added to 
55 |jI buffer plus 10pl of TAMRA 500bp ladder. The samples were 
denatured immediately prior to gel loading by heating the solution 
to 95°C for 10 minutes followed by snap chilling in an ice/water 
bath.
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The Longranger gel containing acrylamide is used as the support 
matrix for enabling the oligonucleotide to be separated under the 
influence of an electrical current.
Solution used
Longranger gel (Acrylamide) 5mls
5 x TBE 10mls
10% APS 250pl
Urea 18gms
TEMED 35 |J I
The above was sufficient to run a gel and each gel was able to 
support and analyse 32 samples. The sequence products were 
run on the ABI Prism 377 DNA sequencer and the results 
analysed using Genescan software (version2.1.1) by Perkin- 
Elmer).
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CHAPTER FIVE
Results and discussions on 
LOH study on Pten gene.
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5.1 Results of LOH analysis
5.1.1 Analysis of sample population
The age range of the prostate cancer population studied (at the 
time of diagnosis of the disease) was 46 -  77 years, with the 
mean age being 65.21 years (Figure 5.1). The preoperative PSA 
range was 2.2 -  252.0 pg/l with a mean of 24.13pg/l (Figure 5.2). 
The distribution was skewed because two patients underwent 
radical prostatectomy with exceptionally high preoperative PSA of 
210pg/l and 252pg/l. If these two patients were omitted from the 
study, the preoperative PSA range would have been 2 -  39.9pg/l 
with a mean of 10.7pg/l. Statistically, the value of the 5% 
trimmed mean for the preoperative PSA was 13.65pg/l. The TRUS 
of these two patients revealed their prostates to have estimated 
volumes of 152grams and194grams respectively. The histology of 
the prostate biopsy specimen revealed adenocarcinoma with 
Gleason scores of five as well as histological evidence of chronic 
active prostatitis in both cases. Neither of these two patients had 
evidence of metastatic spread on bone scan or CT imagining. 
Further histological analysis of their entire prostate gland and 
lymph nodes post radical prostatectomy did warrant upstaging of 
their disease to stage pT2bNoMo and pT3aNoMo respectively. 
The distribution of the TNM stage and Gleason score for the 
prostate carcinoma patients at the time of diagnosis is illustrated 
in Figure 5.3 and Figure 5.4 respectively.
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Figure 5.1: Age distribution in LOH study
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Figure 5.2: Pre-operative PSA distribution in LOH study
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Figure 5.3: TNM staging for the prostate cancer
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GLEASON SCORE
Figure 5.4: Gleason Score for the prostate cancer
population.
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5.1.2 Analysis of LOH study data
A total of 34 tumour specimens were studied. DNA obtained from 
the tumour specimen of each patient was analysed against DNA 
obtained from the corresponding blood sample of that patient. 
The analysis was performed using Genescan software (version 
2.1.1; Perkin-Elmer), which allowed for analyses of size and peak 
height.
In informative cases, allelic loss was scored if the area under one 
allele peak was reduced in the tumour to less than 50% of its 
value in the normal DNA (relative to the other allele), after taking 
account of baseline fluorescence levels. Example of allele loss at 
D10S1765 is shown in figure 5.5.
This threshold for allelic loss takes account of the possibility of 
contaminating normal tissue or other tumour clones in some 
samples. Any loci exhibiting extra bands (alleles) that differed by 
2 base pairs from the normal counterpart were excluded from the 
LOH analysis and classified as “non informative”.
For these case specimens, frequency of allele loss of 48% was 
found at the D10S541 locus. LOH occurred at the D10S1765  
locus at a frequency of 39%, at D10S2492 at a frequency of 32% 
and at the AFMa086wg9 locus at a frequency of 22%. At all four
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microsatellite, the mean (range) LOH was 35.25 (22-48) %. Of the 
34 case specimens 17(50%) showed LOH in at least one of the 
informative marker sites (Table 5.1).
Inspection of the extent of allele loss in individual cases reveals 
that LOH at D10S541 and D10S1765 were often apparently 
associated with a single event (Fisher exact test: p< 0.099). 
There was no significant association between allele loss at 
D10S541 or, D10S2492 and AFMa086wg9 and that LOH at each 
allele appears to be a separate genetic event (Table 5.2). Thus 
there may be more than two separate regions on 10q which tends 
to be lost in prostate cancer.
The results of LOH analysis at Pten using the four microsatellite 
markers is illustrated in figure 5.6
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Figure 5.5: Example of allele loss at D10S1765 in patient 14.
LOH is demonstrated by the reduction in the peak height (of the 
magnitude of 50%) in the al lele A, of the tumour sample relative 
to the allele of the blood sample.
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F i g u r e  5 . 6 : D i s t r i b u t i o n  o f  L O H  a t  t h e  f o u r  m i c r o s a t e l l i t e
m a r k e r s
Refers to Loss of heterozygousity 
Refers to No Loss of heterozygousity 
Refers to Non-informative.
Microsatellite Markers
Patient ID D101765 AFM086wg9 D10S2492 D10S541
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Locus
Number of 
Tumours
Number
Informative
Number 
with LOH
% With 
LOH
D10S541 34 25 12 48
D10S1765 34 31 12 39
D10S2492 34 19 6 32
AFMa086wg9 34 18 4 22
Table 5.1: Frequencies of allele loss at the
microsatellite markers studied.
Number with LOH / Number of informative markers = % with LOH.
D10S541
Loss No Loss Total
(a) D10S1765 Loss 7 3 10
No Loss 4 8 12
Total 11 11 22
(b) D10S2492 Loss 3 3 6
No Loss 6 5 11
Total 9 8 17
(c) AFMa086wg9 Loss 2 4 6
No Loss 4 6 10
Total 6 10 16
Table 5.2: Association between allele losses at
(a) D10S541 and P10S1765, (b) D10S541 and D10S2492 and 
(c) D10S541 and AFMa086wg9.
Only cases informative at both loci being compared are shown. 
Fisher’s exact test gives for (a) p< 0.099 (b) p=0.627 and for 
(c) p=0.608.
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The association between allele loss at these four loci and 
pathological information was evaluated. Table 5.3 illustrates the 
correlation between the frequency of LOH at each microsatellite 
marker and TNM tumour stage. The frequency of LOH in localised 
prostate cancer (pT2a to pT2b) was 31.9% (15/49), compared to 
those for locally advanced disease (pT3a), which was 42.86%  
(18/42). Using Pearson Chi-square test to analysis these results; 
there was no demonstrable difference in the frequency of LOH 
observed in the more advanced stage disease (pT3a) compared 
with clinically localised prostate disease (T1c to T2b) (p=0.226). 
However, when the correlation between the frequency of LOH at 
all 4 microsatellite collectively and TNM tumour stage were 
analysed. There was a statistical significant trend (p<0.0398).
By contrast, the incidence of LOH and Gleason score showed no 
correlation (p=0.274),  with 60% (3/5) in well-differentiated
disease (Gleason score 4), 29.8% (17/57) in moderately
differentiated disease (Gleason score 5 & 6) and 43.8% (7/16) in 
poorly differentiated disease (Gleason score 7&8). The 
correlation between the frequency of LOH at all 4 microsatellite 
collectively and Gleason score did not show a statistical 
significance towards a trend (p=0.798).
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Locus T2a T2b T3a p©
D10S541 1/2 4/8 6/13 0.341
D10S1765 1/5 3/10 8/14 0.784
D10S2492 0/3 4/9 2/7 0.512
AFMa086wg9 0/2 2/8 2/8 0.0782
Total
2/12
(16.6%)
15/37
(37.1%)
18/42
(42.9%)
0.0398
Table 5.3: Frequencies of allele loss at each
marker in relation to the TNM stage for 
prostate cancer. © x2 test for trend. n/N (%). n= 
number of LOH. N=number of informative 
markers. Not total number of tumours.
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Gleason Gleason Gleason Gleason Gleason p*
Locus Score 4 Score 5 Score 6 Score 7 Score 8
D10S541 2/2 4/8 2/5 1/2 0/0 0.341
D10S1765 1/1 4/9 1/10 2/5 1/1 0.784
D10S2492 0/1 4/8 1/5 1/3 0/1 0.512
AFMa086wg9 0/1 0/7 1/5 1/2 0/0 0.078
Total
3/5
(60%)
12/32
(37.5%)
5/25
(20%)
5/12
(41.6%)
1/2
(50%)
0.798
Table 5.4: Frequencies of allele loss at each marker
compared to the Gleason score for prostate 
cancer. *x2 test for trend. n/N (%). n= number of 
LOH. N=number of informative markers. Not 
total number of tumours.
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The correlation between the mean number of loci with LOH and 
prostate cancer stage was analysed (Figure 5.7). The mean 
number of LOH in locally advanced tumours (1.20 for T3) was 
relatively more than that for organ confined tumours (0.79 for T1 
and T2). The difference was approaching statistical significance 
(p<0.065). However, there was no statistical significance (p= 
0.274), in the relationship between the mean number of loci with 
LOH and Gleason score in this study. There was no difference in 
the mean number of LOHs in low-grade tumour (1.50 for Gleason 
score 4), intermediate grade tumour (0.907 for Gleason 5, 6 and 
7) and high-grade tumour (1.00 for Gleason 8) (Figure 5.8).
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Figure 5.7: The mean number of LOH at the four loci in
relation to pathological stage
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Figure 5.8: The mean number of LOH at the four loci in 
relation to Gleason score
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5.2 Discussion
A total of 155 radical prostatectomy specimens were available in 
the histopathology archives at The Royal Free Hospital at the 
onset of this project, however only 34 tumours could be selected 
for analysis from the database due to the strict inclusion criteria. 
The histopathologist had reviewed all H & E stained slides in the 
archives and selected only specimens with large concentrations 
(>70% of a cluster of cells) of prostate cancer cells on the H & E 
stained slides which mirrors the archival paraffin embedded 
radical prostatectomy tissue sections. It was essential to adhere 
to this criterion because my earlier experiments whilst fine-tuning 
the experimental protocol, discovered significant degree of 
contamination of the cancer DNA by stromal DNA. This resulted 
in underestimation of true frequency of LOH.
A hallmark of tumour suppressor gene mutation is Loss of 
heterozygousity in a particular chromosomal region affecting the 
homologous wild-type allele. The existence of a putative tumour 
suppressor gene on chromosome 10q23 is implied by LOH that 
includes this region in many cases of prostate cancer (Ittmann M
1996) (Trybus TM et al, 1996).
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Inactivation of tumour suppressor genes is the most common 
genetic alterations in prostate cancer. Such inactivation is 
frequently accompanied by loss of portions of a chromosome on 
which the tumour suppressor gene resides. Loss of portions of 
long arm of chromosome 10 has been identified in a significant 
percentage of prostate carcinomas (Ittmann M et al, 1996) 
(Trybus TM et a\, 1996).
The Pten gene covers over 100kb of a 400kb region of allelic loss 
common to most prostate tumours (Gray IC et al 1995). LOH on 
chromosome 10q was originally observed by a number of groups 
using restriction fragment length polymorphism (RFLP) analysis 
(Bergerheim US et al, 1991) (Ittmann M et al, 1996). Rates of 
LOH on 10q ranged from 2 0 -4 2 %  of informative cases 
(Bergerheim US et al, 1991) (Ittmann M et al 1996) using RFLP 
technique. Microsatellite PCR is now the method of choice for 
most allelotyping studies. In this thesis the detection frequency 
of LOH in Pten using the panel of four microsatellite markers 
produced a similar result with T.OH ranging from 22- 48% in 
informative cases.
The detection frequency of Pten mutations in prostate cancer was 
lower than anticipated in this thesis. This finding has also been 
observed in studies by other authors (Cairns et al, 1997; Gray IC 
et al 1998; Feilotter HE et al 1998) and could be explained by the
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fact that sequencing as a method of mutation detection is unlikely 
to be 100% efficient. The nature of prostate cancer growth with a 
lack of normal tumour boundary makes it difficult to be certain 
about the level of normal tissue contamination of the dissected 
tumour.
In the LOH experiments in this thesis, efforts were made to 
reduce the degree of contamination by employing the assistance 
of a histopathologist to mark out areas of high tumour 
concentration (>70%) on the H & E stain slides prior to manual 
microdissection. Effort was also made during interpretation of the 
results to ensure that allelic loss was scored only if the area 
under one allele peak was reduced in the tumour to less than 
50% of its value in the normal DNA (relative to the other allele), 
This threshold for allelic loss takes account of the possibility of 
contaminating normal tissue.
Inspection of the extent of allele loss in individual cases reveal 
that the microsatellites 1310S2492 and AFMa086wg9, present 
within the 100Kb thought to contain Pten gene revealed a 
frequency of loss of 32% and 22% respectively. Whereas, D10S 
541 and D10S1765, which are present on either side of the Pten 
gene showed a higher frequency of LOH at 48% and 39% 
respectively. Therefore the assumption could be made that 
D10S541 and D10S1765, D10S2492 and AFMa086wg9 on 10q
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appeared to be because of separate distinct event. Thus, there 
may be at least two separate regions on chromosome 10q that 
tend to be lost in prostate cancer.
This study suggests that the allelic loss at chromosome 10q23 
may be related to the pathogenesis of some cases of prostate 
cancer as demonstrated with the correlation with tumour stage. 
This association was found after scoring LOH in three different 
ways; (i) at least one LOH per chromosome; (ii) the total number 
of LOHs per chromosome: and (iii) the mean number of LOHs per 
chromosome.
Using %2 test for trend, it demonstrated a statistical significant 
correlation between the frequency of LOH at all 4 microsatellite 
collectively and higher TNM tumour stage (p=0.0398). The 
frequency of LOH in localised prostate cancer (T1c to T2b) was 
compared to those for locally advanced disease (T3a). Using %2 
test to analysis these results, I was unable to demonstrate a 
significant correlation between the higher frequency of LOH 
observed in the more advanced stage disease compared with 
clinically localised prostate disease (P=0.52). However a 
correlation between advance clinical stage and LOH on 10q has 
also been noted in other malignant neoplasms including 
glioblastomas (Fults D et al, 1992) and melanomas (Herbst RA et 
al 1994). Perhaps if a larger number of case studies fulfilled the
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inclusion criteria and had been available for this study, the 
results might have shown a clear difference.
The microsatellite analysis in this study showed the stage 
dependence of loss of 10q.This is in keeping with observations 
from studies by Gray et al, Komiya et al and Trybus et al, which 
identified the region at 10q23 between D10S215 and D10S541 to 
demonstrate LOH in up to 58% of advanced prostate cancers.
Among individual markers, the prevalence of LOH at 
AFMa086wg9 showed a trend towards correlating with the 
progression of prostate cancer as defined by a higher stage and 
grade. No other marker correlated with either stage or grade.
Although the detection frequency of Pten mutations in prostate 
cancer was lower than anticipated the frequency of mutations in 
other tumour types such as glioblastomas (Rasheed BK et al
1997) and endometrial carcinoma (Tashiro H et al 1997) was 90% 
and 50% respectively.
Using microsatellite analysis the frequency of LOH in localised 
prostate cancer 30.6%, compared to those for locally advanced 
disease, which was 42.86%. This is comparable to the work by 
Ittmann M et al in which RFLP analysis was performed where 
overall, approximately 20% of clinically localized prostate cancers
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showed LOH on 10q while 50% of the advanced cases showed 
LOH on RFLP analysis (Ittmann M et al, 1996).
Pathological stage and Gleason grade are important predictors of 
prognosis in patients with primary prostate cancer who undergo 
radical prostatectomy. Prostate cancer, however, is a remarkably 
heterogeneous disease. Distinguishing tumours associated with a 
poor outcome at the time of radical prostatectomy is problematic. 
The molecular mechanisms of prostate carcinogenesis remain 
poorly understood.
There are several general possibilities when considering tumour 
suppressor genes. A possibility is that the ability to detect 
mutations in candidate genes may be masked by the inability to 
obtain relative pure tissue samples for analysis, because of 
tumour heterogeneity and mutifocality. This technical explanation 
is quite conceivable because most analysis is still performed with 
relatively large tissue samples that are unlikely to be 
homogenous.
Another possibility is that the candidate genes may be inactivated 
by a mechanism other than a coding region mutation, such as a 
promotor methylation or mutations within regulatory sequences 
that may affect transcription, translation, or mRNA stability. In
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addition, inactivation could occur through alterations of upstream 
or down stream components in a regulatory pathway. A final 
possibility is that haploinsufficiency (loss of a single allele) may 
play an important role in prostate carcinogenesis, perhaps 
consistent with slow rate of progression and indolent phenotype 
of most tumours.
From a practical standpoint, the heterogeneity and mutifocality of 
prostatic lesions, combined with the relatively small size of the 
prostate, make it difficult to obtain reasonably homogenous 
material sufficient for molecular analysis. These factors represent 
significant limitations in identifying regulatory genes associated 
with prostate carcinogenesis, as well as in defining a molecular 
pathway for the imitation and progression of prostate cancer. In 
recent years, these difficulties have been partially circumvented 
by microdissection and laser capture microscopy approaches that 
facilitate analysis of individual neoplastic foci (Emmert-Buck MR 
et al 1995; Macintosh CA et al 1998), and by cell-sorting 
approaches that permit the isolation of relatively pure populations 
of carcinoma cells (Liu AY et al, 1999).
Genetic studies may prove useful in the identification of markers 
of prostate cancer progression. LOH studies of preneoplastic, 
primary and metastatic prostate cancer samples could identify 
loci involved in early and late stages of prostate carcinogenesis.
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The absence of associations between the clinical data and the 
allelic loss data is not surprising. LOH in Pten is thought to occur 
as a late event in the pathogenesis of prostate cancer.
Genetic studies are hampered by the limited availability of 
metastatic prostate tissues and it is particularly rear to have 
tissue from metastases available in a patient who has undergone 
radical prostatectomy. Prostatectomy is performed in patients 
with organ-confined disease. If the disease progresses, the 
metastatic are not usually biopsied. As a result, data for LOH in 
metastatic prostate cancer are lacking in the majority of studies 
on prostate cancer progression.
Studies that have included significant numbers of metastatic 
lesions have generally been limited to only one chromosomal 
region (Sakr WA et al, 1994; Ueda T et al, 1997). As a result, 
most existing data on LOH in prostate cancer have been derived 
from localised prostate cancer from prostatectomy specimens, 
which are most often (approximately 70%) moderately 
differentiated (Gleason score 4-7) (Gleason DF 1992). While 
useful for determination of the earlier genetic events in tumour 
formation, these samples may not be optimal for identification of 
alterations that predict metastatic potential. Additionally, the most 
appropriate samples for defining very early genetic alterations in
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prostate cancer would be precursor lesions. To date, only a few 
studies have analysed allele loss PIN and were limited mostly to 
chromosome 8 (Sakr WA et al, 1994; Emmert-Buck MR et al, 
1995). Thus a comprehensive LOH study on PIN lesions is also 
lacking.
A number of genetic changes have been shown to occur in 
prostate tumourigenesis, yet it is difficult to translate this 
molecular knowledge into widely applicable diagnostic / 
prognostic criteria in the management and treatment of the 
disease.
In order to prove this, large quantity of metastatic prostate tissue 
would be required. This tissue is rarely available as there is no 
clinical indication for obtaining metastatic prostate tissue except 
that which is available at the time of fixation of pathological 
fractures.
My goal was to identify genetic changes associated with 
histological and clinical progression of prostate cancer. The LOH 
studies were performed using polymorphic microsatellite markers 
on microdissected prostate cancer specimens from patients found 
to have organ confined and locally advanced disease.
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In conclusion, the results presented in this thesis provide 
evidence that the 10q23-24 region may involve a putative 
candidate tumour-suppressor gene which might be associated 
with progression of prostate cancer. Moreover, they suggest that 
the loss of Pten may be a late step in the progression of some 
prostate neoplasms.
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5.3 Summary
The objectives in this thesis were to investigate the significance 
of the Pten gene in prostate cancer. In the first series of 
experiments described in the second chapter, none of the three 
intronic polymorphisms showed specific associations with the 
prostate cancer sample group compared with the control group.
By performing these series of experiments I had hoped to 
illustrate an association between prostate cancer and at least one 
of the polymorphisms investigated. If an association had been 
established, a marker could be developed to identify individuals 
at risk of developing prostate cancer and may predict subsequent 
disease behaviour such as the likelihood of disease recurrence or 
progression. As well as a potential role in the natural history of a 
disease, SNPs may well determine an individual’s response to 
treatment such as chemotherapy or radiotherapy.
The second set of experiments attempted to demonstrate the 
frequency and significance of LOH within the Pten gene using our 
panel of four microsatellite markers. This produced a result with 
the frequency of LOH ranging from 22-48% in informative cases. 
There was also a statistically significant trend between the 
frequency of LOH at all four mirosatellites collectively and a 
higher TNM tumour stage (p=0.0398). This finding demonstrates
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that LOH in the pten gene was a late event in prostate cancer 
pathogenesis.
The number of samples that fulfilled the inclusion criteria was of 
a limited number. Perhaps, if a larger quantity of prostate cancer 
sample was available for these studies the results might have 
demonstrated a significant correlation between a higher 
frequency of LOH at pten and late stage prostate cancer. This 
would have been an important finding in the quest to identify a 
genetic marker for prostate cancer. It would allow for genetic 
analysis of prostate tissue obtained following TRUS and biopsy. 
Following the diagnosis of adenocarcinoma of the prostate, such 
a marker could be added to the panel of prognostic markers of 
disease progression currently available and help in stratify 
patients into high and low risk of prostate cancer disease 
progression. This would improve the counselling of patients with 
the diagnosis of localised adenocarcinoma of the prostate and 
allow appropriate treatment stategies to be offered depending on 
the risk group into which the patient is judged to belong.
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Appendix 2: Patient information sheet for the SNPs and
microsatellite study.
Date interviewed:
Study no:
Hospital number:
Pathology specimen number: 
Initials of patient:
Date of birth:
Diagnosis:
Age at first diagnosis:
Date of treatment:
Treatment modality:
Pre diagnosis PSA:
Latest PSA:
Mode of diagnosis:
Pathology findings:
Gleason grade:
Gleason score:
TNM classification of cancer:
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Appendix 3 :Patient data for the SNPs and microsatellite study
ID-
number Age
Pre
op
PSA
Post
op
PSA
Diagnosis
Method
Gleason
Score
TNM
Stage
1 75 50 3 CA BIOPSY 6 pT1 c
2 76 4.3 0.2 CA TURP 6 pT1 b
3 75 1.7 0.1 CA TURP 3 pT1 b
4 72 1 1.4 CA TURP 3 pT1 a
5 56 6 0.1 CA RRP 5 pT2a
6 73 5 0.1 CA RRP 5 pT2b
7 66 31 3.7 CA BIOPSY 7 pT1c
8 65 33 0.2 CA RRP 7 pT3a
9 82 8.4 13.9 CA BIOPSY 6 pT1 c
10 82 4.2 0.2 CA BIOPSY 3 pT1 c
11 71 4.5 0.2 CA BIOPSY 4 pT1 c
12 77 4.4 10 CA BIOPSY 7 pT1 c
13 74 27 2 CA BIOPSY 8 pT1 c
14 75 5.1 11.3 CA BIOPSY 4 pT1c
15 81 13 0.2 CA BIOPSY 2 pT1 c
16 78 8.2 0.2 CA BIOPSY 7 pT1 c
17 91 22.8 12.5 BPH BIOPSY NA NA
18 79 4.1 2 BPH BIOPSY NA NA
19 45 3.2 2 BPH BIOPSY NA NA
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ID-
number Age
Pre
op
PSA
Post
op
PSA
Diagnosis
Method
Gleason
Score
TNM
Stage
20 73 10.5 0.2 CA RRP 7 pT3a
21 75 26.6 2.2 CA BIOPSY 7 pT1c
22 73 425 30.5 CA BIOPSY 6 pT1c
23 84 17.5 21.1 CA TURP 6 pT1a
24 68 13 0.2 CA RRP 8 pT2b
25 59 4.5 4.4 BPH BIOPSY NA NA
26 70 5.4 0.8 CA BIOPSY 5 pT1 c
27 83 12.1 3.4 BPH BIOPSY NA NA
28 68 40 3.3 CA BIOPSY 7 pT1 c
29 62 10.2 0.2 CA RRP 6 pT2b
30 68 35.6 1.7 CA BIOPSY 5 pT1 c
31 79 17.8 11.5 BPH BIOPSY NA NA
32 72 1.6 0.2 CA BIOPSY 4 pT1c
33 77 10.8 10.2 BPH BIOPSY NA NA
34 80 8.4 8.4 BPH BIOPSY NA NA
35 90 8 38 CA BIOPSY 7 pT1 c
36 84 4.5 2.3 BPH BIOPSY NA NA
37 74 26 177 CA TURP 10 pT1a
38 65 8.3 6.1 BPH BIOPSY NA NA
39 66 7.1 5.1 BPH BIOPSY NA NA
40 63 6 0.2 CA RRP 7 pT3a
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ID-
number Age
Pre
op
PSA
Post
op
PSA
Diagnosis
Method
Gleason
Score
TNM
Stage
41 63 10.4 4.5 BPH BIOPSY NA NA
42 76 10.9 0.6 CA BIOPSY 4 pT1 c
43 71 16.9 0.5 CA BIOPSY 6 pT1 c
44 73 7.6 6.2 BPH BIOPSY NA NA
45 78 8.6 0.6 CA BIOPSY 8 pT1 c
46 66 9.9 0.2 CA RRP 5 pT2a
47 75 203 4 CA TURP 6 pT1 b
48 82 34.2 0.1 CA TURP 6 pT1a
49 67 19.3 9.4 BPH BIOPSY NA NA
50 64 186 7.1 CA BIOPSY 5 pT1 c
51 80 16.1 13.9 CA BIOPSY 7 pT1 c
52 76 14.2 0.2 CA RRP 7 pT3a
53 48 4.4 4.3 BPH BIOPSY NA NA
54 59 13 0.7 CA RRP 7 pT3a
55 62 16 0.2 CA RRP 6 pT2a
56 61 5 0.2 CA RRP 7 pT3a
57 71 30 0.4 CA RRP 6 pT2b
58 43 4.3 3.9 BPH BIOPSY NA NA
59 71 31.6 2.7 CA RRP 3 pT3a
60 74 7.5 2 BPH TURP NA NA
61 43 4.3 1.8 BPH BIOPSY NA NA
204
ID-
number Age
Pre
op
PSA
Post
op
PSA
Diagnosis
Method
Gleason
Score
TNM
Stage
62 90 4.1 3.9 BPH BIOPSY NA NA
63 47 3.9 2.9 BPH BIOPSY NA NA
64 86 4.8 1.4 BPH BIOPSY NA NA
65 42 5.2 4.8 BPH BIOPSY NA NA
66 62 6 0.2 CA RRP 4 pT3a
67 74 15.7 13.8 CA BIOPSY 7 pT1 c
68 65 5.5 3.2 BPH TURP NA NA
69 78 5.1 4.2 BPH BIOPSY NA NA
70 66 4.9 3.0 BPH BIOPSY NA NA
71 55 20 0.2 CA RRP 8 pT2a
72 71 3.3 1.3 BPH BIOPSY NA NA
73 57 8 0.2 CA RRP 6 pT3a
74 78 6.2 0.5 CA BIOPSY 4 pT1 c
75 68 8 0.1 CA RRP 7 pT2b
76 84 0.2 0.5 CA TURP 3 pT1 a
77 78 25 0.7 CA TURP 8 pT1 b
78 72 6.2 0.2 CA RRP 6 pT3a
79 74 4.7 4.4 BPH BIOPSY NA NA
80 79 12.6 0.5 CA BIOPSY 5 pT1a
81 69 5 0.1 CA RRP 5 pT3a
82 85 5.2 0.3 CA TURP 7 pT1 b
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ID-
number Age
Pre
op
PSA
Post
op
PSA
Diagnosis
Method
Gleason
Score
TNM
Stage
83 79 9.2 7.1 CA BIOPSY 9 pT1 c
84 74 32 23 CA BIOPSY 7 pT 1c
85 63 48 13 CA TURP 8 pT1a
86 74 26 0.8 CA RRP 5 pT2b
87 63 28 0.2 CA RRP 7 pT3a
88 73 32 0.2 CA RRP 5 pT3a
89 76 3.7 3.7 BPH BIOPSY NA NA
90 63 24.4 0.2 CA RRP 7 pT3a
91 70 11.8 0.2 CA RRP 6 pT3a
92 79 8.6 0.6 CA BIOPSY 4 pT1c
93 60 6 0.2 CA RRP 7 pT2b
94 62 9 0.2 CA RRP 9 pT2b
95 46 6.1 0.2 CA RRP 6 pT2a
96 67 10 0.8 CA RRP 8 pT2a
97 68 17.5 0.2 CA RRP 6 pT2b
98 85 2.1 1.2 BPH BIOPSY NA NA
99 74 59 110 CA TURP 7 pT 1 b
100 70 6.7 2.2 BPH BIOPSY NA NA
101 60 4.3 0.2 CA RRP 6 pT2b
102 65 6.4 0.4 CA RRP 8 pT2a
103 72 9 0.2 CA RRP 5 pT3a
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ID-
number Age
Pre
op
PSA
Post
op
PSA
Diagnosis
Method
Gleason
Score
TNM
Stage
104 69 6.1 0.1 CA RRP 6 pT3a
105 71 5 0.2 CA RRP 4 pT2b
106 77 5.2 0.2 CA RRP 6 pT2a
107 76 72 0.2 CA TURP 9 pT1 b
108 45 4.2 2.1 BPH BIOPSY NA NA
109 63 4.2 4.2 BPH BIOPSY NA NA
110 51 14.8 8.5 BPH BIOPSY NA NA
111 85 10.9 44.8 CA BIOPSY 7 pT1 c
112 73 4.5 2.9 CA BIOPSY 6 pT1 c
113 40 4.9 4.2 BPH BIOPSY NA NA
114 67 18 0.2 CA RRP 6 pT2a
115 65 2.2 0.2 CA RRP 6 pT3a
116 65 210 0.2 CA RRP 5 pT2b
117 66 39 0.5 CA RRP 6 pT3a
118 57 6 0.2 CA RRP 7 pT2b
119 85 8.9 3.6 BPH TURP NA NA
120 68 5 3 CA RRP 6 pT2a
121 83 4.3 0.2 BPH BIOPSY NA NA
122 54 4.1 3.1 BPH BIOPSY NA NA
123 82 1.3 0.2 CA TURP 2 pT1 a
124 52 3.9 4.4 BPH BIOPSY NA NA
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ID-
number Age
Pre
op
PSA
Post
op
PSA
Diagnosis
Method
Gleason
Score
TNM
Stage
125 60 4.8 1.9 BPH BIOPSY NA NA
126 80 17.4 0.3 CA BIOPSY 6 pT1 c
127 65 10 0.2 CA RRP 6 pT2a
128 64 252 0.2 CA RRP 5 pT3a
129 52 12.6 0.5 CA RRP 6 pT2a
130 64 5.9 0.2 CA RRP 5 pT2a
131 67 6.7 0.3 CA RRP 6 pT2b
132 72 13.5 2.2 CA RRP 7 pT2b
138 68 4.6 5.6 BPH BIOPSY NA NA
141 48 12.2 0.2 CA RRP 9 pT3a
142 68 6.1 4.2 BPH BIOPSY NA NA
143 68 11.1 7.9 CA RRP 7 pT2a
144 69 5.4 4.2 BPH BIOPSY NA NA
145 57 6.8 3.2 BPH BIOPSY NA NA
208
BIBLIOGRAPHY
209
BIBLIOGRAPHY
Achanzar WE, Diwan BA, Liu J, Quader ST, Webber MM, Waalkes 
MP. Cadmium-induced malignant transformation of human 
prostate epithelial cells. Cancer Res. 2001; 61:455-458.
Adlercreutz H.: Phytoestrogen: The Epidemiology and the
possible role in cancer protection. Environ Health Perspect 1995; 
103 (Suppl 7): 103-112.
Adolfsson J, Steineck G, Whitmore WF Jr.Recent results of 
management of palpable clinically localized prostate cancer. 
Cancer. 1993; 72:310-22.
Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk 
analysis of men aged 55 to 74 years at diagnosis managed 
conservatively for clinically localized prostate cancer. 
JAMA. 1998; 280:975-80.
Armour JA, Jeffreys AJ. Biology and applications of human 
minisatellite loci. Curr Opin Genet Dev. 1992; 6:850-6.
Bannayan G.A. Lipomatosis, angiomatosis and macrencephalia. A 
previously undescribed congenital syndrome. Arch. Pathol. 1971; 
92, 1-5.
Bastacky SI, Wojno KJ, Walsh PC, Carmichael MJ, Epstein Jl: 
Pathological features of hereditary prostate cancer. J Urol. 1995; 
153 :987 -992 ,
BAUS-British association of Urological surgeons- Cancer 
Registry, 2001- application-jmorrison@baus.org.uk.
Beckman JS, Weber JL. Survey of human and rat microsatellites. 
Genomics. 1992; 12:627-31.
Bellamy CO, Malcomson RD, Harrison DJ, Wyllie AH. Cell death 
in health and disease: the biology and regulation of apoptosis. 
Semin Cancer Biol. 1995; 6:3-16.
Bernal-Delgado E, Latour-Perez J, Pradas-Arnal F, Gomez-Lopez 
LI. The association between vasectomy and prostate cancer: a 
systematic review of the literature. Fertil Steril. 1998; 70:191-200.
Bishop DT, Kiemeney LA.Family studies and the evidence for 
genetic susceptibility to prostate cancer. Semin Cancer Biol. 
1997;8 :45-51 .
Bishop JM. Molecular themes in oncogenesis. Ce//.1991; 64:235-  
48.
210
Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and 
mortality in the European Union: cancer registry data and 
estimates of national incidence for 1990. Eur J Cancer. 1997 Jun; 
33:1075-107.
Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, 
Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, 
Pierart M. Improved survival in patients with locally advanced 
prostate cancer treated with radiotherapy and goserelin. N Engl J 
Med. 1997 ;337:295-300.
Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred 
DC. p53  is mutated in a subset of advanced-stage prostate 
cancers. Cancer Res. 1993; 53:3369-73.
Borresen-Dale AL. Genetic profiling of breast cancer: from 
molecular portraits to clinical utility. Int J Biol Markers. 
2003;18:54-6.
Bostwick DG. Gleason grading of needle biopsies; correlation 
with grade in 316 matched prostatectomies. Am J Surg Pathol 
1994; 18; 796-803.
Bostwick DG, Brawer MK. Prostatic intra-epithelial neoplasia and 
early invasion in prostate cancer. Cancer. 1987; 59:788-94.
Bostwick DG, Montironi R. Prostatic intraepithelial neoplasia and 
the origins of prostatic carcinoma. Pathol Res Pract. 1995; 
191:828-32.
Braaten DC, Thomas JR, Little RD, Dickson KR, Goldberg I, 
Schlessinger D, Ciccodicola A, D'Urso M. Locations and contexts 
of sequences that hybridize to poly (dG-dT). (dC-dA) in 
mammalian ribosomal DNAs and two X-linked genes. 
Nucleic Acids Res. 1988;168:65-81.
Brachman DG, Thomas T, Hilbe J, Beyer DC.Failure-free survival 
following brachytherapy alone or external beam irradiation alone 
for T1-2 prostate tumors in 2222 patients: Int J Radiat Oncol Biol 
Phys. 2000; 48(1): 111-7.
Brawley OW, Kramer BS: Epidermilogy of prostate cancer, in 
vogelsang NJ, Scardino PT, Shipley WU, Coffey DS, (eds): 
Comprehensive Textbook of Genitourinary Oncology. Baltimore, 
Williams & Wilkins. 1996. 565-572.
211
Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman 
JG, Jen J, Isaacs WB, Bova GS, Sidransky D. Frequent 
inactivation of PTEN/MMAC1 in primary prostate cancer.
Cancer Res. 1997;57:4997-00.
Carter BS, Epstein Jl, Isaacs WB. ras gene mutations in human 
prostate cancer. Cancer Res. 1990;50:6830-2.
Catalona WJ, Ritchie JP, Ahmann FB. Comparison of digital 
rectal examination and serum prostate specific antigen in the 
early detection of prostate cancer: J Urol 1994;151:1283-90.
Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan 
J J, Petros JA, Andriole GL.Measurement of prostate-specific 
antigen in serum as a screening test for prostate cancer. N Engl J 
Med. 1991; 324:1156-61.
Chan JM, Giovannucci E, Andersson SO, Yuen J, Adami HO, 
Wolk A.Dairy products, calcium, phosphorous, vitamin D, and risk 
of prostate cancer (Sweden). Cancer Causes Control. 1998; 
9:559-66.
Chelsky MJ, Schnall MD, Seidmon EJ, Pollack HM.Use of 
endorectal surface coil magnetic resonance imaging for local 
staging of prostate cancer. J Urol. 1993;150(2 Pt 1):391-5.
Cheney IW, Johnson DE, Vaillancourt MT, Avanzini J, Morimoto 
A, Demers GW, Wills KN, Shabram PW, Bolen JB, Tavtigian SV, 
Bookstein R. Suppression of tumorigenicity of glioblastoma cells 
by adenovirus-mediated MMAC1/PTEN gene transfer.
Cancer Res. 1998;58:2331-4.
Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, 
Jones GW,.Chisholm GD, Moskovitz B, Livne PM, Warner J. 
Results of conservative management of clinically localized 
prostate cancer. N Engl J Med. 1994;330:242-8.
Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE. Predicting 
radionuclide bone scan findings in patients with newly diagnosed, 
untreated prostate cancer: prostate specific antigen is superior to 
all other clinical parameters. J Urol. 1991; 145:313-8.
Christensson A, Bjork T, Nilsson O. Serum Prostate Specific 
Antigen complexed to alpha-1-antichymotrysin as an indicator of 
prostate cancer. J Urol 1993; 150:100-5.
Clinton SK, Emenhiser C, Schwartz SJ, Bostwick DG, Williams 
AW, Moore BJ, Erdman JW Jr. cis-trans lycopene isomers, 
carotenoids, and retinol in the human prostate. 
Cancer Epidemiol Biomarkers Prev. 1996;5:823-33
212
Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson 
M, Olsson CA, Korsmeyer S, Buttyan R. Detection of the 
apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory 
human prostate cancers. Am J Pathol. 1993;143:390-400.
Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, 
Terry WJ, Igel TC, Kidd DD. Prostate cancer detection in a 
clinical urological practice by ultrasonography, digital rectal 
examination and prostate specific antigen. J Urol. 1990;143:1146- 
52; discussion 1152-4.
Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, 
Wojno KJ. Distinct regions of allelic loss on 13q in prostate 
cancer. Cancer Res. 1996;56:1142-5.
Cotran RS, Kumar V & Robbins SL. Pathologic basis of disease: 
Neoplasia; 4 th ed. W.B Saunders company. 1989. 239-305.
Crawford ED.Hormonal therapy of prostatic carcinoma. Defining 
the challenge. Cancer. 1990;66(5 Suppl):1035-8.
Dalkin BL, Ahmann FR, Kopp JB: Prostate specific antigen levels 
in men older than 50 years without clinical evidence of prostatic 
carcinoma. J Urol 1993;150:1837-42
Edwards A, Civitello A, Hammond HA, Caskey CT. DNA typing 
and genetic mapping with trimeric and tetrameric tandem repeats. 
Am J Hum Genet. 1991;49:746-56.
Eeles RA, Dearnaley DP, Ardern-Jones A, Shearer RJ, Easton 
DF, Ford D, Edwards S, Dowe A. Familial prostate cancer: the 
evidence and the Cancer Research Campaign/British Prostate 
Group (CRC/BPG) UK Familial Prostate Cancer Study.Br J Urol. 
1997; 79 Suppl 1: 8-14.
Elghany NA, Schumacher MC, Slattery ML, West DW, Lee JS. 
Occupation, cadmium exposure, and prostate cancer. 
Epidemiology. 1990;1:107-15.
Ellis WJ, Lange PH. Prostate cancer. Endocriniology Metab Clin 
North Am 1994;23:809-24
Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, 
Goldstein SR, Weiss RA, Liotta LA.Laser capture microdissection. 
Science. 1996;274:998-1001.
213
Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings 
SB, Florence CD, Zhuang Z, Bostwick DG, Liotta LA, Linehan 
WM. Allelic loss on chromosome 8p12-21 in microdissected 
prostatic intraepithelial neoplasia. Cancer Res 1995;55:2959-62.
Eng C. Cowden syndrome and Lhermitte-Duclos disease in a 
family: a single genetic sydrome with pleiotropy? J. Med Genet. 
1994;31 458-461.
Evans CW. The invasive and metastatic behaviour of malignant 
cells.In: The metastatic cell behaviour and biochemistry. 1st ed, 
Chapman & Hall. 1991.Pp 137-217.
Evans Gl. Induction of apoptosis in fibroblasts by c-myc protein. 
Cell 1992; 69:119 -128.
Farkas A, Schneider D, Perrotti M, Cummings KB, Ward WS. 
National trends in the epidemiology of prostate cancer, 1973 to 
1994: evidence for the effectiveness of prostate-specific antigen 
screening. Urology. 1998 ;52:444-8.
Fearon ER, Vogelstein B. A genetic model for colorectal 
tumorigenesis. Cell. 1990; 61(5):759-67.
Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM.Analysis of 
PTEN and the 10q23 region in primary prostate carcinomas. 
Oncogene. 1998 ;16:1743-8.
Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon 
RM.p53 mutation and loss of heterozygosity on chromosomes 17 
and 10 during human astrocytoma progression. Cancer Res. 
1992; 52:674-9.
Gao X, Zacharek A, Salkowski A. Loss of heterozygousity of the 
BRCA1 and other loci on chromosome 17q in human prostate 
cancer. Cancer Res 1995; 55:1002-5
Giovannucci E, Clinton SK. Tomatoes, lycopene, and prostate 
cancer. Proc Soc Exp Biol Med. 1998 ;218:129-39.
Giovannucci E, Tosteson TD, Speizer FE, Ascherio A, Vessey 
MP, Colditz GA.A retrospective cohort study of vasectomy and 
prostate cancer in US men. JAMA. 1993;269:878-82.
Gleason DF: Histological grading for prostate cancer. A
perspective. Hum Pathol 1992;23: 273-279.
Glover FE Jr, Coffey DS, Douglas LL, Russell H, Cadigan M, 
Tulloch T, Wedderburn K, Wan RL, Baker TD, Walsh PC.Familial 
study of prostate cancer in Jamaica. Urology. 1998;52:441-3.
214
Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, 
Isaacs WB, Pitha PM, Davidson NE, Baylin SB. E-cadherin 
expression is silenced by DNA hypermethylation in human breast 
and prostate carcinomas. Cancer Res. 1995;55:5195-9.
Gray IC, Phillips SM, Lee SJ, Neoptolemos JP, Weissenbach J, 
Spurr NK. Loss of the chromosomal region 10q23-25 in prostate 
cancer. Cancer Res. 1995;55:4800-3.
Gray IC, Stewart LM, Phillips SM, Hamilton JA, Gray NE, Watson 
GJ, Spurr NK, Snary D. Mutation and expression analysis of the 
putative prostate tumour-suppressor gene PTEN. Br J Cancer. 
1998;78:1296-300.
Graves HC, Sensabaugh GF, Blake ET. Postcoital detection of a 
male-specific semen protein. Application to the investigation of 
rape. N Engl J Med. 1985;312:338-43.
Gronberg H, Damber L, Damber JE. Total food consumption and 
body mass index in relation to prostate cancer risk: a case- 
control study in Sweden with prospectively collected exposure 
data. J Urol. 1996;155:969-74.
Gronberg H, Damber L, Damber JE. Familial prostate cancer in 
Sweden. A nation-wide register cohort study. Urology 1997;3: 
374-8
Hacia JG, Fan JB, Ryder O, Jin L, Edgemon K, Ghandour G, 
Mayer RA, Sun B, Hsie L, Robbins CM, Brody LC, Wang D, 
Lander ES, Lipshutz R, Fodor SP, Collins FS.Determination of 
ancestral alleles for human single-nucleotide polymorphisms 
using high-density oligonucleotide arrays. Nat Genet. 
1999;22:164-7.
Hall JM, Lee Mk, Newman B et al. Linkage of early onset familial 
breast cancer to chromosome 17q21. Science 1990; 250: 1684-9
Hamada H, Seidman M, Howard BH, Gorman CM. Enhanced gene 
expression by the poly (dT-dG).poly(dC-dA) sequence. Mol Cell 
Biol. 1984;4:2622-30.
Henke RP, Kruger E, Ayhan N, Hubner D, Hammerer P, Huland H. 
Immunohistochemical detection of p53 protein in human prostatic 
cancer. J Urol. 1994 ;152:1297-301.
Herbst RA, Weiss J, Ehnis A, Cavenee WK, Arden KC.Loss of 
heterozygosity for 10q22-10qter in malignant melanoma 
progression. Cancer Res. 1994;54:3111-4.
215
Hricak H, White S, Vigneron D, Kurhanewicz J, Kosco A, Levin D, 
Weiss J, Narayan P, Carroll PR.Carcinoma of the prostate gland: 
MR imaging with pelvic phased-array coils versus integrated 
endorectal—pelvic phased-array coils. Radiology. 1994;193:703-9.
Hsieh K, Albertsen PC.Populations at high risk for prostate 
cancer. Urol Clin North Am. 2003 ;30:669-76.
Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect 
of castration, of estrogen and of androgen injection on serum 
phosphatases in metastatic carcinoma of the prostate. 1941. J 
Urol. 2002;167(2 Pt 2):948-51.
Humphrey PA, Frazier HA, Vollmer RT, Paulson DF. Stratification 
of pathologic features in radical prostatectomy specimens that 
are predictive of elevated initial postoperative serum prostate- 
specific antigen levels. Cancer. 1993;71:1821-7.
Isaacs SD, Kiemeney LA, Baffoe-Bonnie A, Beaty TH, Walsh 
PC.Risk of cancer in relatives of prostate cancer probands. 
J Natl Cancer lnst.5\87:991-6.
Isaacs WB. Molecular genetics of prostate cancer. Cancer Surv. 
1995;25:357-79.
Ittmann M. Allelic loss on chromosome 10 in prostate 
adenocarcinoma. Cancer Res. 1996;56:2143-7.
Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. 
Cancer statistics, 2003. CA Cancer J Clin. 2003; 53: 5-26.
Jensen OM, Esteve J, Moller H, Renard H. Cancer in the 
European Community and its member states. Eur J Cancer. 
1990;26:1167-1172.
Johansson JE. Watchful waiting for early stage prostate cancer. 
Urology. 1994;43:138-42.
Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami 
HO. Fifteen-year survival in prostate cancer. A prospective, 
population-based study in Sweden. JAMA. 1997;277:467r71.
Kakizoe T. Chemoprevention of cancer-focusing on clinical trials. 
Jpn J Clin Oncol. 2003; 33:427-42.
Kehinde EO: The geography of prostate cancer and its treatment 
in Africa. Cancer Surv 1995;23:281-286.
Kirk D. MRC study: when to commence treatment in advanced 
prostate cancer. Prostate Cancer Prostatic Dis. 1997 ; 1:11-15.
216
Klein G, Klein E. Evolution of tumours and the impact of 
molecular oncology. Nature 1985; 315: 190-195
Knudson AG Jr. Hereditary cancer, oncogenes, & antioncogenes. 
Cancer Res. 1985;45:1437-43.
Kwok PY, Deng Q, Zakeri H, Taylor SL, Nickerson DA. Increasing 
the information content of STS-based genome maps: identifying 
polymorphisms in mapped STSs. Genomics. 1996; 31:123-6.
Konishi N, Tao M, Nakamura M, Kitahaori Y, Hiasa Y, Nagai H. 
Genomic alterations in human prostate carcinoma cell lines by 
two-dimensional gel analysis. Cell Mol Biol. 1996;42:1129-35.
Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE, 
Diamond P, Levesque J, Belanger A. Screening decreases 
prostate cancer death: first analysis of the 1988 Quebec 
prospective randomized controlled trial. Prostate. 1999;38:83-91.
Lander ES and Schork NJ. Genetic dissection of complex traits. 
Science. 1994; 265: 2037-2048.
Landstrom M, Zhang JX, Hallmans G, Aman P, Bergh A, Damber 
JE, Mazur W, Wahala K, Adlercreutz H.Inhibitory effects of soy 
and rye diets on the development of Dunning R3327 prostate 
adenocarcinoma in rats. Prostate. 1998;36:151-61.
Laster WR. Success and failure in treatment of solid tumours. 
Kinetic parameters and cell cure of moderately advanced ca 755. 
Cancer chemoth Rep 1969; 53:169-188.
Lee WH et at. The retinoblastoma susceptibility gene encodes a 
nuclear phosphoprotein associated with DNA binding activity. 
Nature (Lond) 1988; 327:642-645.
Leitzmann MF, Stampfer MJ, Wu K, Colditz GA, Willett WC, 
Giovannucci EL. Zinc supplement use and risk of prostate cancer. 
J Natl Cancer Inst. 2003;95:1004-7.
Lesko SM, Louik C, Vezina R, Rosenberg L, Shapiro S. 
Vasectomy and prostate cancer. J Urol. 1999;161:1848-52.
Levinson G, Gutman GA. Slipped-strand mispairing: a major 
mechanism for DNA sequence evolution. Mol Biol Evol. 
1987;4:203-21
Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor 
locus, is a novel protein tyrosine phosphatase regulated by 
transforming growth factor beta. Cancer Res. 1997;57:2124-9.
217
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, 
Miliaresis C,Rodgers L, McCombie R, Bigner SH, Giovanella BC, 
Ittmann M, Tycko B, HibshooshH, Wigler MH, Parsons R. PTEN, a 
putative protein tyrosine phosphatase gene mutated in human 
brain, breast, and prostate cancer. Science. 1997;275:1943-7.
Liaw D. Germline mutations of the PTEN gene in Cowden 
disease, an inherited breast and thyroid cancer syndrome. Nature 
Gent. 1997;16: 64-67.
Lilja H, Abrahamsson PA: Three predominant proteins secreted 
by human prostate gland. Prostate. 1988;12: 29-34
Limon J, Lundgren R, Elfving P, Heim S, Kristoffersson U, 
Mandahl N, Mitelman F.An improved technique for short-term 
culturing of human prostatic adenocarcinoma tissue for 
cytogenetic analysis. Cancer Genet Cytogenet. 1990;46:191-9.
Liotta LA. Cancer and Angiogenesis. An imbalance of positive 
and negative regulation. CELL. 1991; 64. 327 -336 .
Litt M, Luty JA. A hypervariable microsatellite revealed by in vitro 
amplification of a dinucleotide repeat within the cardiac muscle 
actin gene. Am J Hum Genet. 1989;44:397-401
Lunn RM, Bell DA, Mohler JL, Taylor JA.Prostate cancer risk and 
polymorphism in 17 hydroxylase (CYP17) and steroid reductase 
(SRD5A2). Carcinogenesis. 1999;20:1727-31.
Lu-Yao GL, Yao SL. Population-based study of long-term survival 
in patients with clinically localised prostate cancer. 
Lancet. 1997;349:906-10.
Macintosh CA, Stower M, Reid N, Maitland NJ.Precise 
microdissection of human prostate cancers reveals genotypic 
heterogeneity. Cancer Res. 1998;58:23-8.
Marsh D.J. Allelic imbalance, including deletion of PTEN/MMAC 1 
at the Cowden disease locus on 10q22-23, in hamartomas from 
patients with Cowden syndrome and germline PTEN mutation. 
Genes Chromosom. Cancer 1998; 21: 61-69.
McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von 
Eschenbach AC, Brisbay S, Logothetis CJ. Expression of bcl-2 
oncoprotein and p53 protein accumulation in bone marrow 
metastases of androgen independent prostate cancer. 
J Urol. 1997; 157:569-74.
218
McNeal JE, Redwine EA, Frieha FS, Stamey TA. Zonal 
distribution of prostate adenocarcinoma: correlation with
histologic pattern and direction of spread. Am J Surg Pathol; 
1998; 12:897-906.
Mettlin C.Impact of screening on prostate cancer rates and 
trends. Microsc Res Tech 2000,51 :415-8
Middleton RG, Thompson IM, Austenfeld MS, Cooner WH, Correa 
RJ, Gibbons RP, Miller HC, Oesterling JE, Resnick Ml, Smalley 
SR, et al. Prostate Cancer Clinical Guidelines Panel Summary 
report on the management of clinically localized prostate cancer. 
The American Urological Association. J Urol. 1995.;154:2144-8.
Mitelman F, Heim S. Consistent involvement of only 71 of the 329 
chromosomal bands of the human genome in primary neoplasia -  
associated rearrangements. Cancer Res 1988;48:7115 -9 .
Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, 
Parsons R, Tonks NK. P-TEN, the tumor suppressor from human 
chromosome 10q23, is a dual-specificity phosphatase. Proc Natl 
Acad Sci U S A .  1997;94:9052-7.
Nowell PC. The clonal evolution of tumor cell populations. 
Science 1976 ;194:23-8.
Oesterling JE.Prostate specific antigen: a critical assessment of 
the most useful tumor marker for adenocarcinoma of the prostate. 
J Urol. 1991; 145(5):907-23.
Oesterling JE, Chan DW, Epstein Jl, Kimball AW Jr, Bruzek DJ, 
Rock RC, Brendler CB, Walsh PC. Prostate specific antigen in the 
preoperative and postoperative evaluation of localized prostatic 
cancer treated with radical prostatectomy. J Urol. 1988;139:766-  
72.
Oliver SE, Gunnell D, Donovan JL. Comparison of trends in 
prostate-cancer mortality in England and Wales and the USA. 
Lancet. 2000;355:1788-9.
ONS- Office of National Statistics. Mortality Statistics. Cause. 
Series DH2 no. 24 & MB1 no.31. Review of the registrar General 
on deaths by cause, sex and age, in England and Wales, 2001. 
London: The Stationery Office.
Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, 
Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, Grignon 
D. Phase III trial of androgen suppression using goserelin in 
unfavorable-prognosis carcinoma of the prostate treated with
219
definitive radiotherapy: report of Radiation Therapy Oncology 
Group Protocol 85-31. J Clin Oncol. 1997;15:1013-21.
Plaskon LA, Association of smoking and cancer. Eur J Clin Invest. 
2003; 20:225-35.
Platz EA, Helzlsouer KJ.Selenium, zinc, and prostate cancer. 
Epidemiol Rev. 2001 ;23:93-101.
Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada 
KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R.Mutation 
of Pten/Mmac1 in mice causes neoplasia in multiple organ 
systems. Proc Natl Acad Sci U S A .  1999 96:1563-8.
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, 
Walsh PC. Natural history of progression after PSA elevation 
following radical prostatectomy. JAMA. 1999; 281: 1591-7.
Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman 
AH, Friedman HS,Bigner DD, Bigner SH. PTEN gene mutations 
are seen in high-grade but not in low-grade gliomas. Cancer Res. 
1997;57:4187-90.
Reis LAG, Kosary CL, Hankey BF et al (eds): SEER. Cancer 
Statistical review, 1973-1994. Bethesda, National cancer 
Institute. 1997; 97:2789-94.
Risch N Merikangas K The future of genetic studies of complex 
human diseases. Science. 1996;273:1516-7.
Rotruck JT, Pope AL, Ganther HE, Hoekstra WG. Prevention of 
oxidative damage to rat erythrocytes by dietary selenium. J Nutr. 
1972;102:689-96.
Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The 
frequency of carcinoma and intraepithelial neoplasia of the 
prostate in young male patients. J Urol. 1993 ;150:379-85.
Sakr WA, Macoska JA, Benson P, Grignon DJ, Wolman SR, 
Pontes JE, Crissman JD.Allelic loss in locally metastatic, 
multisampled prostate cancer. Cancer Res. 1994;54:3273-7.
Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, 
Fair WR, Herr HW, Reuter VE. Nuclear overexpression of p53 
protein in transitional cell bladder carcinoma: a marker for 
disease progression. J Natl Cancer Inst. 1993 ;85:53-9.
Schlotterer C, Tautz D. Slippage synthesis of simple sequence 
DNA. Nucleic Acid Res 1992; 20: 211-15.
220
Schwartz GG, Hulka BS. Is vitamina D deficiency a risk factor for 
prostate cancer? Anticancer Res 1990;10:1307-12
Sellers TA, Potter JD, Rich SS. Familial clustering of breast and 
prostate cancers and risk of postmenopausal breast cancer. J 
Natl Cancer Inst 1994;86: 1860-5.
Shibata A, Whittemore AS, Imai K, Kolonel LN, Wu AH, John EM, 
Stamey TA, Paffenbarger RS.Serum levels of prostate-specific 
antigen among Japanese-American and native Japanese men. J 
Natl Cancer /nsf.1997;89:1716-20
Shimizu H, Ross RK, Bernstein L. Cancers of the prostate and 
breast among Japanese and whit immigrants in Los Angeles 
County. Br J Cancer 1991:63; 963-6.
Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, 
Perez CA, Kuban DA, Hancock SL, Smith CD.Radiation therapy 
for clinically localized prostate cancer: a multi-institutional pooled 
analysis. JAMA. 1999;281:1598-604.
Sikka SC.Role of oxidative stress response elements and 
antioxidants in prostate cancer pathobiology and 
chemoprevention— a mechanistic approach. Curr Med Chem. 
2003;10:2679-92.
Sobin LH & Wittekind CH. TNM classification of Malignant 
Tumours. Fifth edition. UICC: 1997.
Stapleton AM, Timme TL, Gousse AE, Li QF, Tobon AA, Kattan 
MW, Slawin KM,Wheeler TM, Scardino PT, Thompson TC.Primary 
human prostate cancer cells harboring p53 mutations are clonally 
expanded in metastases. Clin Cancer Res. 1997;3:1389-97.
Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, 
Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, 
Swedlund B, Teng DH, TavtigianSV. Identification of a candidate 
tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is 
mutated in multiple advanced cancers. Nat Genet. 1997;15:356-  
62.
Stehelin D, Varmus H E, Bishop JM, Vogt. DNA related to the 
transforming gene(s) of avian sarcoma virus is present in normal 
avian DNA. Nature. 1976; 260:170 -1 7 3
Suzuki H, Komiya A, Emi M, Kuramochi H, Shiraishi T, Yatani R, 
Shimazaki J. Three distinct commonly deleted regions of 
chromosome arm 16q in human primary and metastatic prostate 
cancers. Genes Chromosomes Cancer. 1996;17:225-33.
221
Takahashi S, Shan AL, Ritland SR, Delacey KA, Bostwick DG, 
Lieber MM, Thibodeau SN, Jenkins RB. Frequent loss of 
heterozygosity at 7q31.1 in primary prostate cancer is associated 
with tumor aggressiveness and progression. Cancer Res. 
1995;55:4114-9.
Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, 
Parsons R, Ellenson LH. Mutations in PTEN are frequent in 
endometrial carcinoma but rare in other common gynecological 
malignancies. Cancer Res. 1997;57:3935-40.
Tautz D, Renz M. Simple sequences are ubiquitous repetitive 
components of eukaryotic genomes. Nucleic Acids Res. 
1984;12:4127-38.
Tautz D. Hypervariability of simple sequences as a general 
source for polymorphic DNA markers. Nucleic Acid Res 1989 17; 
6436 -6471 .
Teh BS, Mai WY, Grant WH 3rd, Chiu JK, Lu HH, Carpenter LS, 
Woo SY, Butler EB. Intensity modulated radiotherapy (IMRT) 
decreases treatment-related morbidity and potentially enhances 
tumor control. Cancer /nvesf.2002;20:437-51.
Templeton DJ, Weinberg RA. Principles of cancer biology. 
American cancer society textbook of clinical oncology. Eds Holleb 
AL, Fink DJ, Murphy GP. American cancer society Inc. Atlanta. 
1991 ;678 -689 .
Trybus TM, Burgess AC, Wojno KJ, Glover TW, Macoska JA. 
Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldason H. Risk of 
prostate, ovarian, and endometrial cancer among relatives of 
women with breast cancer. BMJ. 1996;305:855-7.
Tyler-Smith C, Willard HF. Mammalian chromosome structure. 
Curr Opin Genet Dev. 1993;3:390-7.
Ueda T, Komiya A, Emi M, Suzuki H, Shiraishi T, Yatani R, Masai 
M, Yasuda K, Ito H.Allelic losses on 18q21 are associated with 
progression and metastasis in human prostate cancer. Genes 
Chromosomes Cancer. 1997;20:140-7.
Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, 
Schaafsma HE,Debruyne FM, Isaacs WB. Expression of the 
cellular adhesion molecule E-cadherin is reduced or absent in 
high-grade prostate cancer. Cancer Res. 1992;52:5104-9.
222
Van Den Berg C, Guan XY, Von Hoff D, Jenkins R, Bittner, Griffin 
C, Kallioniemi O, Visakorpi, McGill, Herath J, et al. DNA 
sequence amplification in human prostate cancer identified by 
chromosome microdissection: potential prognostic implications. 
Clin Cancer Res. 1995;1:11-8.
van den Brandt PA, Zeegers MP, Bode P, Goldbohm RA.Toenail 
selenium levels and the subsequent risk of prostate cancer: a 
prospective cohort study. Cancer Epidemiol Biomarkers Prev. 
2003;12:866-71.
Vesalainen S, Lipponen P. Expression of retinoblastoma gene 
(Rb) protein in T12M0 prostatic adenocarcinoma. J Cancer Res 
Clin Oncol. 1995;121:429-33.
Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, 
Nakamura Y, White R. Allelotype of colorectal carcinomas. 
Science. 1989;244:207-11.
Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D, Parsons 
R. Somatic mutations of PTEN in glioblastoma multiforme.
Weber JL. Informativeness of human (dC-dA)n.(dG-dT)n 
polymorphisms. Genomics. 1990;7:524-30.
Weinstein IB. “The origin of human cancer”. The molecular 
mechanisms of carcinogenesis and their implications for cancer 
prevention and treatment. Cancer Res, 1998. 48; 4135-4143.
Weissenbach J. Microsatellite polymorphisms and the genetic 
linkage map of the human genome. Curr Opin Genet Dev. 
1993;3:414-7.
Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said 
JW, Isaacs WB, Sawyers CL. Inactivation of the tumor suppressor 
PTEN/MMAC1 in advanced human prostate cancer through loss of 
expression. Proc Natl Acad Sci U S A .  1998 ;95:5246-50.
Wieder JA, Soloway MS. Incidence, etiology, location, prevention 
and treatment of positive surgical margins after radical 
prostatectomy for prostate cancer. J Urol. 1998 ;160:299-315.
Williams BJ, Jones E, Zhu XL, Steele MR, Stephenson RA, Rohr 
LR, Brothman AR. Evidence for a tumor suppressor gene distal to 
BRCA1 in prostate cancer. J Urol. 1996;155:720-5.
Wilt TJ, Brawer MK. The Prostate Cancer Intervention Versus 
Observation Trial: a randomized trial comparing radical
prostatectomy versus expectant management for the treatment of 
clinically localized prostate cancer. J Urol. 1994;152:1910-4
223
Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick 
PC. Interpretation of free prostate specific antigen clinical 
research studies for the detection of prostate cancer. J Urol 1998; 
159:5-12.
Woolf CM. An investigation of familial aspects of carcinoma of the 
prostate. Cancer 1960; 13: 739-44.
Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL.The 
PTEN/MMAC1 tumor suppressor phosphatase functions as a 
negative regulator of the phosphoinositide 3-kinase/Akt pathway. 
Proc Natl Acad Sci U S A . 1998 ;95:15587-91.
Xue W, Irvine RA, Yu MC, Ross RK, Coetzee GA, Ingles 
SA.Susceptibility to prostate cancer: interaction between
genotypes at the androgen receptor and prostate-specific antigen 
loci. Cancer Res. 2000;60:839-41.
Zonana J, Rimoin D.L and Davis D.C. Macrocephaly with mutiple 
lipomas and hemangiomas. J Paediatr. 1976;89:600-3.
224
British Journal of Cancer (2000) 82(10), 1671-1676
© 2000 Cancer Research Campaign ^
DOI: 10.1054/ bjoc.2000.1211, available online at http://www.ideaGbrary.com on
The expression profile for the tum our suppressor gene 
PTEN and associated polymorphic m arkers
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Summary PTEN, a putative tumour suppressor gene associated with prostate and other cancers, is known to be located within the 
chromosomal region 10q23.3. Transcription of the PTEN gives rise to multiple mRNA species. Analyses by Northern blots, using cell lines 
which express PTEN together with cell iines which have lost the PTEN or carry a truncated version of the gene, has allowed us to 
demonstrate that the pseudogene is not transcribed. In addition, 3' RACE studies confirmed that the multiple mRNA species arising from the 
gene probably result from the use of alternative polyadenylation sites. No evidence for tissue- or cell-specific patterns of transcription was 
found. Analysis by 5' RACE placed the putative site for the start of transcription around 830 bp upstream of the start codon. A map of the 
location of the PTEN gene with a series of overlapping YAC, BAC and PACs has been constructed and the relative position of eight 
microsatellite markers sited. Two known and one novel marker have been positioned within the gene, the others are in flanking regions. The 
more accurate location of these markers should help in future studies of the extent of gene loss. Several polymorphisms were also identified, 
all were within introns. Four of the common polymorphisms appear to be linked, in blood, DNA from 200 individuals, including normal, BPH 
and prostate cancer patients, confirmed this link. Only two samples of 200 did not carry the linked haplotype, both were patients with 
advanced prostate cancer. It is possible that such rearrangements within PTEN could be evidence of predisposition to prostate cancer in this 
small number of cases. ©  2000 Cancer Research Campaign
Keywords: PTEN; microsatellite markers; polymorphisms; prostate; transcription
Allelic loss at the chromosomal region 10q23-25 has been reported 
for prostate and several other cancers (Gray et al, 1995; Bose et al, 
1998; Cairns et al, 1998; Feilotter et al, 1998; Maier et al, 1998; 
Robertson et al, 1998). Analysis of loss of heterozygosity (LOH) in 
microdissected prostate tumours initially placed the minimum 
region of loss between the markers D10S1644 (AFMal24wd9) and 
D10S583 (Gray el al, 1998) and was subsequently refined to a 
region of 400 kb between D10S1765 and D10S541 (Gray, unpub­
lished data). A putative tumour suppressor gene called PTEN, 
MMAC1 or TEPl (Li and Sun, 1997; Li et al, 1997; Steck et al,
1997) has been located within this region and was mutated in 
glioblastomas, endometrial and prostate tumours (Cairns et al, 
1997; Rasheed et al, 1997; Tashiro et al, 1997; Feilotter et al, 1998; 
Gray et al, 1998). In addition, germline PTEN mutations have been 
found to be associated with Cowden’s disease (Liaw et al, 1997) 
and related syndromes such as Bannayan-Zonana syndrome 
(Marsh et al, 1997).
PTEN has regions of homology to chicken tensin and auxilin 
(Li et al, 1997) and incorporates phosphatase domains which are 
active against both lipid and protein substrates (Myers et al, 
1997; Maehama and Dixon, 1998). Evidence for a tumour 
suppressor function for PTEN comes from experiments in which 
transfection of PTEN into a medulloblastoma cell line null 
for PTEN expression caused inhibition of proliferation and 
anchorage-dependent growth (Cheney et al, 1998). Total gene
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disruption resulted in embryonic lethality in mice, whereas 
animals heterozygous for PTEN expression showed hyperplastic- 
dysplastic changes in epithelial tissues and an increased 
incidence of tumours (D i Cristofano et al, 1998). The tumour 
suppressor activity of PTEN may result from its demonstrated 
ability to dephosphorylate the second messenger phosphatidy- 
linosilol-3,4,5-triphosphale (PIP3), thereby restricting cell 
growth and allowing apoptosis to occur (Maehama and Dixon, 
1998; Tamura et al, 1998). In addition, the ability of PTEN to 
dephosphorylate focal adhesion kinase may prevent cell migra­
tion (Tamura et al, 1999), and the inactivation of PTEN has 
recently been associated with increased angiogenesis in prostate 
carcinomas (Giri andlttmann, 1999).
Analysis of the PTEN mRNA species has revealed a complex 
pattern of different sized transcripts (Steck et al, 1997; Gray et 
al, 1998) some of which could have arisen from alternate splice 
events. Additionally a pseudogene for PTEN (\|/ PTEN) has been 
identified on chromosome 9 which has been claimed to be tran­
scribed (Dahia et al, 1998). In this paper we investigate origins 
of the major mRNA species seen on Northern blots and describe 
BAC/PAC coverage of the region along with the exact location 
of several polymorphic markers and identification o f single 
nucleotide polymorphisms.
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MATERIALS AND METHODS
YAC, BAC and PAC isolation
YAC 821D2 was identified from the CEPH Mega YAC library by 
using the ‘infoclone’ program (Chumakov et al, 1995) to screen 
for YACs bearing CA repeat markers spanning the minimal region 
and a clone obtained from the UK HGMP Resource Centre in 
Cambridge. BAC and PAC clones were identified from Human 
BAC pools and RPCI Human PAC libraries (Research Genetics) 
by polymerare chain reaction (PCR) screening with CA repeat 
markers. BAC146B18 was isolated as a clone from which we 
could amplify the T7 (telomeric) end of BAC46B12 and whose 
centromeric end sequence could be amplified from BAC122L22. 
Insert size was estimated by restriction enzyme digests using 
infrequently cutting restriction endonucleases, followed by 
separation by pulsed field gel electrophoresis using manufac­
turer’s recomended conditions (BioRad).
Cell lines
The lymphoblastoid line Bristol 8 (BRI8) has been previously 
described (Gray et al, 1998), DU145, PC3 and A172 were from 
ATCC, and UMUC3 was provided by Prof. M  Knowles (Aveyard 
et al, 1998). A second vial o f DU145 was obtained from Dr R 
Schrock (Introgen Therapeutics Inc.). A ll lines were grown in 
Dulbecco’s modified Eagles medium (DM EM ) supplemented with 
10% fetal calf serum.
Exon, intron and microsatellite marker amplification
Exons were amplified as previously described (Gray et al, 1998) 
using primers based on intronic sequences. Primer sequences for 
Chemical Cleavage of Mismatches (CCM) were obtained from 
BAC sequence data obtained within the laboratory, and the 5' end 
of each 3' primer was PIG-tailed to facilitate CCM (Brownstein 
et al, 1996). CCM cycling conditions were as follows: lOmin at 
96°C followed by 35 cycles o f 96°C for 30 s, 49-60°C for 30 s, 
72°C for 5 min in a Perkin-Elmer 9600 thermal cycler and using 
Taq Gold (Perkin-Elmer). Annealing temperature was dependent 
on primer pair used.
BAC sequencing
BACs were prepared using a modified Qiagen midi prep method. 
Two hundred millilitres cultures were grown in selective medium 
and processed by the Qiagen midi prep protocol, except that 15 ml 
of P I, P2 and P3 were used in place of the recommended 4 ml. 
After centrifugation DNA was precipitated from the supernatant 
with isopropanol, the pellet washed with 70% ethanol and 
resuspended in 1 ml of d H ,0 (heavy water) and 0.25 ml o f 10 m 
NH4Ac. Non-soluble particles were removed by centrifugation and 
DNA was ethanol precipitated. After centrifugation, the pellet was 
redissolved in 2 ml o f H20  and 10 ml of QBT buffer. Qiagen 
protocols were followed thereafter. The DNA was finally resus­
pended in a total of 120 pi, and 6-8 p.1 used per sequence reaction. 
DNA sequence reactions were performed using Big Dye 
Terminator Cycle Sequencing Ready Reaction Kits (Perkin- 
Elmer) and analysed on an ABI377.
Chemical cleavage of mismatches
CCM in heteroduplexes formed between two different alleles was 
performed using the hydroxylamine method (Rowley et al, 1995). 
The reaction products were analysed on a 6% acrylamide/urea gel 
with 12-cm plates at 950 volts for 3.5-4 h on an ABI 377 DNA  
sequencer. The results were analysed using Genescan 2.1.1 soft­
ware. When cleavage products were detected, PCR products span­
ning the relevant interval were purified using Qiagen PCR cleanup 
columns and sequenced using the amplification primers to deter­
mine the exact nature o f the mismatch.
5'- and 3'-rapid amplification of cDNA ends (RACE)
5'- and 3'-R ACE reactions were performed using 0.1-0.2 ng of 
Marathon-Ready prostate cDNA (Clontech) and Advantage-GC 
cDNA PCR buffer and polymerase mix (Clontech). PCR reactions 
were carried out in a 9700 thermal cycler (Perkin-Elmer) in a total 
volume of 50 jil. Cycling parameters for 5'-RACE were either 
94°C for 1 min followed by 35 cycles of denaturation for 30 s and 
extension for 3 min at 68°C or ‘touchdown’ PCR where a 30 s 
denaturation step was followed by 5 cycles of 94°C for 10 s and 
72°C for 4 min, 5 cycles of 94°C for 10 s and 70°C for 4 min and 
25 cycles of 94°C for 10 s and 67°C for 4 min. When touchdown 
PCR conditions were used for the primary PCR, the nested PCR 
parameters were denaturation for 30 s followed by 5 cycles of 
94°C for 10 s, 62°C for 30 s, 68°C for 2 min, 5 cycles of 94°C for 
10 s, 60°C for 30 s, 68°C for 2 min and 25 cycles of 94°C for 10 s, 
59°C for 30 s, 68°C for 2 min. The following primers were used 
in the primary 5'-RACE reactions: GSP1, S'-GGCAGAA- 
GCTGCTGGTGGCGGGG; GSP2, 5'-GCCGCCGTGTTGGAG- 
GCAGTAGAAGGGG; GSP3, 5'-AACTGAGCGCAGTCGCGT- 
CCCAGCGC and A PI (Clontech). In the nested 5'-RACE 
reactions the primers were NGSP1, 5'-GGAAATGGCTCTG- 
GACTTGGCGG; NGSP2,5'-ACCAACTCTCCGGCGTTCCC- 
AGC; NGSP3, 5'-C AGCGC ATA AAG AGTCCTGCCAC and AP2 
(Clontech). Cycling parameters for 3'-RACE were 94°C for 1 min 
followed by 6 cycles of 94°C for 10s and 67°C for 3 min and 30 
cycles o f 94°C for 10 s and 64°C for 4 min. The following primers 
were used in the 3 "-RACE reactions in combination with the 
A PI and AP2 primers from Clontech: 3'GSP2, 5'-CATC- 
CACAGGGTTTTGACAC; 3'NGSP2, 5'-GGTTGTGTAGCTGT- 
GTCATG; 3'GSP3, 5'-CGGGTTAGGGCAATGGAGGGGAA- 
TGC; 3'NGSP3, 5'-CGAGGAATTGGCCGCTGTCACTGC. The 
RACE products were gel purified (Qiagen) and cloned into 
pGEM-T Easy Vector (Promega) or sequenced directly.
RNA and Northern analysis
Messenger RNA was extracted from the cell lines UMUC3, BR18, 
DU145 and A 172 using FastTrack RNA isolation kit (Invitrogen). 
Five micrograms of mRNA from each cell line were size-fraction­
ated on a 1% formaldehyde agarose gel and transferred to a 
Hybond N"* membrane (Amersham) using 20 x SSC 
(sodium-saline citrate) as transfer buffer. A full length PTEN 
cDNA probe was labelled with 32P-dCTP using Megaprime DNA 
labelling system (Amersham). A probe fragment was generated 
for the 3'UTR region by PCR using primers 5'-GACTGAAAG- 
GTTTTCGAGTCC and 5'-GAGGAGCTACAAAGGACTTGG 
and labelled with 32P-dCTP as described previously (Gray et al, 
1998). RNA hybridization was carried out using ExpressHyb
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hybridization solution (Clontech) according to the manufacturer’s 
instructions. Membranes were washed in 2 x SSC and 0.1% 
sodium dodecyl sulphate (SDS) at room temperature for 50 min 
with several changes of wash solution. X-ray film (Fuji) was 
exposed to the Northern blots in the presence of 2 screens for 1-3 
days.
RESULTS
LOH of the chromosomal region around PTEN occurs in several 
cancer types, and to allow a more detailed analysis o f this loss a 
map of overlapping BACs and PACs was constructed and several 
microsatellite markers positioned on this map along with the 
exons/introns of PTEN  (Table 1). The PTEN gene covers approxi­
mately 100 kb and the markers D10S2491 and DIOS 1765 which 
are located 5' or telomeric to the gene were found to be identical. 
D10S608 which has previously been used to map PTEN LOH is 
not located within the designated region and is at least 160 kb 
telomeric of the PTEN gene. Markers AFMa086wg9 (intron 2) and 
D10S2492 (intron 8) are located within PTEN. In addition a 
further CA repeat was identified from sequencing within intron 8 
which was heterozygous in 45% of a sample of blood DNAs 
from a group of 200 individuals when these were analysed by 
microsatellite methods.
Comparison o f genomic and BAC sequencing with database 
sequences for intron 1 (Genebank sequence -  BAC 265N13) 
showed that there was probably a deletion in the database submis­
sion. Genomic sequences we have obtained from around PTEN 
have been lodged with Genbank (Accession Nos AF143312, 
AF143313, AF143314, AF143315, AF143316, AF143317 and 
AF143318).
In addition to microsatellite markers a search for single 
nucleotide polymorphisms was undertaken. PTEN intronic 
sequence primers were used to PCR amplify 1-1.5 kb fragments of 
DNA from 20 normal human blood samples. PTF.N regions ampli­
fied included 1.9 kb downstream of exon 3, approximately 6.7 kb 
upstream of exon 4, all o f intron 4, 1.5 kb downstream of exon 5, 
and 1 kb downstream of exon 6. These fragments, which covered 
around 12 kb of sequence in total, were analysed by CCM to 
identify polymorphisms and potential changes were confirmed by 
sequencing. Polymorphisms and levels o f heterozygosity are listed
in Table 2; some of these polymorphisms have been described 
previously but confirmed by CCM and sequencing during the 
course of our studies.
Four polymorphic markers located within the PTEN  gene had a 
similar frequency of heterozygosity of around 40% and were used 
to analyse the DNA obtained from the blood o f 200 individuals 
(these included 97 prostate cancer patients, 43 patients with benign 
prostatic hyperplasia and 60 other non-cancer patients). From this 
analysis it appeared that two distinct haplotypes existed. For the 
four markers 1, 4, 5 and 8 respectively (Table 2), the linkage was 
either G,A,+,G or A,G,-,T. O f the 200 DNAs tested, 45.5% were 
heterozygous at each of the markers, 12% were homozygous for 
A ,G ,-,T haplotype and 41.5% were homozygous for G,A,+,G 
haplotype. Only two out of 200 individuals did not carry the linked 
haplotype in their blood DNA and both were cancer patients, their 
genotypes were A,G,-,G /T and A,G/A,+/-,G/T.
To analyse the complex pattern of transcription found for PTEN 
a number of cell lines were studied. Five cell lines were analysed 
by PCR for the presence or absence of PTEN and y/PTEN. To 
distinguish PTEN from y/PTEN, primers complementary to intron 
sequences were used to amplify PTEN exons ( y/PTEN is processed 
and has no introns). In cell lines where all nine PTEN exons were 
present these exons were sequenced. The B lymphoblastoid cell 
line BRI8 and the prostate line DU145 contained all PTEN exons 
and carried no mutations. DU 145 has been described as carrying a 
mutation at codon 145 (Li et al, 1997); we were unable to find this 
mutation in two independent sources of DU 145. Consistent with 
published results the glioblastoma cell line A 172 contains only 
exons 1 and 2, and the bladder cell line UMUC3 has lost all PTEN 
exons (Li et al, 1997; Steck et al, 1997; Aveyard et al, 1998). PC3 
cells used for these studies contained only exons 1 and 2. The pres­
ence of the PTEN pseudogene in these cell lines was determined 
using PCR primers from the boundary of exons 3 and 4 and from 
exon 6, which could only generate a product when no intronic 
sequences were present. PTEN pseudogene sequences were found 
to be present in all ceil lines examined. Multiple PTEN transcripts 
(Steck et al, 1997; Gray et al, 1998) were evident in BRI8 and 
DU 145 cells, but no mRNA transcripts were detected in UMUC3 
cells which were null for PTEN but positive for the y/PTEN. A 
shortened transcript was detected in the mRNA from the A 172 cell 
line which has only exons 1 and 2 (Figure 1).
Table 1 Microsatellite and PTEN content of YACs, BACs and PACs and their alignment in the region of LOH
Approx D10S OIOS D10S Exon Exon AFM Exons D10S 8/9 Exon D10S
size 608 215 1765 1 2 a086wg3 3-8 2492 CA 9 541
(kb) (2491)
Y738B12 1330
Y821-D2 1141
P72G8 165
P274D21 150
B2F20 90
B46B12 230
B60C5 160
B146B18 110
B122L22 105
Black squares indicate the presence and white squares the absence of the marker or exon. Primers used for the amplification of the exons can be 
found in the Genome Database (http://www.GDB.org) with the exception of CA8/9 which was amplified using the primer pair 5'-CAGCACTTTGG- 
GAGGCTAAG/5'- TTTCACTTAAAACGTGCAGGGG. B146B18 overlaps B122L22 and B60C5 but does not contain a marker or exon.
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Table 2 Polymorphisms in PTEN and their frequency in normal DNA samples.
No. Intron Position Polymorphism Heterozygosity (%)
1 1 -  96 exon 2 A/G 40
2 3 + 329 exon 3 T/C 15
3 3 + 3362 exon 3 A/C 6
4 3 -1606  exon 4 A/G 39
5 4 + 109 exon 4 ATCTTia«s/del(+/-) 36
6 4 + 403 exon 4 T/C 5
7 7 + 461 exon 6 G/A 6
8 8 + 32 exon 8 T/G 37
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Figure 2 Northern blot analysis of multiple tissue blots probed with: (A) a 
PTEN cDNA; and (B) a probe from sequence located 3 kb downstream of the 
PTEN termination codon
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Figure 1 Northern blot analysis of mRNA fiom cell lines probed with a 
PTEN cDNA done. BRI 8 -  B lymphoblastoid cell line; DU145 -  prostate cell 
line; UMUC3 -  bladder cell line; A172 -  glioblastoma cell line
Previously we reported that a 121 bp probe fiom position 338 to 
459 upstream of the ATG start codon of PTEN hybridized to a 
single transcript on Northern blots (Gray et al, 1998), which could 
be evidence of alternate splicing. However, when this probe was 
used on a Northern blot containing mRNA from BRI8, DU 145, 
UMUC3 and A 172 cells a band of approximately 5.5 kb was 
detected in cell lines that are both positive and negative for PTEN. 
Exact alignment o f Northern blots showed that this band was 
marginally smaller than the expected 5.5 kb transcript detected 
with a PTEN exon 1 probe (data not shown; Gray et al, 1998).
3'-RACE was employed to confirm the use o f alternate 
polyadenylation sites, which would give rise to multiple transcripts, 
and extension of transcription beyond the end of the published 
MMAC1 sequence (GenBank accession U92436). 3'-RACE prod­
ucts generated using primers 3,NGSP2 (located 204 bp downstream 
of the PTEN stop codon) and AP2 terminated with poly-adenosine 
(poly-A) tails either 290-300 bp downstream from the stop codon 
and within 20-40 bp of two AAUAAA elements, or where the 
published MMAC1 sequence terminates 910 bp from the stop codon 
(data not shown). 3'-RACE products produced using the primers 
3/NGSP3 and AP2 terminated in the vicinity of the end of the 
MMAC1 sequence with a poly-A tail. Longer 3VRACE products
were not generated with the conditions used. However, while this 
work was in progress a search of the GenBank database revealed 
one EST, IMAGE clone 361374 (Accession Nos AA017563 and 
AA017584), which extended 271 bp downstream of the end of the 
MMAC1 sequence, indicating that transcription can progress beyond 
the end of the MMAC1 sequence. Furthermore, a probe from the 3' 
untranslated region located 2471 2680 bp downstream of the termi­
nation codon, and prior to a group of polyadenylation signals in the 
genomic sequence, gave a single band on Northern blots equivalent 
to the largest mRNA species (Figure 2), providing further evidence 
for transcription extension.
To identify the putative transcription start site and to explore the 
possibility that long PTEN transcripts may result from alternate 
splicing involving novel 5' exons, 5' RACE was performed using 
three sets of nested primers: GSP1 + NGSPI, GSP2 + NGSP2, 
GSP3 + NGSP3. The PCR primer set GSP3 + NGSP3, located 
860 nt upstream of the longest published cDNA sequence (Li and 
Sun, 1997), did not result in a PCR product suggesting the coding 
sequence does not extend into this region. Several PCR fragments 
were generated using GSP1 + NGSPI and GSP2 + NGSP2 which 
displayed sequence identity with previously published sequence 
(Li and Sun, 1997). The largest fragment extended 827 bp in the 5' 
direction from the start codon, 35 bp further than the TEP1 cDNA 
sequence. A second fragment also finished at this point while a 
third finished 824 bp from the start codon.
DISCUSSION
The PTEN gene covers over 100 kb of a 400 kb region of allelic 
loss common to most prostate tumours (Gray et al, 1995). 
Although the detection frequency of PTEN mutations in prostate
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tumours is lower than anticipated (Cairns et al, 1997; Teng et al, 
1997; Feilotter et al, 1998; Gray et al, 1998), the frequency of 
mutations in other tumour types such as glioblastoma and endome­
trial carcinoma (Liaw et al, 1997; Rasheed et al, 1997; Tashiro et 
al, 1997; Teng et al, 1997; Duerr et al, 1998; Risinger et al, 1998), 
taken together with the data from in vitro cell growth experiments 
and the targeted disruption of PTEN in mice (Di Cristofano et al, 
1998), support the view that PTEN is a tumour suppressor gene. 
We have mapped CA repeat markers D10S608, AFMa086wg9, 
D10S2491 and D10S2492 precisely around PTEN and identified a 
number of other common intragenic polymorphisms including a 
novel CA repeat within intron 8 o f PTEN. These polymorphisms 
could prove useful for future studies on PTEN  and will provide a 
panel of markers for more detailed mapping of I .OH. We have also 
identified the existence, within the population, of two distinct 
haplotypes covering this region, although no polymorphisms were 
found within the coding sequence of PTEN.
We have attempted to dissect the complex PTEN mRNA tran­
script profile. Two cell lines, UMUC3 and A 172, were used to 
determine whether a known pseudogene on 9p21 (Dahia et al,
1998) contributes to the pattern of PTEN mRNA transcripts. Both 
cell lines retain the pseudogene but UMUC3 has completely lost 
both copies of the PTEN gene and A172 retains exons 1 and 2 of 
PTEN. On Northern blot analysis no transcript was identified for 
UMUC3 and an altered message profile was found in A 172 cells 
consistent with the truncated copy of PTEN present in this cell 
line. These results indicate that the pseudogene is not transcribed 
and does not contribute to any of the transcripts identified in cell 
lines studied. The pseudogene was originally identified by cloning 
from RT-PCR implying that transcription was taking place (Kim  
et al, 1998) and has subsequently been reported as occurring as a 
major mRNA species (Fujii et al, 1999). Although we cannot 
exclude the possibility that there could be some cell/tissue-specific 
transcription o f the pseudogene, the similarity o f the multiple 
species seen on Northern blots with mRNA from a variety of 
different tissues (Gray et al, 1998) and the FTE/V-positive cell lines 
described here, taken together with data described by others 
(Dahia et al, 1998) makes it appear more likely that the pseudo­
gene is not transcribed.
We previously reported that a probe derived from the 5' 
sequence of PTEN detects only a 5.5 kb transcript whereas full 
length cDNA probes or probes derived from individual exons all 
give a complex pattern with major RNA species at 2.1 kb, 2.4 kb 
and 5.5 kb (Gray et al, 1998). When this probe was used to analyse 
RNA from PTEN null cells a single band was seen in both 
UMUC3 and A 172 which was identical to the pattern seen for 
P7£W-expressing cells. Therefore this 5.5 kb band is distinct from 
the similarly sized transcript detected with probes derived from the 
PTEN coding region. Consequently it is unlikely to have arisen 
from alternate PTEN splicing and is more likely to be the result of 
cross-hybridization to an unrelated RNA wife some sequence 
similarity to the PTEN 5' UTR.
Published cDNA sequence of the PTEN 5' UTR extends 790 bp 
upstream of the ATG translation start site. To determine the region 
of initiation of transcription a commercial prostate cDNA library 
was analysed by 5'-RACE. The clones obtained extend the longest 
previously reported cDNA sequence (L i and Sun, 1997) by 38 
bases. Primers derived from genomic sequence 5' to this region 
and 5' to the published TEP1 cDNA sequence did not produce a 
PCR product. This suggests that the transcription start site is in the 
region of the sequence described by Li and Sun (1997), which
would give a 5' untranslated sequence of around 827 bp, with a 
gene sequence of 1209 bp and the first polyadenylation sites at 
60 bp and 290 bp from the translation termination signal. These 
distances correlate with the size of the smaller mRNA species of 
2.1 and 2.4 kb seen on Northern analysis (Gray et al, 1998). The 
larger 5.5 kb species is likely to result from a further poly­
adenylation site approximately 3 kb downstream of the second 
polyadenylation signal. This conclusion is supported by Northern 
blot analysis where the 5.5 kb mRNA species was identified with a 
probe from a region 3 kb downstream of the termination codon 
(Gray et al, 1998). cDNA sequences in the database and 3' RACE 
experiments confirm that alternative polyadenylation sites are used 
and that poly-A tails are added at the equivalent position to the 2.1 
and 2.4 kb and that longer species are also transcribed. This 
analysis taken in conjunction with the analysis of PTEN null and 
PTEN truncated cell lines suggests that the complex pattern of 
mRNAs seen on Northern blots arises largely from alternative 
polyadenylation sites and that no major contribution to this pattern 
is made by pseudogene transcription, alternate splicing or cross­
hybridization to related gene family members. The significance of 
the variable 3' I  JT sequences is unclear but regulatory elements in 
this region in other genes have been associated with cell differenti­
ation (Rastinejad and Blau, 1993), mRNA stability particularly in 
cancer cells (Rajagopalan and Malter, 1997) and tissue-specific 
expression (Coy et al, 1999).
PTEN appears to be an important tumour suppressor gene which 
is lost in many cancers. In some cases, particularly in glioblast­
omas and endometrial cancers, the presence of LOH and mutations 
in the second gene is consistent with the Knudson two-hit hypoth­
esis (Knudson, 1991). In the case of prostate cancer, LOH is 
common (Gray et al, 1995) but mutations in the remaining gene 
are rare (Gray et al, 1998), although loss o f transcription due to 
methylation has been reported in some tumour samples (Whang 
et al, 1998). The detailed genomic map and an analysis of PTEN 
transcripts should assist in the understanding of the genomic 
changes which contribute to tumour progression by the inactiva­
tion o f PTEN in prostate and other tumours.
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